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Summary
The aim of this study was to identify the gene which was affected by proviral 
integration within the Fit-1 common integration locus. The Fit-1 locus was 
identified in the cat as a common site of insertion for feline leukaemia virus 
(FeLV) in thymic lymphomas induced by FeLV-myc recombinant viruses. Thus 
precedent suggested that it harbours a gene which cooperates with c-myc in Txell 
leukaemogenesis. Using a zooblot positive probe from the major insertion 
cluster, the mouse homologue was mapped to chromosome 10 and the human 
homologue to chromosome 6 (N. Barr et al, in press and Appendix 2). A cosmid 
clone containing homologous human sequences was isolated and used to generate 
a PAC clone contig around the human Fit-1 locus, revealing that it is only lOOkb 
upstream of the c-myb gene.
A number of retroviral insertion sites have been mapped close to c-myb on mouse 
chromosome 10, Mm/1, Ahi-1 and Mis-2. Thus, the close proximity of c-myb and 
Fit-l in the human genome and the lack of obvious transcribed sequences at these 
loci might suggest that retroviral insertions within this cluster of loci activates the 
c-myb gene by long-range activation. However, analysis of c-myb expression in 
tumours rearranged at A hi-1, Mis-2 and Mm/1 failed to show evidence of long- 
range activation. In contrast, careful analysis of the FT1 cell line which carries 
an insertion at Fit-l and c-myc revealed evidence of approximately 2-fold over­
expression of c-myb which may, at least in part, be due to a decreased turnover of 
c-myb RNA. This subtle change in expression may have been missed in previous 
analyses of primary tumour RNA from tumours rearranged at Fit-1, Ahi-1 or Mis- 
2. These results raised the unexpected prospect that Myc and Myb can 
collaborate in T-lymphoma development.
In addition to over-expression of the c-myb gene in the FT1 cell line, there was 
also evidence of an altered c-myb transcript structure in this cell line. Further 
analysis revealed that this was due to alternative splicing of the c-myb gene 
involving the alternative exon 9A, a form which was approximately 5-fold over­
13
expressed in FT1 cells. Although this form has been associated with both normal 
and activated forms of c-myb, levels seen in the FT1 cell line were higher than in 
previous studies.
Thus, it appears that c-myb may be the true target o f insertions at the Fit- 
\/M mll/Ahi-l/M is-2  cluster and that, at least for Fit-1, retroviral integration may 
promote the alternative splicing of c-myb, possibly favouring a more oncogenic 
isoform.
14
CHAPTER 1
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Chapter 1
1. Introduction
Cancer is essentially a genetic disease of which around 200 different forms have 
been recognised in man. Despite the vastly different pathologies o f cancers, they 
all share the same key features at the molecular level, namely uncontrolled cell 
division and inappropriate survival. Tumour growth is typically a slow, multi- 
step process in which 5 or 6 separate genetic, or epigenetic, events must occur to 
produce the fully malignant phenotype (reviewed in (1)). The multi-step nature 
of this disease can be illustrated by the correlation of an increased risk of cancer 
with age. The incidence of cancer increases exponentially with time as 
individuals are exposed to mutagens thus increasing the risk of cancer as we get 
older.
There are basically two categories of genes which are the frequent targets of 
somatic mutations during the development of cancer. Firstly, proto-oncogenes, 
which generally exhibit dominant behaviour when mutated (becoming an 
oncogene). Proto-oncogenes are often involved in proliferation and cell signaling 
pathways and it is usually their deregulation which is responsible for their 
tumorigenic potential. Secondly, tumour suppressor genes are frequently 
implicated in cancer where their function is lost by the acquisition of mutation(s). 
Tumour suppressor genes are involved in, for example, the repair and 
maintenance of DNA and regulation of the cell cycle. They are generally 
recessive where loss of function of both copies of the gene is required for their 
tumorigenic potential.
Most cancers will have lost suppressor gene and gained oncogene functions. This 
could occur by, for example, exposure to mutagens such as chemicals, ionising 
radiation or tumour viruses. Such mutations often lead to deregulated 
proliferation. However, equally important is the deregulation of the normal 
processes leading to programmed cell death (apoptosis) or terminal 
differentiation.
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A major goal of cancer research has been to identify the genes which contribute 
to tumour development and which genes can collaborate in this multi-step 
process. A major contribution to the identification of cellular oncogenes have 
come from retroviruses. Retroviral oncogenesis is associated with either 
transduction or insertional mutagenesis of a host cell proto-oncogene. The 
isolation of the sequence which has been transduced by the virus or the sequence 
flanking the integrated provirus has provided a vast amount of knowledge of 
genes and pathways involved in tumorigenesis.
1.1 Retroviral oncogenesis
Retroviral infection is causally associated with a wide range of lymphoid 
malignancies, of which lymphomas of T cell origin are the most common and 
best characterised in the domestic cat (2). The malignant potential o f such 
lymphomas can be directly attributed to a transduced oncogene (acute 
transforming retroviruses) or to proviral integration in the host genome which 
activates a host cell proto-oncogene (chronic transforming retroviruses). This 
forms the basis o f two loosely categorised divisions o f oncogenic retroviruses 
which have examples in cats, birds and rodents. However, it must be emphasised 
that retroviruses which are classified as chronic may also fall into the acute 
transforming category, indeed acute transforming retroviruses are usually formed 
de novo from the chronic type (2). Nevertheless, it is a useful way to separate the 
two major ways in which retroviruses promote cancer in animal models.
a) Acute transforming retroviruses
Some oncogenic retroviruses can induce tumours in animal models with a 
relatively short latency period and can transform cells in vitro (3-5). Further 
analysis reveals that these retroviruses have replaced some of their replicative 
genes with sequences (v-onc) which are related to proto-oncogene sequences 
from the host cell genome (c-onc). Such transduction of proto-oncogenes occurs 
very rarely in nature however, it is relatively prevalent in sporadic lymphomas in 
cats associated with feline leukaemia virus (FeLV) infection (6). It is this, often
17
mutated or de-regulated transduced cellular gene, which is responsible for 
transformation with such short latency. For example, the proto-oncogene c-myc 
is a frequent target for transduction by FeLV in naturally occuring feline T cell 
leukaemias (7-9) resulting in a replication deficient, recombinant FeLV carrying 
the Myc oncogene (w-myc). The acquisition of Myc by FeLV induces T cell 
lymphomas with relatively short latency (8-12 weeks after infection), however it 
does not expand the spectrum of tumours induced by FeLV alone, possibly due to 
tissue tropism encoded by FeLV (3).
b) Chronic/slow transforming retroviruses
Retroviruses which do not carry cellular genes induce tumours with a much 
longer latency, often months or years after the viral challenge. Furthermore, the 
tumours are mono- or oligoclonal and the viruses cannot transform cells in tissue 
culture (reviewed in (10)). The tumorigenic potential of this type of retrovirus 
can be directly attributed to integration of the provirus in the cellular genome. 
Most studies suggest that retroviral integration within the host genome is 
essentially random. If the retrovirus integrates within a proto-oncogene in such a 
way as to activate (or inactivate) its expression, then that cell will have a selective 
growth advantage and will grow and divide in a clonal fashion. An oncogene or 
suppressor gene mutated in this way is effectively tagged by the presence of a 
virus nearby or within the gene. Therefore identifying regions of common 
proviral integration in independently derived tumours represents a method for 
cloning novel oncogenes or suppressor genes in the immediate vicinity of the 
integrated provirus which are involved in tumour development.
Retroviruses have been used for a number of years to identify genes involved in 
tumorigenesis. The first example was in 1981 when Hayward et al found that 
cellular sequences with homology to v-myc were activated in chicken bursal 
lymphomas by insertion of avian leukosis virus (ALV) (11). Since then greater 
than 60 genes have been identified as targets for insertional mutagenesis in 
retrovirus-induced tumors of the mouse, chicken and cat (Table 1.1 and reviewed 
in (12)). Most of these mutations result in the activation of dominant
18
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oncogene(s) which act in growth signalling pathways, thus leading to 
inappropriate survival of these cells. The set of genes identified in this way 
overlaps significantly with those subject to retroviral transduction and non-viral 
mutational processes such as chromosomal translocations and gene amplification, 
illustrating the value of retroviruses as tags for the genes which are central to 
neoplastic cell growth. The utility o f this approach has been demonstrated further 
by the identification of collaborating genes in oncogene transgenic mice arid in 
elucidating functionally related genes in knockout mice (13; 14).
1.1.1 The structure and life-cycle of FeLV
Feline leukaemia virus (FeLV) is a member of the oncovirinae subfamily of 
exogenous retroviruses which are horizontally transmitted among the domestic 
cat population (15). FeLV infection has been causally associated with a number 
of lymphoid malignancies as well as degenerative diseases of the domestic cat 
(16). There are three FeLV subgroups: A, B and C. FeLVs of subgroup A are 
ecotropic and found in all infected cats, while FeLV B and C are amphotropic 
and are found in 50% and 1% of infected cats respectively. Most oncoviruses are 
type C and include avian leukosis virus (ALV), murine leukaemia virus (MuLV) 
as well as FeLV, around which this study is centred. However, an exception to 
this is the mouse mammary tumour virus (MMTV) which is a type B retrovirus 
that causes carcinomas of mammary epithelial tissue. In MMTV induced 
carcinomas, the int genes or oncogenes that belong to the Wnt family or the F gf 
family of growth factors are frequent targets of pro viral insertions. However, 
MMTV induced mammary carcinomas will not be discussed further.
Type C retroviruses share similar structures and mode of replication (15). The 
structural gene order of FeLV is gag-pol-env (Figure 1.1 A), gag and env encode 
the major structural proteins which form the internal non-glycosylated 
components and the glycosylated virion surface glycoproteins respectively (96). 
The pol region is responsible for the protease, integrase and reverse transcriptase 
products. The FeLV genome, like other retroviruses, also consists of 5' and 3' 
long terminal repeat (LTR) sequences containing U3, U5 and R regions which are
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Figure 1.1 Genetic structure and life-cycle of FeLV. (A) The FeLV 
genome structure and expression. (B) Schematic overview of the FeLV 
life-cycle. RT, reverse transcriptase; LTR, long terminal repeat; An, 
polyadenylation; cap, the capped nucleotide at the 5' end of the viral RNA.
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copied to form the proviral LTR. The LTRs contain sequence responsible for the 
initiation of transcription as well as for polyadenylation of viral RNA. The U3 
region of the LTR contains enhancer elements which promote viral (and cellular) 
transcription.
Retroviruses can exert their mutagenic effect during a natural step in their life­
cycle as the provirus integrates into the host genome where it may disrupt or 
deregulate a cellular oncogene involved in growth or development. The first 
stage of the life-cycle (Figure 1.1B) involves the synthesis o f double stranded 
DNA and the integration of the pro virus in the host cell chromosome. This is 
accomplished without any help from the host cell and involves the virally 
encoded enzymes, reverse transcriptase and integrase. However, once integrated 
the provirus relies on the host cell machinery for transcription and processing of 
RNA. Finally, new virus particles are assembled and released by budding 
through the host cell membrane resulting in an envelope surrounding the viral 
core which is composed of host cell membrane enriched with viral glycoproteins.
1.1.2 Mechanisms of retroviral insertional mutagenesis
Viral integration within or adjacent to cellular proto-oncogenes can alter the 
structure or level of expression of such genes, thereby conferring a selective 
growth advantage to the target cell and its progeny. The ability of the integrated 
provirus to activate the transforming capacity of the adjacent gene is an inherent 
property of the viral LTR which contains the powerful viral transcriptional 
control sequences. As retroviral integration shows little sequence specificity, the 
identification of preferred integration sites in more than one independently 
derived virus-induced cancer has generally been interpreted as evidence of a 
selective advantage arising from these insertions and the presence of a nearby 
target gene. That cell will then grow and divide in a clonal fashion contributing 
to the outgrowth of a tumour. Thus, an oncogene activated by the virus is 
effectively tagged by the presence of the virus nearby or within the gene.
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This property has been used to detect both novel and previously identified 
oncogenes such as v-myc, w-myb, \-m os and v-ras which were identified as 
components of acutely transforming viruses (10; 12). Screening both naturally 
occuring and experimentally derived tumours for the presence of common sites of 
retroviral integrations is the first step in the identification of novel common 
insertion loci.
The major mechanisms by which a proto-oncogene is activated by the insertion 
of a retrovirus within or nearby the coding sequence are described below (and 
reviewed in (97)). It is important to point out, however, that each mechanism is 
not mutually exclusive and more than one mechanism of activation may occur at 
any one time.
1.1.2.1 Promoter insertion
Tumours which have proviral insertions at the 5' end of a gene in the same 
transcriptional orientation are predominantly activated by LTR promotion. This 
generally takes two forms: 5' and 3' promotion. In 5' promotion, transcription 
initiates at the relatively strong 5' promoter of the proviral LTR rather than the 
normal cellular promoter (Figure 1.2A i and ii). This results in abnormally high 
levels o f the hybrid transcript and often involves cryptic splicing of the virus to a 
splice acceptor site in the adjacent proto-oncogene. 5' promoter insertion can be 
exemplified by the classic case of avian B cell lymphoma where c-myc 
transcription is driven by the viral promoter situated 5' to the gene (11). 3' LTR 
promoter insertion is similar to 5' promotion except that transcription is initiated 
at the 3' promoter of the LTR (Figure 1.2A iii). The proviruses in tumours 
activated in this way often suffer large deletions and aberrant splicing patterns. 
For example, the Lck gene activated by 5' and 3' promoter insertion in Moloney 
murine leukaemia virus (M-MuLV) induced T cell lymphomas in rats, involved 
aberrant splicing which removed 5' regulatory sequences (58).
25
Figure 1.2 Mechanisms of retroviral insertional mutagenesis
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Figure 1.2 Mechanisms of retroviral insertional mutagenesis. The examples 
shown illustrate the mechanisms involved in the insertional activation of 
proto-oncogenes by retroviral insertion, however more complex retroviral 
deletions and splicing events are not shown. Shown at the top are diagrams of 
the structural features of a provirus, and a proto-oncogene (c-one) which consists 
of 3 coding exons as well as 5" and 3V untranslated, regulatory regions. See text 
for details of activation for each of the mechanisms illustrated.
(A) Activation by promoter insertion, (i) transcription initiated from the 5V LTR 
promoter; (ii) transcription initiated from the 5V LTR promoter and splicing 
involving a cryptic splice donor in the proviral genome. (B) Activation by 
enhancer insertion. The broken line in this figure indicates that the pro virus may 
be situated close to the proto-oncogene, or far away to exert enhancment of the 
gene, (i) provirus situated upstream  and in the opposite transcrip tional 
orientation to c -one; (ii) provirus situated dow nstream  and in the same 
transcriptional orientation to c-onc. (C) Truncation of the gene product by 
proviral insertion within coding sequence, also often involves enhancement of the 
truncated product, or results in the inactivation of the gene. (D) Stabilisation of 
an unaltered c-one by removal of RNA stabilising motifs in the 3' UTR. 
Abbreviations and key: LTR, long terminal repeat; TI, transcription initiation; 
SD, splice donor; SA, splice acceptor; pA, polyadenylation signal; UTR, 
untranslated region. ■  protein coding DNA; □  untranslated DNA;
“  mRNA; v splicing.
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1.1.2.2 Enhancer insertion
Eukaryotic enhancer elements can activate transcription of a linked gene by a cis 
acting mechanism. Their effect on transcription is independent of orientation and 
they preferentially stimulate transcription from the most proximal promoter but 
have the ability to function over long distances (reviewed in (98)). The U3 
domains of viral LTRs contain powerful enhancer elements which act as targets 
for cellular transcription factors. The enhancer elements are responsible for the 
tissue specificity seen with some retrovirally induced cancers, presumably due to 
their interaction with tissue specific factors. FeLV proviruses isolated from 
naturally occuring feline thymic lymphomas revealed a high degree of 
heterogeneity in their LTR enhancer sequences, with up to three repeats of the 
LTR enhancer in one tumour (99; 100). In situations where enhancer duplications 
were observed, there was a concomitant increase in functional binding sites for 
transcription factors.
Thus, viral enhancers play an important role in FeLV induced leukaemogenesis
(2) where they activate transcription by cis acting mechanisms from the promoter 
of a nearby cellular proto-oncogene, often over-riding normal cellular 
transcriptional control. Enhancer insertional activation is characterised by the 
integration of a provirus either at the 5' end of a proto-oncogene in the opposite 
transcriptional orientation, or at the 3' end in the same transcriptional orientation 
(Figure 1.2B i and ii). The net result of such insertions in the tumour is the 
upregulation of an otherwise normal oncogene.
Enhancer insertion is by far the most common mode of retroviral activation, 
possibly because of the flexibility of position and orientation of provirus to 
produce an oncogenic effect. Some examples of genes activated by enhancer 
insertion are listed in Table 1.1.
1.1.2.3 Long distance effects
Some proviruses appear to activate genes at distances of up to 300kb away. This 
again is due to the proviral LTR enhancer which, as eluded to above, can exert
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their effect on promoters located long distances from the provirus (Figure 1.2B). 
Evidence in favour of this mechanism comes from the activation of the c-myc and 
Evi- 1 genes by proviruses situated at great distances from these genes. Insertions 
at the Mlvi-1 and Cb-\/Fim-3 loci activate transcription from the normal 
promoters of c-myc and Evi-1 respectively, even though the proviruses are 
located up to 300kb away (28;64). This demonstrates why it can, in some cases, 
be very difficult to locate a transcription unit at a common proviral insertion site.
1.1.2.4 Truncation of the gene product
If a provirus integrates within the coding sequence of a gene, this can have 
profound effects on the resulting protein, inactivating or mutating it in such a way 
as to produce an oncogenic protein (Figure 1.2C). For example, c-myb has 
frequently been found as the target o f proviral integration in myeloid leukaemias 
of pristane primed BALB/c mice infected with M-MuLV (69; 101; 102). Proviral 
insertions were found at both the 5' and 3' ends of the Myb gene, resulting in 
amino- or carboxy-terminal truncations respectively. The resultant truncated 
proteins are oncogenic most likely because both termini of the gene negatively 
regulate Myb activity. Therefore the removal of these regulatory elements will 
result in the inappropriate expression of an oncogenic Myb protein. Furthermore, 
enhancer or promoter insertion may also play a role to increase the levels of the 
truncated, oncogenic form of the protein.
1.1.2.5 Effects on RNA stability
When proviral integration occurs within the 3' untranslated region (UTR) of a 
proto-oncogene in the same transcriptional orientation, transcription is 
prematurely terminated at the polyadenylation signal in the 5' LTR (Figure 
1.2D). The net result of integrations of this type is often the stabilisation of 
mRNA transcripts by the removal o f sequences in the 3' untranslated region 
which contain negative regulatory elements, such as mRNA-destabilising motifs. 
This frequently occurs in concert with enhancer insertion to up-regulate 
transcription of the oncogene. Frat- 1 is activated by stabilisation of mRNA 
together with enhancer insertion in M-MuLV induced transplanted lymphomas of
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Pirn-1 or Myc transgenic mice (51). Similarly, N-myc has been shown to be 
activated by proviral insertions in the 3' untranslated region of the gene in MuLV 
induced T cell lymphomas (77).
1.1.2.6 Inactivation of a gene
Inactivation of a gene by proviral integration is a relatively rare event because it 
requires insertion at both alleles of a gene. However, it has occurred on at least 
three occasions, resulting in the inactivation of p53, Evi-2/Nfl or Fli-2. Friend 
murine leukaemia virus (F-MuLV) induced erythroleukaemia was shown to have 
integrated pro viruses in both alleles of the tumour suppressor gene p53 resulting 
in no detectable expression of p53 protein (78). An alternative mode for the 
inactivation of a gene is by proviral insertion in one allele and loss o f the other 
allele by, for example deletion or point mutation. A common insertion locus in 
myeloid leukaemia of BXH-2 mice, Evi-2, has been shown to have pro virus 
inserted in both allelles (33). This results in the truncation and inactivation of the 
NF1 tumour suppressor protein, a GTPase activating protein. Fli-2, a common 
integration site in F-MuLV erythroleukaemias, also has a provirus integrated in 
one allele of the NF-E2 transcription factor and this is accompanied by deletion 
of the other allele resulting in the inactivation of NF-E2 in this erythroleukaemia 
cell line (48).
1.1.3 Transduction
The transduction of cellular genes by retroviruses is a rare event in nature, 
possibly due to the number of complicated recombination events which must take 
place in order to generate such a hybrid. However, transduction of the c-myc 
proto-oncogene by FeLV (FeLV-myc) has been found in a number of naturally 
occurring thymic lymphomas (7-9). In all myc-transducing FeLV isolates the 
entire coding sequence of c-myc from exons 2 and 3 have been acquired by the 
hybrid virus (2;6) suggesting that the N- and C-termini of v-myc are crucial for 
oncogenesis by FeLV-myc. The potency of the truncated Myc allele may also be 
enhanced as the v-myc gene is placed outwith normal, cell specific controls and is 
expressed under the control of viral signals.
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Figure 1.3 shows a possible mechanism for the production of an FeLV-myc 
recombinant virus based on the model proposed by Swanstrom et al (103) for the 
genesis of Rous sarcoma virus which has transduced a cellular gene (c-src). The 
first step involves the integration of a provirus upstream and in the same 
transcriptional orientation as c-myc. A recombination event between the 
retrovirus and c-myc followed by a deletion fuses the viral and c-myc coding 
sequences. Following transcription and splicing, the hybrid transcript is co­
packaged with helper virus involving the 5' LTR. On subsequent infection a 
second recombination event generates a retrovirus with a 3' viral LTR resulting 
in a novel hybrid FeLV genome which includes the transduced portion of c-myc. 
This model is supported by the fact that the v-onc gene has been processed to 
remove intron sequences.
FeLV provirus
c -myc
-CD 1 j_J-— C l
^proviral integration
 CD 1 2 h
i deletion
^transcription, splicing and packaging 
^recombination and integration
FeLV-myc
Figure 1.3 Model for the generation of FeLV-myc recombinant virus. The 
proposed mechanism is based on the model of Swanstrom et al (103).
1.1.4 Concerted activation in retroviral leukaemogenesis
Cancer is a multi-step process of genetic and epigenetic events where tumours 
require the accumulation of multiple mutations before the fully malignant
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phenotype can develop. Although the activation of a cellular oncogene by, for 
example proviral integration, is a crucial step in this process, secondary changes 
are required for progression through multi-step carcinogenesis. A second 
proviral insertion could be one such event which offers a further selective 
advantage to the initiating tumour cell.
Thus, there are several lines of direct evidence that proviral activation of-two 
oncogenes can occur in the same tumour cell with synergistic effects on tumour 
development. For example, both c-myc and Pim- 1 have been shown to be 
activated by proviral insertion in the same tumour cell clone (74; 104). In these 
studies MuLV induced T cell lymphomas in mice resulted in the activation of one 
or both of these genes in tumours which developed after a short latency. 
Although some were oligoclonal, at least one of the tumours was found to be 
monoclonal on transplantation into a syngenic mouse (74). Together this 
suggests the presence of a modified c-myc and Pim-1 allele by proviral insertion 
within the same cell population and that this is associated with tumour onset with 
relatively short latency. This was one of the first illustrations of synergy between 
c-myc and Pim- 1 in T cell lymphomagenesis.
1.2 Identification of genes at retroviral insertion sites
The multistep evolution of tumour development can explain why most tumours 
are monoclonal in origin: only an individual cell which has accumulated the 
necessary mutations will form the fully malignant phenotype. Those which have 
not will die or become overwhelmed by the rapid proliferation of the tumour 
clone. Our understanding of the events involved in this process is constantly 
growing as an increasing number of genes are identified which are mutated or 
deregulated in cancer (see (105) for a comprehensive listing of oncogenes and 
tumour suppressor genes).
The molecular cloning of genes which have been activated by proviral insertion 
as well as the identification of genes which have been transduced by a retrovirus,
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have together been responsible for the isolation of the majority of proto­
oncogenes to date (see Table 1.1, and reviewed in (12)). Examples can be drawn 
from various growth signalling pathways where they generally have regulatory 
roles in cellular growth and development. Examples include growth factors (sis 
(PDGF)), growth factor receptors (c-er6B/(EGF-R), Gfi-2/IL-9R), cytoplasmic 
protein kinases (Pim-1, Pim-2, Tpl-2), GTPases (ras), GDP exchangers (Tiam-1), 
nuclear transcription factors (c-myc, c-myb, Bmi-1, Gfi-l, Fli-2/Nfel) and"cell 
cycle regulators (Fw-l/Cyclin D l, Fw-l/Cyclin D2). Mutations which alter the 
expression of one or more of these genes may lead to deregulated growth and 
development. The elucidation of the pathways involved in this have been central 
to cancer research and the more that is known about the various genes involved in 
this process the greater our understanding will be.
Following the discovery of a common insertion site, the arduous task of 
identifying the gene which is affected by proviral integration begins. Table 1.2 
provides an overview of a selection of common leukaemia virus insertion loci at 
which the relevant genes have been identified, a selection of which are discussed 
in more detail below. Following the identification of a transcript (most 
commonly by northern blot analysis) conventional cDNA cloning is invariably 
used to characterise the gene. However, a number of common insertion loci 
remain uncharacterised with respect to the genes involved (see Table 1.1), 
including Bla-1, D si-1, F/vz-1, Gin- 1 and Tic-1.
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Table 1.2 Identification of genes at type C retroviral insertion sites
Locus Method Other clues References
Ahi-\ Exon trapping CpG island (17; 18)
Bmi-\/Flvi-2 Northern CpG island (19;20;23)
Cb-\! Fim-3 Linkage to Evi- V (26-28)
Evi-1 Northern (30;31)
Evi-2/Nf-lb Northern Zooblot (32;33)
Evi- 3 Northern CpG; Zooblot (34)
Evi- 5 Linkage to Gfi- l a Northern (35-39)
Fis-l/Cyl-1 Linkage to CyclinDl3 CpG island (40;41)
Fit-1 Linkage to c-myb a’b (25;42)
Fli-l/Sic-l Northern (43-45)
Fli-2/Nfe-2c Northern (47;48)
Frat-\ Northern Zooblot (51)
Gfi-1 Northern (53)
Gfi-2/IL-9R Northern (55)
Mis-2 Linkage to c-myb (18)
M lvi-1 Linkage to c-myca Northern; Zooblot (60;63;64)
Mlvi-4 Linkage to c-myc and 
Mlvi-1a
Northern (63-65)
Pal-\IEvi-5 / Eis-1 Linkage to Gfi- l a (20;37-39)
Pim-1 Northern (25;79)
Tblvi-1 Northern Zooblot (84)
Tiam-1 Northern Zooblot (85)
77/-1/CBFA1 Northern Zooblot (88;89)
Tpl-\ Northern (90)
Tpl-2/Cot Northern (9l;92)
Vin-MCCND2 Northern CpG island (94;95)
a Evidence for long range activation. 
b This thesis
c Insertional inactivation.
1.2.1 Methods for the identification of genes at retroviral insertion sites
Retrovirally induced leukaemogenesis is characterised by the outgrowth of a 
clonal cell population carrying retroviral insertions at distinct regions of the 
chromosome. The term ‘common insertion site’ refers to a region of the 
chromosome which carries a proviral insertion in more than one independently 
derived tumour. Generally, a common insertion site would be identified by 
isolating a single copy DNA probe from the flanking sequence which would then 
be used on Southern blot analysis of DNAs from various tumour and control 
samples. A region of chromosomal DNA which is frequently targeted by proviral
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integration would be identified by the presence of a rearranged band in addition 
to the genomic band in more than one independently derived tumour sample.
The majority of common insertion sites are then characterised by northern blot 
analysis using unique sequence probes from the DNA flanking the provirus 
cluster. The techniques involved in this are discussed in more detail in section
3.1.3 and Figure 3.3. Usually a tumour specific transcript pattern or over­
expression of the normal transcript is detected in tumours with proviral insertion.
Other methods which have been used in the identification of genes affected by 
proviral integration include 1) Chromosomal localisation where the common 
insertion locus is linked to known genes, some of which show evidence of long 
range activation (Table 1.2 and section 1.2.6). 2) Exon trapping (106) was
developed as a strategy whereby fragments of cloned genomic DNA which have 
been spliced during cycling of the vector in the host cell may be recovered as 
cDNA. This technique has been successfully used to identify a gene at the Ahi- 1 
common site of Abelson-MuLV integration in pre-B lymphoma (P. Jolicoeur, 
Clinical Research Institute of Montreal, Canada, personal communication). 3) 
Zooblot analysis to identify DNA which is evolutionarily conserved using unique 
sequence probes from the insertion cluster which hybridise to DNA from various 
species immobilised on a Southern blot (a so-called zooblot). A unique sequence 
probe which is positive on zooblot analysis suggests conservation of this 
sequence during evolution which may be due to the presence of coding sequence.
4) CpG islands often serve as landmarks in the search for transcription units 
(107). CpG islands are clusters of non-methylated G-C dinucleotides which are 
relatively rare in eukaryotic DNA, with only a fifth of the number expected. This 
composition can be accounted for by the tendancy of methylated cytosines to 
decay to TpG and CpA while non-methylated cytosines do not (107; 108). CpG 
islands span an average of l-2kb and are often associated with the 5' ends of 
genes, particularly house-keeping genes (108; 109). They often extend beyond 
the promoter region and into the first or even second exon. Therefore, they
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represent ideal tags to identify transcripts. Restriction enzymes have been used to 
detect potential gene sequences by detecting clusters of sites for certain rare- 
cutting restriction enzymes which specifically recognise non-methylated, C-G 
containing sequences (110). Thus, by generating a long-range restriction map 
with such restriction enzymes using pulsed-field gel electrophoresis (PFGE), a 
number o f proto-oncogenes have been detected by association with CpG islands 
(see Table 1.2).
Discussed below is an overview of a selection of genes identified at common 
insertion sites, principally by northern blot analysis with DNA probes from the 
locus. Other evidence for the presence of a gene at these loci will also be 
discussed.
1.2.2 The Pim family
The Pim-1 gene, which was first identified as a common proviral integration site 
in M-MuLV induced murine T cell lymphomas (79), encodes a serine/threonine 
protein kinase (80). The gene affected by M-MuLV insertion at Pim- 1 was 
identified by northern blot analysis with probes derived from DNA flanking the 
insertion cluster. Proviral insertions were 3' and in the same transcriptional 
orientation as the gene, therefore enhancer insertion was proposed as the 
mechanism of activation of Pim-1. Pim-1 was also identified as the target of 
FeLV integration in feline T cell lymphomas where rearrangements were 
observed in both spontaneously and experimentally induced lymphomas with 
FeLV or FeLV-rayc isolates (25).
Pim- 1 knockout mice exhibit very subtle phenotypes (14;81) implying functional 
redundancy between Pim- 1 and other genes (discussed further in section 1.3.3). 
Indeed two additional Pim family members were identified in this system which 
may be able to compensate for the loss of Pim-1. Pim-2, not to be confused with 
Tic- 1 which was formerly known as Pim-2 (86), was identified in Pim- 1 null 
mutant mice using degenerate PCR primers (81). Furthermore, Pim-2 was a 
frequent site of proviral integration in tumours induced by M-MuLV infection in
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these mice. cDNA cloning revealed that Pim-2 is 53% identical to Pim -1 at the 
amino acid level and northern blot analysis demonstrated that the normal gene is 
over-expressed by enhancer insertion in lymphomas with proviral insertions at 
Pim-2 (81). The oncogenic potential of Pim-2 was demonstrated when an 
activated copy of this gene was introduced into the germline of mice (82). In this 
study, Pim-2 transgenic mice were predisposed to T-cell lymphomas similar to 
those of Pim-1 transgenic mice. Furthermore, these mice exhibited a strong 
synergy with an Ep-myc transgene in pre-B cell leukaemia with a latency of 3 to 
4 weeks.
In an analogous system, another Pim family member, Pim-3, was detected as a 
common M-MuLV insertion site in tumours from Pim-1/2 knockout mice again 
in conjunction with a degenerate PCR approach (14).
1.2.3 Bmi-llFlvi-2
Bmi-l was identified as a target for retroviral insertion in E \x-myc transgenic mice 
infected with M-MuLV (19;20) and in FeLV-myc induced feline lymphomas (23) 
resulting in B and T cell lymphomas respectively. The coding potential of this 
common insertion locus was identified primarily by screening for CG-rich 
sequences using rare cutting restriction endonucleases (20). Probes flanking the 
CpG island were then used on northern blot analysis to identify a transcript which 
was over-expressed in tumours carrying insertions near Bmi-l. The enhanced 
expression was due to either enhancer insertional activation or promoter insertion 
where the relatively strong 3' LTR drove transcription leaving the coding domain 
intact (19;20;24). The oncogenic potential of Bmi-l was formally established in 
bitransgenic E\x-Bmi-l/myc mice (111), substantiating the synergy between Bmi- 
1 and Myc. However, this relationship may not be exclusive (1 ;25) implicating 
activation of Bmi-l as an early event in the development o f lymphoma.
Bmi-l is highly conserved in evolution and encodes a protein with homology to a 
family of nuclear transcription factors which contain a cysteine-rich zinc finger 
binding domain, termed RING finger (19;20). The Drosophila homologue of
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Bmi- 1 was subsequently found to share homology with the polycomb group (Pc- 
G) of transcription factors which are responsible for maintaining the segment 
specific repression of homeotic genes, such as Posterior Sex Combs, during 
Drosophila development (21;22).
1.2.4 The Gfi-1 locus
The Gfi- 1 common insertion locus was identified in a rat T lymphoma interleukin 
2 (IL-2) dependent cell line where it is involved in the progression to IL-2 
independence (53). The gene affected by proviral integration was identified by 
northern blot analysis and was found to be highly expressed in cell lines carrying 
insertions at Gfi-1, primarily owing to transcription initiating from the proviral 
LTR. However, additional tumour cell lines with no Gfi-1 rearrangement also 
exhibited high levels of Gfi-1 transcript. Subsequent studies have shown that 
proviral integrations at Gfi-1 and its surrounding loci, Pal-l/Evi-5/Eis-l, all 
appear to upregulate Gfi-l transcription suggesting that Gfi- 1 is the target for 
insertions at these loci (37-39). Insertions at these loci which are located within a 
50kb domain, are thought to activate Gfi-l by a long range enhancer insertion 
mechanism operating over distances of up to 25kb.
1.2.5 The Evi genes
A number of common ecotropic MuLV insertion sites have been identified in 
tumours in AKXD or BXH-2 recombinant inbred mice: Evi-1, 2, 3 and 5 
(30;32;34;35).
Evi-l was identified as a common site of integration in AKXD-23 mice which 
developed myeloid tumours at a high frequency (30). Subsequently, integration 
at Evi- 1 was shown to activate a novel gene with homology to the zinc finger 
family of transcription factors in IL-3 dependent myeloid leukaemia cell lines 
which have failed to differentiate (31).
Upregulation of Evi- 1 transcription was shown to be due to promoter insertional 
activation where transcription initiates in the 5' or 3' LTR. However,
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integrations at the Cb-HFim-3 common F-MuLV insertion locus 90kb from Evi- 
1, were also shown to activate transcription of Evi-l (26-28). Evidence that 
integration at Cb-l/Fim-3 activates Evi-1 transcription in cis is several-fold. 
Firstly, no transcript sequences have been identified at the Cb-l/Fim-3 locus. 
Secondly, the proviral insertions at Fim-3 are all orientated 5' and in the opposite 
transcriptional orientation to Evi-\ suggesting an enhancer insertional activation 
mechanism. Indeed, enhancers have been shown to be active from distances of 
up to 300kb (41;64). Furthermore, in cells which are rearranged at Evi-1, one 
allele of the Evi-l gene was shown to be hypermethylated while none of the 
myeloid cell lines lacking Evi-1 rearrangements showed hypermethylation. 
However, /rypermethylation is normally associated with gene inactivity (112). 
Bartholemew et al (28) proposed that hypermethylation o f Evi-l might allow the 
interaction with proteins which specifically bind to methylated DNA to realise 
their tumorigenic potential.
Transcripts at the Evi-2 locus were identified by northern blot analysis using a 
unique sequence probe which was found to be evolutionarily conserved on 
zooblot analysis (32). cDNA cloning identified the Evi-2 gene as a leucine zipper 
transmembrane protein which is the murine homologue of the human 
neurofibromatosis type 1 (NF-1) tumour suppressor gene. NF-1 encodes a 
GTPase activating protein, neurofibromin, which is involved in the development 
of neurofibrosarcomas and myeloid leukaemia (32). Integration at Evi-2 resulted 
in the production of truncated Nf-\ transcripts and no stable, full length 
neurofibromin (33). Furthermore, the other Nf-\ allele was shown to be 
inactivated in one case by a second proviral insertion at Evi-2.
A cluster of proviral insertions at Evi-3 were shown to occur within a CpG island 
suggesting that they may lie within the 5' region of a gene. Further evidence that 
a gene is located in this region came from zooblot analysis with unique sequence 
probes which were found to be evolutionarily conserved. Promoter insertion is 
the most likely mode of activation since proviruses were inserted in the same
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transcriptional orientation within a CpG island resulting in the inappropriate 
expression of Evi-3 transcripts during B cell lymphomagenesis (34).
As discussed above, proviral insertion at the Evi-5 common insertion site has 
been shown to activate the Gfi-l oncogene which is located 18kb downstream of 
Evi-5 (35;37-39). However, a recent study has identified a novel transcript by 
northern blot analysis which is activated by proviral integration within the 3' 
UTR of the Evi-5 gene (36). Zooblot analysis showed that, not only is Evi-5 well 
conserved, but that it is a member of a multigene family consisting of three 
homologous genes. Although the coding potential of Evi-5 has not been directly 
demonstrated, the Evi-5 transcript does show homology to cell cycle regulators 
thus suggesting a role for Evi-5 in cell cycle control, the over-expression of 
which may be involved in the development of T cell lymphoma.
1.2.6 Mlvi-1 and Mlvi-4
M-MuLV induced rat T cell lymphomas has led to the identification of two 
common insertion loci which map close to the c-myc proto-oncogene on rat 
chromosome 7: M lvi-1 which mapped 270kb 3' of c-myc and was found to be 
identical to the pvt-MMis-2 locus (60;61); and Mlvi-4 which mapped 30kb 3' of 
c-myc (65). Genes at both loci have been identified which are activated by 
proviral insertion. At the Mlvi-1 locus a tumour specific RNA transcript was 
identified by northern blot analysis using an evolutionarily conserved probe from 
immediatedly 5' o f the insertion cluster (63). At the Mlvi-4 locus a tumour 
specific transcript was also identified by northern analysis, which was activated 
by promoter insertion and is transcribed in the same transcriptional orientation as 
c-myc (65).
In addition to activation of Mlvi-1 transcripts, provirus insertion at M lvi-1 has 
also been shown to activate c-myc expression 270kb away (63). Similarly, 
insertion at Mlvi-4 activates c-myc, Mlvi-l and Mlvi-4 expression (63;65). Thus, 
provirus insertion in the Mlvi-4 locus affects the expression of at least three genes 
within 300kb.
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The ability of proviruses at either locus to exert a long range cis effect on Myc 
expression was demonstrated by cell hybrid analysis (64). Cell hybrids between 
two rat T lymphoma cell lines carrying a provirus in either M lvi-1 or Mlvi-A and a 
murine T lymphoma line demonstrate that enhanced expression of rat c-myc co­
segregated with the rearranged M lvi-1 or 4 loci whereas expression of murine c- 
myc was unaffected. This provides direct evidence of the ability of Viral 
enhancer elements to exert their effects in cis over large distances of up to 300kb 
and is substantiated by other reports o f regulatory elements which can act over 
long distances in cis. For example, a translocation (6; 15) in murine 
plasmacytomas, termed pvt-1, which joins c -myc to the immunoglobulin k  locus 
results in the over-expression of c-myc over a distance of at least 72kb (113). 
This translocation is functionally equivalent to M-MuLV integration at Mlvi-1, 
illustrating the value of this approach in the identification of genes involved in 
the development of human neoplasia.
1.2.7 Progression loci: Tiant-1, Tpl-\ and Tpl-2
Retroviral tagging is not only useful in the identification of dominant oncogenes, 
but can also provide insight into subtle functions involved in tumour progression. 
By a method of proviral tagging in combination with in vitro selection for 
invasiveness, Tiam-1 was identified in T cell lymphoma (85). Invasive variants 
of a T cell lymphoma line were generated by MuLV infection and selection for 
their ability to infiltrate monolayers of fibroblasts. An evolutionarily conserved 
probe identified the Tiam-1 transcript which was activated by proviral insertions 
resulting in both N- and C-terminal truncated proteins. The predicted Tiam-1 
protein shows homology with GDP-GTP exchangers. Transfection studies of 
non-invasive cells showed that the invasive phenotype was induced with both Isl­
and C-terminally truncated Tiam-1 fragments suggesting a direct role for Tiam-1 
in invasion during T cell lymphomagenesis.
Two additional progression loci have been identified by prolonged culture of 
cells derived from M-MuLV induced rat T cell lymphomas: Tpl-\ (90) and Tpl-2
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(92). Genes have been identified at both these common insertion loci by northern 
blot analysis where they were found to encode respectively an ets transcription 
factor and a cot serine/threonine protein kinase involved in the MAP kinase 
pathway (90-93).
1.2.8 Myc
Discussed above is an overview of a selection of oncogenes which have been 
identified by retroviral insertional mutagenesis (Table 1.2). However, many 
common insertion loci have been found to correspond to proto-oncogenes which 
have already been identified by other means. For example, Myc has been 
identified by chromosomal translocation in Burkitt’s lymphoma (114), gene 
amplification (115), as an oncogenic sequence transduced by acute-transforming 
retroviruses (7-9; 116) as well as by retroviral insertional activation by ALV (11), 
MuLV (73;74) and FeLV (7). Both promoter and enhancer insertional activation 
have been observed in retrovirally induced T and B cell lymphomas. In general, 
the enhanced expression of an otherwise normal Myc protein is significant for 
tumorigenesis, rather than a structural change.
The expression of c-myc is a key feature of proliferating cells (117) and the over­
expression of Myc due to the loss of the normal control predisposes to tumours 
(118; 119). A significant role for Myc in feline thymic lymphomagenesis was 
demonstrated when FeLV carrying a transduced myc gene (FeLW-myc) was 
inoculated into newborn kittens. The induction of T cell lymphoma occurred 
with a relatively short latency, usually within 12-14 weeks, compared to 
approximately 2 years with standard FeLV strains (3;4). However, these tumours 
were invariably clonal or oligoclonal in origin (4) suggesting that additional 
events are required to induce complete transformation. This observation is 
consistent with both the hypothesis of multistep tumorigenesis (120) and previous 
studies suggesting that Myc alone is insufficient to cause disease (121). A 
significant emphasis has, therefore, been placed on the identification of genes 
which could collaborate with Myc in tumours induced with FeLV-myc 
(23;25;42;49). This system is analogous to proviral tagging of E\x-myc transgenic
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mice to identify collaborating oncogenes discussed in section 1.3 (19;20). It is 
worth noting, however, that the outbred domestic cat has one major advantage 
over highly inbred mouse models in that it gives greater insight into natural 
disease processes.
The v-myc gene was first detected in avian myelocytomatosis virus MC29 as a 
transduced gene which was responsible for the transforming potential of" this 
retrovirus (116). The c-myc gene is now known to be a member of a family of 
proto-oncogenes which also includes N -myc (122) and L-myc (123). The 
proteins encoded by the various Myc genes are nuclear phosphoproteins with very 
short half-lives which can bind DNA (reviewed in (124)). Myc contains, in 
addition to the N-terminal transactivation domain, a number of C terminal motifs 
reminiscent of a nuclear transcription factor, namely a basic region, a helix-loop- 
helix motif and leucine zipper domain (Figure 1.4). These regions confer the 
ability of Myc to bind DNA in both a sequence specific and non-specific manner 
(125).
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Figure 1.4 Structure of the Myc protein. The major Myc domains are illustrated: 
transactivation domain; acidic domain, NLS, nuclear localisation domain; BR, 
basic region; F1LH, helix-loop-helix domain; LZ, leucine zipper domain. Also 
shown are the alternative N-terminal regions which initiate translation from a 
CUG codon in exon 1 (p67 Myc product) or from a AUG codon in exon 2 (p64 
Myc product).
Furthermore, the C-terminal domain is responsible for hetercdimerisation with 
the Myc binding partner, Max (126). Max is a highly stable protein which also
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contains a helix-loop-helix motif and leucine zipper domain but which lacks the 
transactivation domain. Max is capable o f forming homodimers but 
preferentially forms heterodimers with Myc. Moreover, Max binding has been 
shown to be required for efficient DNA binding and transformation by Myc 
(127; 128). Therefore, the transcriptionally inactive, stable Max homodimer 
which can bind DNA acts as a repressor of Myc in quiescent cells. Max is 
relieved of its repression by the over-expression of c-myc during proliferation by 
shifting the equilibrium towards the active Myc-Max heterodimers (129). Max 
can also form heterodimers with its alternative partners, Mad and Mxi-1, and 
these complexes also serve as antagonists of the active Myc/Max heterodimer by 
sequestering Max and through competition for DNA binding targets (130).
Myc was shown to be directly involved in the control of growth factor dependent 
proliferation when microinjection of c-Myc protein into the nuclei of quiescent 
cells resulted in the stimulation of DNA synthesis (117). Furthermore, the 
expression of c-myc increases as quiescent cells enter the Gj/S phase of the cell 
cycle (Figure 1.5). Although the levels of c-myc increase dramatically when 
resting cells enter the cell cycle, c-myc expression is invariant throughout the cell 
cycle (131). Downregulation of c-myc correlates with the onset of differentiation 
and enforced expression has been shown to inhibit differentiation. Therefore, it 
was proposed that Myc acts as a molecular switch directing cells either to 
terminal differentiation or continued proliferation (132).
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Figure 1.5. c-Myc and the cell cycle. The levels of cellular c-Myc increase 
during the Gj/S phase of the cell cycle and decrease as cells enter G0. The effects 
of over-expression of c-Myc (in parenthesis) on terminal differentiation is also 
indicated.
Myc is tightly controlled by both growth factors and the repressors Max and Mad 
(130). Tight control of Myc is paramount because of its involvement in the 
control of proliferation where the inappropriate expression of c-myc could lead to 
uncontrolled growth and cancer. The risk of Myc over-expression may be 
lessened by its tendency to promote apoptosis instead of proliferation in the 
absence of suitable survival factors (Figure 1.6). High levels of Myc allow the 
cell to enter the cell cycle and divide when stimulated by mitogens, but in the 
absence of survival factors, the cell will die by apoptosis (133). However, in 
cancer cells the over-expression of Myc often leads proliferation even when no 
exogenous mitogenic signal is present. The apoptotic cell death which would 
normally occur in response to Myc can be prevented by the co-expression of the 
anti-apoptotic gene, Bel-2 (134; 13 5). Other genes which cooperate with Myc in 
tumorigenesis could also influence this decision of life or death by rescuing cells 
from Myc-induced apoptosis, thus maintaining the continued survival o f the cell. 
Therefore, the identification of genes which synergise with Myc in this process 
represents a major goal in cancer research and is discussed further in section 1.3.
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Figure 1.6 Myc links the decision between proliferation and apoptosis by the 
presence or absence of survival factors (SF).
1.3 Retroviruses as tools to study multistage tumorigenesis
1.3.1 Proviral tagging in transgenic mice
Proviral tagging in mouse model systems has made an important contribution to 
our understanding of the sequential steps involved in the accumulation of 
mutations resulting in cancer (for reviews see (12; 136)). When an oncogene such 
as c-myc is transferred to the germline of the mouse genome under the control of 
the immunoglobulin heavy chain enhancer (E\x-myc), the transgenic animals 
invariably develop B cell lymphomas (19;20). However, the tumours occur with 
variable latency and are generally monoclonal, suggesting that the abnormal 
expression of the transgene in itself is not sufficient for the development of 
malignancy but that other additional events are also required for full 
transformation.
Thus, the expression of an oncogene in transgenic mice can be viewed as the 
initiating event in the multistage process. In an effort to identify the events which 
cooperate with the transgene in tumorigenesis, proviral tagging has successfully 
been employed (19;20;81;87;88;137). M-MuLV infection of newborn mice 
which carry the transgene in their genome characteristically show a dramatic 
increase in the incidence and acceleration of the development of tumorigenesis 
compared to their non-transgenic littermates. Thus, identifying genes at common 
insertion sites in these tumours represents an efficient way of identifying gene(s) 
which synergise with the transgene. However, even the tumours induced in this
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way are generally mono- or oligo-clonal suggesting that further events are 
involved in the development of the fully malignant phenotype. This is in 
agreement with the conjecture that 3-6 separate events are required for 
tumorigenesis (reviewed in (1)).
The first reported use of proviral tagging in transgenic mice was in 1989 by van 
Lohuizen et al. Ep-Pzm-1 transgenic mice neonatally infected with M-MuLV 
showed a rapid acceleration of T lymphomagenesis compared to their non- 
transgenic littermates (137). The oncogene Pim -1 encodes a cytoplasmic 
serine/threonine protein kinase (80) and was originally discovered as a common 
insertion site in M-MuLV induced thymic lymphomas (79). E\i-Pim-\ transgenic 
mice showed a low incidence of clonal tumours after a long latency of around 7 
months. However, on infection with M-MuLV, clonal T lymphomas developed 
after 7-8 weeks in transgenic animals compared to 22 weeks in non-transgenic 
controls. In all these lymphomas either c-myc (80%) or N -myc (20%) was 
activated by proviral insertion resulting in high levels of expression of the 
respective Myc genes. This strongly suggests that Pim-1 can cooperate with both 
c- and N-myc in T cell lymphomagenesis. Formal confirmation that Pim -1 and c- 
myc directly synergise in lymphomagenesis came when E \x-myc mice were 
crossed with E\i-Pim-\ mice to yield double transgenic mice over-expressing 
both oncogenes (138). These mice developed pre-B cell lymphomas in utero, 
and represent the strongest collaboration observed between c-myc and another 
oncogene to date. However, despite their severe phenotype and the speed of 
onset, the lymphomas of these double transgenic mice were frequently clonal 
indicating that further events had occured during the development o f the cancer.
The system described above led to the identification of genes which collaborate 
with Pim-1 in lymphomagenesis. To determine whether genes which collaborate 
with c-myc in B cell lymphomagenesis could be identified in the same way, Ep- 
myc transgenic mice were infected neonatally with M-MuLV (20). In addition to 
the anticipated activation of Pim-1, three novel common insertion sites were 
identified: Bmi-1, Pal-1 and Bla-1. Together they encompassed 75% of these
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tumours suggesting there are still a number of genes activated by proviral 
insertion in these lymphomas which can also synergise with c-myc. A similar 
study led to the identification of not only Pim-1 and Bmi-\ as potential 
collaborators with c-myc, but also the novel loci Tic-\ (previously known as Pim- 
2) and Emi-1 (19).
In another Myc/Pim-1 bitransgenic system, Gfi-\ and its neighbouring loci, Pal- 
l/Evi-5/Eis-l, were identified as targets of proviral integration in a high 
percentage of the tumours which arose following neonatal retroviral infection of 
these mice (37-39). All of these integrations resulted in the over-expression of 
Gfi-1 suggesting that the zinc finger protein efficiently cooperates with both Myc 
and Pim-1 in the development of T cell lymphomagenesis. This system also 
identified Tiam-1 as a target for M-MuLV integration in 12% of the tumours, 
suggesting that this gene can also act in concert with Myc and Pim-1 in 
tumorigenesis.
Other transgenic systems have been generated to identify novel genes involved in 
tumorigenesis. For example, c-myc has been linked to a T cell specific regulatory 
element, the locus control region from the human CD2 gene. This results in the 
over-expression of Myc specifically in the T cell compartment (139). In M- 
MuLV accelerated lymphomas of CD2-myc transgenic mice, the 77/-1 locus was 
identified as a common site of retroviral integration in 33% of the T cell tumours 
(88). Viral insertions at 777-1 have subsequently been found to transcriptionally 
activate the CBFA1 (PEBP2aA) transcription factor, suggesting that this gene 
also cooperates in the development of T cell lymphoma (89).
Proviral tagging of transgenic mice and subsequent transplantation of primary 
tumours to syngeneic hosts represents another variation on the theme. This 
provides an opportunity to identify novel genes contributing to tumour 
progression. The novel proto-oncogene Frat-1 was identified in this way (51). 
Primary tumours of Pim-1 or Myc transgenic mice induced by M-MuLV were 
transplanted and the resultant tumours analysed to identify common insertion
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loci. Frat-1 was found to be activated in a minor fraction of primary tumours, 
while the transplanted tumours were rearranged in 17% and 30% of tumours in 
the Pim-1 and Myc transgenic mice respectively. Thus a novel oncogene has 
been identified which collaborates with both Pim -1 and Myc in T cell 
lymphomagenesis which is specifically involved in tumour progression.
By analogy to studies of proviral tagging of transgenic mice to identify genes 
which collaborate with the transgene, the initiating event may be a transduced 
oncogene introduced with the viral inoculum. For example, Tsatsanis et al 
showed that FeLV carrying a transduced Myc allele led to the identification of 
genes which act in concert with Myc in the accelerated T cell lymphomas (25). 
Thus, Flvi-2 (the feline homologue of Bmi-1), Pim-1 and Fit-\ can collaborate 
with c-myc in T cell lymphomagenesis in the cat.
1.3.2 Complementation groups
Certain combinations of activated oncogenes confer a selective growth advantage 
on a tumour cell, while others do not. As discussed above, proviral tagging has 
been a very useful strategy for the identification of genes which can synergise 
during tumorigenesis in transgenic mice. However, some combinations of 
activated oncogenes are never observed together in these systems. For example, 
in E\x-Pim-\ transgenic mice infected with MuLV, the tumours frequently had 
activated c- and N -myc genes (137). However, the activation of both genes was 
never observed in a single cell. This suggests that not only is Myc an efficient 
collaborator of Pim-1, but that the activation of c-myc does not offer any further 
selective growth advantage to a cell which is already carrying an activated N-myc 
gene, and vice versa.
From this, and other experiments, the concept of complementation groups 
evolved where c-, N- and L-myc belong to the same complementation group 
(Figure 1.7). Genes which have the ability to complement or substitute for 
another gene are often part of the same gene family which have similar functions 
or act in the same growth control pathway, for example the Myc gene family.
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However, as discussed below, some examples exist where genes appear to fall 
into the same complemention group but which are structurally unrelated, for 
example Bmi-1 and Gfi-l. The observation that many oncogenes show functional 
overlap suggest that a limited number of growth control pathways are involved. 
The elucidation of the functions of redundant genes in growth and development 
will lead to an increased understanding of these processes and how they are 
deregulated during tumorigenesis.
c-myc 
N -myc 
L -myc
Pim- 1 
Pim-2 
Pim-3
Bmi-\IBla-\
Gfi-1*
Pal- 1 
Eis- 1 
Evi-5 _  
Bel- 2
Figure 1.7 Oncogene complementation groups. There are three main 
complementation groups of structuarlly or functionally related oncogenes which 
were originally described by A. Bems et al (39) by establishing synergy in 
double transgenic mice. The asterisk next to Gfi-l signifies that this gene is the 
target of insertions at Pal-\/Evi-5/Eis-l.
Integrations within the Gfi-l/Pal-l/Evi-5/Eis-l locus are mutually exclusive with 
activation of Bmi-1 indicating that they fall within the same complementation 
group (19;20;38;39). Furthermore, activation of Bmi-1 in lymphomas of M- 
MuLV infected E\x-bcl-2 transgenic mice is never seen, although c-myc is a 
frequent target of proviral insertion in this system. Thus, Bmi-1 and Bel-2 may 
also fall within the same complementation group along with Gfi-1, all of which 
can synergise with Myc in lymphoma development.
This strong synergy with Myc can be rationalised by looking at the functions of 
Bmi-1, Bel-2 and Gfi-l. The Gfi-l proto-oncogene encodes a zinc finger
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repressor protein which collaborates with Myc in lymphomagenesis (111). A 
recent report from Grimes et al demonstrates that over-expression of the Gfi-1 
proto-oncogene represses Bax expression and inhibits T cell death (54). They 
show that the promotion of interleukin 2 (IL-2) independence by Gfi-1 in an IL-2 
dependent T cell line is not only due to stimulation of cell cycle progression, but 
also to inhibition of apoptosis. This anti-apoptotic property can be directly 
attributed to the repression of Bax, a member o f the Bel-2 gene family. The over­
expression of Bel-2 inhibits apoptosis (140), whereas Bax can induce apoptosis 
(141). Therefore the repression of Bax by Gfi-1 is thought to inhibit apoptosis, 
possibly by modulating the balance between Bax and Bel-2. Thus the over­
expression of Gfi-1 is equivalent to the over-expression of Bel-2 during 
oncogenesis. This could explain the strong collaboration of Gfi-1 and Myc during 
tumorigenesis since c-myc induced apoptosis is inhibited by Bel-2 (134; 135), for 
which Gfi-1 may be able to substitute. Furthermore, this might explain the 
functional redundancy between activation of Gfi-l and Bel-2 because both have 
an inhibitory effect on apoptosis when over-expressed.
Bmi-1 is another oncogene which has been shown to collaborate with Myc in 
tumorigenesis (111) and has been placed within the same complementation group 
as Gfi-l and Bel-2 (39;87). As for Gfi-l and Bel-2, it has been suggested that 
activation of Bmi-l may act to inhibit apoptosis (87), although this has not been 
formally demonstrated. Again this might explain the strong collaboration 
between Myc and Bmi-l. Thus the activation of B m i-l, Bel-2 and Gfi-l in any 
combination is rarely seen during tumorigenesis since this would not offer that 
cell any further growth advantage.
1.3.3 Complementation tagging
Complementation tagging is a further approach which has been developed to 
investigate the pathways in which oncogenes act in multi-step tumorigenesis 
(14;81). This technique involves proviral tagging in mice where the gene of 
interest has been deleted. Complementation tagging has been successfully used 
to identify genes which can substitute for the Pim-1 gene (81). As discussed
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before Pim-1 and c-myc are strong collaborators in lymphomagenesis. Therefore, 
proviral tagging in E\i-myc mice which lack a functional Pim -1 gene (Ep- 
myc/Pim-X'1') should identify gene(s) which act downstream or in parallel to Pim- 
1 in lymphomagenesis and which can collaborate with c-myc. Together with a 
PCR-based screen, Pim-2 was identified as a common insertion site in 80% of 
these tumours (81). Pim-2 was found to be 53% identical to Pim -1 at the amino 
acid level and Ep-Pzm-2 mice were very similar to E \x-Pim-1 mice in oncogenic 
behaviour. In addition, the activation of Pim-2 in mice lacking functional Pim-1 
could rescue the Pim-1 null phenotype (82). Furthermore, the functional 
redundancy between Pim-1 and Pim-2 was demonstrated by the lack of activation 
of Pim-2 in M-MuLV induced lymphomas of Ep-Pzm-l mice (81). Both genes 
can collaborate with c-myc and Gfi-1 or Bmi-l (39;82).
In a parallel study, transgenic E\i-myc mice which were homozygous null for 
both Pim-1 and Pim-2 were infected with M-MuLV (14). Again Bmi-1 and the 
Gfi-\/Pal-\/Evi-5/Eis-l locus were frequent targets of proviral insertional 
activation. However, two novel common insertion sites were also identified: 1) 
Pim-3, which is closely related in sequence to the other two Pim family members; 
and, 2) cot, a serine/threonine kinase which was identified as the mouse 
homologue of the Tpl-2 common insertion site in rats (92). Thus, 
complementation tagging of Myc collaborating oncogenes which are functionally 
equivalent to Pim -1 has led to at least three oncogenes which may act 
downstream or in parallel to Pim-1 in tumorigenesis.
In conclusion, proviral tagging in transgenic mice has led to the assignment of at 
least three major complementation groups which can all collaborate with each 
other but not with members of the same group (Figure 1.7 and (39)). 1) The Myc 
family of structurally and functionally related oncogenes (c-myc, N-myc and L- 
myc). 2) The Pim family of structurally and functionally related of oncogenes 
(Pim-1, Pim-2 and the recently identified Pim-3). 3) The group of structurally 
unrelated, putative anti-apoptotic oncogenes (Bel-2, Gfi-1 and Bmi-1). Although
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Bmi- 1 has been assigned to the latter group, its function as an inhibitor of cell 
death is circumstantial (87).
1.4 Aims
The aim of this study was to identify the gene which is targeted by retroviral 
integration at the Fit-l locus in FeLV-myc induced T cell lymphomas o f the 
domestic cat. The Fit- 1 common insertion locus was previously found to be 
occupied by an FeLV pro virus in 16% of tumours screened using a single copy 
probe flanking the insertion site from one of these tumours (25;42). Despite the 
isolation of a conserved open reading frame from within the major insertion 
cluster and 30kb of cloned genomic DNA, no transcription units affected by 
proviral insertion in these tumours was identified. However, the recently 
generated FT1 cell line which is rearranged at both Fit- 1 and c-myc allowed a 
more thorough analysis of the Fit-1 locus to search for a gene affected by 
insertion by screening for sequences that are single copy, conserved in evolution 
and expressed as RNA.
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Chapter 2
2. Materials and Methods 
2.1 Materials
Described below are a number of the most commonly used reagents.
2.1.1 Eukaryotic cell lines
FT1: A feline T cell line which was established from a spontaneous thymic 
lymphosarcoma with a FeLV integration at c-myc (142) and at Fit-1.
3201: FeLV negative feline T cell line with a germ line rearrangement of c-myc 
derived from a naturally occurring thymic lymphosarcoma (143).
F422: Feline T cell line, containing an FeLV transduced with w-myc, established 
from a thymic lymphosarcoma of a kitten inoculated with the second passage of 
the Rickard strain of FeLV (144).
T3: FeLV positive lymphoid tumour cell line established from a naturally
occurring thymic lymphosarcoma, contains a replication-competent FeLV helper 
and recombinant FeLV provirus with a w-myc oncogene (7).
T17: FeLV positive cell line established from a naturally occurring thymic
lymphosarcoma, contains transduced c-myc and T cell receptor (3 chain, as well 
as helper virus (145).
FL74: FeLV positive cell line established from a naturally occurring thymic 
lymphosarcoma (146).
M val: Interleukin 2-dependent feline T-lymphoblastoid cell line (147).
CEM: Human T lymphoblastoid cell line derived from peripheral buffy coat of a 
4 year old Caucasian female with acute lymphoblastic leukaemia (148)
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Jurkat: The Jurkat E61 clone is a human acute T cell leukaemia cell line (149).
SupT l: Human T cell lymphoblastic lymphoma line (150).
2.1.2 Bacterial strains
E. coli D H 5a: MAX Efficiency DH5a Competent Cells, Life Technologies, 
GibcoBRL.
E. coli IN V aF ': One Shot Competent cells, Invitrogen. F' endAX recAX hsdRX7 
(rk‘, m k+) supE44 thi-1 gyrA96 relAX (j)80/<2cZAM15 A(lacZYA-arg¥)U\69 X'.
E. coli TOP 10: One Shot Competent cells, Invitrogen. F" mcrA A(mrr-hsdRMS- 
mcrBC) (|)80/<2cZAM15 AlacX74 recAX deoR araDX39 A(ara-leu)7691 galU 
galK rpsL (StrR) endAX nupG.
2.1.3 Cloning vectors
pCR2.1: lacZ+, amp\ kan\ T7 promoter and priming site, M l3 forward and
reverse primer annealing sites. Plasmid vector for the direct insertion of a PCR 
product that has been generated by Taq polymerase which has a non-template 
dependent activity that adds a single deoxyadenosine to the 3' ends of PCR 
products (Invitrogen).
pCRII: As above but also has SP6 promoter and priming sites (Invitrogen).
pUC18/19: pBR322 based cloning vector. lacZ+, amp\ multiple cloning site and 
M l3 forward and reverse primer annealing sites (GibcoBRL).
pBluescriptll KS/SK: A pUC19 derived phagemid. lacZ+, amp\ multiple cloning 
site and M13 forward and reverse primer annealing sites (Stratagene).
2.1.4 Chemicals and enzymes
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Most of the chemicals used were purchased from Sigma, BDH, Boehringer 
Mannheim, Pharmacia or GibcoBRL unless otherwise stated. All chemicals were 
of Analar quality. Enzymes and the appropriate buffers were purchased from 
GibcoBRL Life Technologies unless otherwise stated.
2.1.5 Radiochemicals
a (32P) dCTP, specific activity 3000Ci/mmol was supplied by Amersham Life 
Science.
2.1.6 Media and antibiotics
L. broth: 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) sodium chloride 
in ddH20  autoclaved and stored at room temperature.
L-aear: as for L-broth but also containing 1.5% (w/v) agar.
2 X YT: Bacto-tryptone, bacto-yeast extract, NaCl (GibcoBRL). 31gm adeup in  
1 litre of ddH20 , autoclaved and stored at 4 °C.
Ampicillin: 50mg/ml in ddH20  . Filtered through a 0.22pm filter, aliquotted and 
stored at -20°C. Used at a final concentration of lOOpg/ml.
Kanamvcin: As above but used at a final concentration of 25pg/ml.
RPMI-1640: Tissued culture medium supplemented with 10-20% foetal calf
serum (FCS), lOOunits/ml penicillin, lOpg/ml streptomycin and 2mM glutamine 
(all GibcoBRL).
Ciprofloxacin: Anti-mycoplasma antibiotic added to tissue culture medium as 
necessary to a final concentration of lOpg/ml (Miles, Bayer Diagnostics).
2.1.7 Stock solutions and general reagents
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Ammonium persulphate: 10% (w/v) stock solution in ddH20 , freshly made.
Denaturation buffer: 1.5M NaCl, 0.5M NaOH in dH20 . Stored at room
temperature.
Denhardt’s solution f50XL 1% bovine Serum Albumin (BSA), 1% Ficol, 1% 
polyvinyl pyrollidone in ddH20 . Aliquoted and stored at -20°C.
DNA size markers: <|>X174 RF DNA///aeIII fragments and XDNA///mdIII
fragments (GibcoBRL). 5kb ladder and X ladder (Bio-Rad).
DEPC-treated ddFFO: For RNase free H20 , ddH20  was treated with 0.05% 
diethyl pyrocarbonate (DEPC) overnight at room temperature. To remove any 
trace DEPC, the DEPC-H20  was autoclaved for 30 minutes at 151b.
Ethidium bromide: lOmg/ml stock in ddH20 . Working concentration 0.5pg/ml. 
Stored at room temperature protected from light.
Gel loading buffers:
1. DNA- 50% glycerol, 0.5% bromophenol blue, 0.5% xylene cyanol, lOOmM 
EDTA in ddH20 . Stored at room temperature and used at a 1:10 dilution.
2. RNA - 50% formamide, 2.2M formaldehyde, IX MOPS, in ddH20 . Made 
fresh.
Gene screen f20X): 0.5M NaH2P 0 4, 0.5M Na2H P04, pH6.5. Stored at room 
temperature.
High Prime: Premixed solution for random primed DNA labelling using (a 32P) 
dCTP and random oligonucleotides as primers (Boehringer Mannheim).
Hvbond N/N+: Nylon membrane for the transfer of nucleic acids (Amersham 
Life Science).
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MOPS buffer (lOXk 200mM MOPS pH7.0, 50mM potassium acetate, lOmM 
EDTA. Stored at 4°C in the dark.
Neutralisation buffer: 1.5M NaCl, 0.5M Tris-HCl pH8.0 in dH20 . Stored at 
room temperature.
Nick column: Sephadex G-50, Pharmacia Biotech, stored at room temperature.
Oligonucleotides: Unlabeled and IRD-41 fluorescent labeled oligonucleotides 
were synthesised by MWG Biotech. Unlabeled oligonucleotides resuspended to 
1 mg/ml in ddH20 , IRD-41 labeled oligonucleotides to lpmol/pl. Stored at -20°C 
(IRD-41 labeled oligos were also protected from light).
Polyacrylamide solution: Acrylamide/Bis acrylamide stock solution. 30% (w/v) 
acrylamide, 1.579% (w/v) bis acrylamide, ratio 19:1. Severn Biotech Ltd., stored 
in the dark at 4 °C.
Polyacrylamide (4%) solution with urea: 4.8ml Sequagel XR ultra pure
concentrate (National Diagnostics), 25.2g urea, 7.2ml 10X TBE in a total volume 
of 60ml with ddH20 . 400pl of 10% ammonium persulphate and 40pl of TEMED 
was added for each sequencing gel using the 66cm Li-Cor gel apparatus.
Phosphate buffered saline fPBSk lOOmM NaCl, 80mM di-sodium hydrogen 
orthophosphate, 20mM sodium di-hydrogen orthophosphate, adjusted to pH7.5. 
Autoclaved and stored at 4°C.
Pre-hvbridisation buffer:
1) Southern blots: 6 X SSC, 0.5% SDS, 5X Denhardt’s solution and 30pg/ml 
heat denatured, sheared salmon sperm DNA.
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2) Northern blots: 50% deionised formamide, 4 X Denhardt’s solution, 4 X 
SSC, 1.6 X Gene Screen, 0.1% SDS, 8% Dextran Sulphate and 30pg/ml heat 
denatured, sheared salmon sperm DNA.
RNA ladders: 0.24-9.5kb RNA ladder, stored at -70°C. 3-5pg/lane (GibcoBRL).
RNase A : Prepared as a lOmg/ml stock in lOmM Tris-HCl pH7.5 and 15mM 
NaCl. Boiled for 15 minutes and cooled slowly. Stored at 20°C.
RNAzol B : Total RNA was extracted from cell lines or tissue using RNAzol B 
(Biogenesis). Stored at 4°C in the dark.
SSC f20X): 3M NaCl, 0.3M Sodium Citrate in dH20  and adjusted to pH7.0. 
Stored at room temperature.
STET: 8% sucrose, 50mM Tris-HCl pH8, 50mM EDTA pH8, 5% triton X I00 
made up in ddH20 , filtered (0.22 pm). Aliquots stored at 4°C or -20°C.
TAE (50Xk 2M Tris-HCl pH8.15, 1.5M NaOAc, 1M NaCl, 0.1M EDTA. 
Stored at room temperature.
TBE (IPX ): 0.9M Tris-HCl, 0.9M Boric acid, 25mM EDTA pH8.3. Stored at 
room temperature.
TE: lOmM Tris-HCl, ImM EDTA adjusted to pH8.0. Autoclaved and stored at 
room temperature.
X-Gal (5-bromo-4-chloro-3-indolvl-p-ealactosideT 160mg/ml in dimethyl- 
formamide (DMF) added to L-agar to a final concentration of 80pg/ml. Stored in 
aliquots at -20°C in the dark.
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2.2 Methods
2.2.1 Eukaryotic cell culture
2.2.1.1 Maintenance of eukaryotic cells
Eukaryotic feline and human T cell suspension cells were grown in plastic flasks 
(Costar Corporation, USA) at 37°C in an atmosphere of 5% C 0 2 in air. Growth 
medium is as outlined in 2.1.6 with the exception of the Mya 1 and T17 cell lines 
which were supplemented with lOOunits/ml of recombinant human IL-2 and 2 x 
10'5 moles/ml of 2-mercaptoethanol. Cells were subcultured every 2-3 days and 
maintained at densities of between 5 x 105 and 1 x 106 cells/ml. Cells numbers 
were determined using a Coulter Counter ZM, Coulter Electronics Ltd.
2.2.1.2 Separation of healthy from non-viable cells
The separation of live cells from dead or non-viable cells was performed by 
phase separation in Ficoll-paque (Pharmacia). Briefly, cells were resuspended in 
5ml of medium in a 15ml Falcon tube and underlayed with 5ml Ficoll followed 
by centrifugation at 2000rpm for 10 min. Live cells form an interphase between 
the medium and the Ficoll while dead cells form a pellet. The interphase was 
then removed and the live cells diluted to 50% with medium to remove any 
remaining Ficoll. Live cells were pelleted at 1500rpm for 5 min and cultured as 
above.
2.2.1.3 Long term storage of eukaryotic cells
Cells were resuspended at approximately 3 x 106 cells/ml in growth medium 
supplemented with 10% dimethyl sulphoxide (DMSO, Koch-Light Laboratories 
Ltd.), frozen at -l°C/min to -70°C and stored in liquid nitrogen.
2.2.2 Preparation of DNA and RNA
2.2.2.1 Isolation of plasmid, cosmid and PAC DNA
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Recombinant plasmid DNA was isolated using a number of different procedures 
depending on the intended use as outlined below. In all cases, a single colony 
was inoculated into L-broth containing the appropriate antibiotic unless otherwise 
stated.
2.2.2.2 Small scale purification of plasmid DNA
‘Miniprep’ DNA was isolated by the STET method as outlined in Maniatis et al 
(151). Briefly, 1.5ml of an overnight culture was pelleted and resuspended in 
lOOpl STET containing 3mg/ml lysozyme and 100pg/ml RNaseA. The samples 
were boiled for 45 sec and centrifuged at 14000rpm for 15 min. The DNA was 
precipitated with lOOpl propan-2-ol, pelleted by centrifugation, washed in 70% 
ethanol, dried and resuspended in the desired volume of TE pH8.0. DNA was 
stored at -20°C.
2.2.2.3 Purification of sequencing grade plasmid and cosmid DNA
Large quantities o f high quality plasmid or cosmid DNA was purified from 
100ml or 500ml respectively of an exponentially growing overnight culture of 
recombinant bacteria using the QIAGEN Plasmid Purification Maxi kit according 
to the manufacturer’s instructions. Small scale purification of sequencing grade 
plasmid DNA was purified from 1.5 - 3ml of an overnight culture using the 
QIAwell 8 Plasmid Purification kit according to the manufacturer’s instructions. 
500ng of DNA was used per cycle sequencing reaction. DNA was stored at - 
20°C.
2.2.2.4 Purification of bacteriophage Pl-derived (PAC) constructs
PAC DNA was isolated using a variation of the QIAGEN Plasmid Maxi Kit 
protocol. Briefly, 0.5ml of an overnight culture of the recombinant PAC clone 
was inoculated into 500ml of 2 X YT containing 25qg/ml kanamycin. The 
culture was grown with vigorous shaking at 37°C until an A550 of 0.15 was 
reached. 5ml of freshly made, filter-sterilised 0.1M IPTG was then added to the 
500ml culture and grown at 37°C until an A550 of 1.3-1.5 was reached. The 
remainder of the protocol is identical to the QIAGEN Plasmid Maxi Kit protocol.
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2.2.2.5 Isolation of genomic DNA
High molecular weight genomic DNA was prepared from 1 x 107 - 108 cells 
using the Nucleon BACC2 kit (Scotlab) according to the manufacturer’s 
instructions, except for the DNA precipitation stage: the precipitated DNA was 
spooled, washed in 70% ethanol, briefly air dried and resuspended in an 
appropriate volume of TE pH8.0. The concentration of DNA was calculated on 
the basis that a 50pg/ml solution of double stranded DNA has an OD260 
measurement of 1. DNA was stored at 4°C and remains stable for a number of 
years.
2.2.2.6 Isolation of total cellular RNA
Total cellular RNA was prepared using RNAzol B (Biogenesis) which is based 
on the guanidinium thyocyanate-phenol chloroform extraction method of 
Chomczynski and Sacchi (152). The manufacturer’s instructions were followed 
using 2ml of RNAzol B per 107 cells. All procedures were performed at 4°C 
using DEPC treated ddH20  and RNase free tubes and pipette tips. The 
concentration of RNA was calculated on the basis that a 40pg/ml solution of 
RNA has an OD260 measurement of 1. RNA was stored at -70°C in DEPC treated 
ddH20 .
2.22,1 Isolation of poly A+ mRNA
Using total RNA as the starting material (above), the poly(A) mRNA fraction 
was isolated using PolyATtract mRNA Isolation Systems (Promega) according to 
the manufacturers instructions. All procedures were performed at 4°C using 
DEPC treated ddH20  and RNase free tubes. The concentration of RNA was 
calculated on the basis that a 40p.g/ml solution of RNA has an OD260 
measurement of 1. RNA was stored at -70°C in DEPC treated ddH20 .
2.2.3 Gel electrophoresis
Gels containing 0.6 - 2% agarose (w/v) in 1 X TBE or 1 X TAE were used to 
separate DNA (151). 50, 100, 200 or 400ml gels were poured in perspex tanks
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and wells were cast using appropriate combs. Gel loading buffer was added to 
samples at a final concentration of 1 X, samples were then electrophoresed in 1 X 
TBE or 1 X TAE. When TAE gels were used, the running buffer was changed 
frequently to prevent buffer exhaustion. Known concentrations o f DNA size 
markers were run alongside the samples in order to gauge both product size and 
yield. Gels were stained either by adding 0.25pg/ml ethidium bromide to the 
molten agarose prior to casting, or by staining the gel after electrophoresis for 20 
min in running buffer or dH20  containing 0.5pg/ml ethidium bromide. Gels were 
viewed on a short wave UV transilluminator (UVP Inc.) and photographed using 
the MWG 2000i gel documentation system (MWG-Biotech). Further analysis of 
band intensities and molecular weights of product was carried out as necessrary 
using Phoretix ID Plus (Phoretix International, NonLinear Dynamics Ltd.).
2.2.4 Purfication of DNA from agarose gels
Following electrophoresis, a DNA fragment o f interest was excised from an 
agarose gel using a clean scalpel. Highly purified DNA was obtained with the 
QIAquick Gel Extraction kit (Qiagen) according to the manufacturers 
instructions.
2.2.5 Restriction endonuclease digestion
Restriction endonucleases (GibcoBRL) were used with the buffers supplied in 
accordance with the manufacturer’s recommendations. 10 units of enzyme was 
generally used to digest lpg  of miniprep DNA at 37°C for 1 hour, and 100 units 
per 20pg of genomic DNA for 12-24 hours.
2.2.6 Polymerase chain reaction (PCR)
The polymerase chain reaction (PCR) allows the rapid, specific amplification of 
DNA sequences between two specific oligonucleotides using very little starting 
material. The Perkin Elmer Gene Amp PCR Core Reagents kit was used 
according to the manufacturers instructions. The kit utilises a recombinant, 
thermostable Taq DNA polymerase encoded by a modified form of the Thermus 
aquaticus (Taq) DNA polymerase gene. The thermostable property of Taq
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allows the cyclical heat denaturation of double stranded DNA at 95°C. This step 
is followed by the annealing of the two complementary primers to the 3' 
boundaries of the target sequence, typically carried out at 55°C unless otherwise 
stated. Finally the primers are extended at 72°C. The target temperature at each 
stage is maintained for 1 minute and carried out for 20 - 35 cycles. Standard 
reaction conditions were, depending on the template, lOng - 1 fig of template 
DNA in a 50pl reaction mixture containing lOmM Tris-HCl pH8.3, 50mM KC1, 
1 . 5 - 3  mM MgCl2, lOOpM of each nucleotide, lpg  of each primer and overlaid 
with 25pl of mineral oil. Thermal cycling was carried out in 0.5ml reaction tubes 
in a programmable thermal cycler (Perkin Elmer DNA Thermal Cycler). 5pi of 
the product was analysed by acrylamide or agarose gel electrophoresis.
2.2.7 Cloning of hybrid DNA molecules
2.2.7.1 Ligation of DNA fragments
Fragments of DNA generated by restriction digestion were ligated into 
approximately 50ng o f vector using T4 DNA ligase (GibcoBRL) according to the 
manufacturers instructions. Vector DNA was linearised using an appropriate 
restriction enzyme. To prevent re-circularisation of the vector DNA, both 5'- 
phosphate groups were hydrolysed with 0.5 units of calf intestinal alkaline 
phosphatase (CIAP, Promega) at 37°C for 30 min. If one or both ends generated 
by a restriction enzyme digest must be converted into blunt ends for cloning, the 
5' or 3' protruding ends can be ‘filled-in’ or removed using T4 DNA polymerase 
(GibcoBRL) which has a 5'-3' polymerase activity as well as a 5'-3 ' exonuclease 
activity. Ligation of DNA fragments generated by PCR were carried out 
according to the manufacturer’s instructions with the Original TA Cloning Kit or 
the TA-TOPO Cloning Kit (both from Invitrogen). Generally, 50ng of vector 
DNA and a three fold molar excess of insert DNA were ligated. Ligations were 
carried out overnight at 14°C except when using the TA-TOPO kit where 
ligations were carried out at room temperature for 5 min.
2 2 .1 2  Bacterial transformation
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l-2pl of a 1:5 dilution of ligation mix was added to 20pl of competent bacterial 
cells (DH5a, GibcoBRL), or lp l o f TA cloned DNA was added to 50pl of 
INVaF' or TOP 10 One Shot Competent cells (Invitrogen) along with 2 pi of 2- 
mercaptoethanol. In all cases the mixtures were then incubated on ice for 30 min. 
Cells were subsequently heat shocked at 42°C for exactly 45 seconds and 
returned to ice for 2 min. 250pl o f SOC medium (Invitrogen) was then added 
and incubated with shaking for 30 - 60 min. Cells were then plated onto L-agar 
plates containing lOOpg/ml ampicillin and 80pg/ml X-gal. These plates were 
incubated overnight at 37°C.
2.2.7.3 Identification of recombinants
For transformation using lacZ complementation, white colonies were picked from 
plates containing X-gal and used to inoculate 5ml of L-broth containing 
ampicillin (100pg/ml) and grown overnight at 37°C with shaking. Colonies 
containing the appropriate inserts were identified by small-scale plasmid 
purification and restriction digestion, or by performing PCR on a colony which 
has been added to 50pl of ddH20  and boiled for 10 min then centrifuged for 10 
min. Alternatively, when a large number of colonies need to be screened to 
identify recombinants, colony hybridisation analysis was performed using the 
method first described by Grunstein and Hogness in 1975 (153). Briefly, white 
or pale blue colonies were picked and spotted on nitrocellulose filters over L 
broth agar plates containing lOOpg/ml ampicillin and on a reference plate. 
Colonies were grown overnight at 37°C then the DNA was denatured, neutralised 
and crosslinked to the filter as for Southern blots (see below). Colonies which 
contain the sequence of interest were identified by hybridisation with an 
appropriate probe (see below) and the relevant colony picked from the reference 
plate for further analysis.
2.2.8 DNA and RNA hybridisation analysis
2.2.8.1 Southern blot transfer of DNA
This was carried out essentially as described by Southern (154). Generally, 20pg 
of high molecular weight genomic DNA was digested with 100 units of the
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appropriate restriction endonuclease overnight, precipitated with half volume of 
7.5M ammonium acetate and two volumes of 100% ethanol and the DNA pellet 
dried and resuspended for several hours in TE pH8.0. DNA samples were 
electrophoresed as described above on a 0.6 - 0.8% agarose gel in 1 X TAE 
buffer overnight at 25V. 5xl03 counts per minute o f end labeled marker (5kb 
ladder and/or X Hindlll DNA) together with 500ng of unlabeled marker were also 
loaded on the gel. Following electrophoresis, the gels were stained and 
photographed as described above, submerged in denaturation buffer for 30 min, 
followed by submersion in neutralisation buffer for 30 min. The gel was 
equilibrated in 20 X SSC and the DNA was transferred onto Hybond-N 
(Amersham) nylon membrane by capillary blotting overnight in 20 X SSC. The 
membrane was removed and rinsed briefly in 2 X SSC and the DNA crosslinked 
to the membrane (Spectrolinker X L-1500 UV Crosslinker, Spectronics 
Corporation).
2.2.8.2 Northern blot transfer of RNA
10-40pg of total cellular RNA or l-5pg of polyA+ mRNA was lyophylised (VR-1 
Hetovac, Heto) then resuspended in 20pl of RNA loading buffer and denatured 
for 15 min at 65°C. Subsequently, 3-5pl o f RNA running dye was added and the 
samples electrophoresed for 3 hours at 100V in 200ml of a 1% agarose gel 
containing 1 X MOPS and 2.2M formaldehyde in IX MOPS buffer that was 
continually recirculated. 5pg of RNA ladders (GibcoBRL), which were treated 
in the same way as the RNA samples, were used as molecular weight markers. 
Following electrophoresis, the marker lanes were removed using a clean scalpel 
and stained in 3pg/ml ethidium bromide for 30 min, then destained overnight and 
photographed. The rest of the gel was washed twice in ddH20  for 20 min to 
remove formaldehyde, then equilibrated in 10 X SSC and transferred overnight 
onto Hybond-N in 10 X SSC. The membrane was removed and rinsed briefly in 
2 X SSC and the RNA crosslinked to the membrane (Spectrolinker X L-1500 UV 
Crosslinker, Spectronics Corporation). All northern blots were probed with a rat 
gapdh probe to control for RNA loading and integrity. The gapdh probe is a 
750bp EcoRl fragment purified from the plasmid pGapdh.
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2.2.8.3 Preparation of radiolabeled DNA probes
PCR or restriction fragment DNA probes were gel-purified from non-specific or 
vector sequence and radioactively labeled using a ‘random prime’ DNA labeling 
kit (155) (High Prime, Boehringer Mannheim), and a (32P) dCTP, specific activity 
3000Ci/mmol (Amersham). Generally, 20-50ng of heat denatured DNA was 
radiolabeled using 50pCi (1.85Mbq) of a (32P) dCTP and 4pl o f High PrimeTn a 
final volume of 20pl, following the manufacturer’s instructions. Unincorporated 
nucleotides were removed by gel-filtration through Sephadex-G50 beads (Nick 
Columns, Pharmacia) and labeled fragments were eluted in 400p,l o f TE buffer 
and the activity of 2 pi was determined. Typically, incorporations of 108 - 109 
cpm/pg were achieved.
2.2.8.4 End labeling of DNA size markers
lpg  of DNA size marker was dephosphorylated using 0.5 units o f calf intestinal 
alkaline phosphatase (CIAP, GibcoBRL), 1 X CIAP buffer and lOmM Tris-HCl 
pH8.0 for 15 min at 37°C followed by 15 min at 56°C. The DNA was extracted 
with phenol/chloroform and precipitated using 0.3M NaOAc and 100% ethanol. 
The DNA was resuspended in ddH20  and 6pl of 5 X forward reaction buffer 
(GibcoBRL) and denatured at 90°C for 3 min. 170pCi of y(32P) dCTP 
(Amersham) and 10 units of T4 polynucleotide kinase (GibcoBRL) was added to 
a total volume of 30pl and incubated at 37°C for 1 hour. The reaction was 
stopped with lp l of 0.5M EDTA. Unincorporated nucleotides were removed as 
above. The activity of 2pl was determined and the sample diluted appropriately. 
Typically, 103 cpm per lane were loaded alongside unlabeled markers
2.2.8.5 Hybridisation of labeled probes to membrane bound nucleic acids
Standard high stringency conditions for the hybridisation of specific radiolabeled 
probes on nucleic acids immobilised on nylon membranes were as follows: 
membranes which had been pre-wetted in 2 X SSC and rolled into Hybaid 
hybridisation bottles were pre-hybridised in 10-20ml of the appropriate pre­
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hybridisation buffer (see section 2.1.7) at 65°C (Southern blots) or 42°C (northern 
blots) for at least 2 hours in a Hybaid oven with continual rotation. Freshly 
boiled DNA probe was added to the pre-hybridisation solution: 106 cpm/ml was 
used for genomic Southerns and northerns and 105 cpm/ml was used for plasmid 
DNA Southern blots. Filters were hybridised overnight as above. After rinsing 
briefly with 2 X SSC, the membrane was washed for 20 min with three changes 
of 0.1 X SSC, 0.5% SDS at 60°C, unless otherwise stated. Membranes were then 
sealed in polythene and exposed to X-ray film (Kodak). Following hybridisation, 
filters were stripped of probe by continuous shaking in boiling dH20  containing
0.1%SDS until the solution has cooled to room temperature.
2.2.9 DNA sequence analysis
Cycle sequencing reactions were carried out using IRD41-labeled primers 
(MWG-Biotech) and the ThermoSequenase Fluorescent Labeled Primer Cycle 
Sequencing Kit with 7-deaza-dGTP (Amersham Life Science). Cycle sequencing 
is based on the chain termination method of Sanger (156), but uses a 
thermostable DNA polymerase to give multiple rounds of high temperature DNA 
synthesis. Briefly, 500ng of plasmid DNA, lpmol of IRD-41 labeled primer 
(MWG-Biotech) and 2pl of reaction mix which contains 45pM each of dGTP, 
dATP, dTTP and dCTP, reaction buffer and thermostable DNA polymerase, were 
mixed in a 0.5ml reaction tube. The reaction is made up to 8pi with ddH20  and 
overlaid with 20pi of mineral oil and denatured for 5 min at 95°C then passed 
through 25 cycles of 95°C for 30 seconds, 48-60°C for 30 seconds and 72°C for 
30 seconds. The mineral oil was removed by running each sample down a 
parafilm gradient and collecting the aqueous phase at the bottom of the slope. 
4pi of formamide loading buffer supplied with the kit was added and the 
reactions separated on denaturing gels (Sequagel XR ultra pure concentrate 
(National Diagnostics). Data recording was performed on a Li-Cor model 4000 
DNA sequencer (MWG-Biotech). Typically 800-1000bp of sequence was 
generated from one run.
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DNA sequence was analysed using the GCG package (Wisconsin Package 
Version 9.1, Genetics Computer Group (GCG), Madison, Wisconsin) and 
database searches were carried out by FastA searches in GCG or BLAST 
searches (Basic Local Alignment Search Tool, National Center for Biotechnology 
Information (NCBI): http://www.ncbi.nlm.nih.gov/BLAST/).
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Chapter 3
3. Feline Fit-1 and the search for transcribed sequences in the FT1 cell line
3.1 Introduction
Cancer is a multi-step process in which a normal cell develops into a fully 
malignant tumour via a mechanism of clonal expansion triggered by genetic 
events leading to deregulated proliferation. Retroviruses have been used for a 
number of years to identify genes involved in this process (12;97). As discussed 
in chapter 1, the basis of retrovirus-induced tumours appears to be an 
accumulation of somatic mutations, at least a number of which can be directly 
attributed to proviral integration within the host DNA. Although most 
integrations will have no significant effect on the host cell, some will inevitably 
affect critical cellular gene(s) involved in the regulation of cellular proliferation 
and differentiation. Therefore, a cell which has undergone an insertional 
mutation event affecting such an (onco)gene will have an increased survival 
potential allowing that cell to grow and divide in a clonal fashion, often leading 
to the outgrowth of a tumour.
Thus, retroviruses serve as useful tools to identify novel oncogenes in the vicinity 
of an integrated provirus. Indeed, retroviruses have been used to identify greater 
than 60 cellular genes as targets for insertion in tumours of the mouse, rat, 
chicken and cat (Table 1.1 in chapter 1 and reviewed in (12)). This study will 
focus on retrovirus-induced lymphomas of the domestic cat where a number of 
parallels can be drawn from the better characterised murine system.
Cats inoculated with feline leukaemia virus (FeLV) isolates which carry a 
transduced Myc gene (FeLV-myc) were shown to develop thymic lymphomas 
with a relatively short latency period, 12-14 weeks post infection (3;4). Despite 
this short latency, the tumours were clonal, suggesting that Myc alone is not 
sufficient to induce full malignant transformation and that other genetic events 
may be required. Therefore, the possibility that helper proviral insertional 
mutagenesis played a role by activating a gene which collaborates with Myc was
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investigated. This method of ‘proviral tagging’ has been frequently used to 
identify novel genes involved in tumorigenesis, whereby host DNA sequence 
flanking the provirus in one tumour is used to identify regions of chromosomal 
DNA interrupted commonly in independent tumours (7; 11; 12). This technique 
led to the identification o f the Fit-1 common insertion locus (FeLV integration 
site in T cell lymphoma) (25;42). Identification of a gene at Fit-l was expected 
to lead us to a gene which collaborates with Myc in the development of T cell 
neoplasia.
3.1.2 Background on the Fit-1 common integration locus
Fit- 1 was cloned by inverse PCR from tumour F422-1T (Figure 3.1) and used to 
screen a panel of 63 thymic lymphomas. 16% of these tumours were found to be 
rearranged at Fit- 1 (25;42). This is highly significant considering the low 
probability of 10 independent proviral integration events occuring at random in 
the same lOkb genomic fragment (10). Eight of these lymphomas were induced 
by naturally-occurring FeLV strains carrying a v-myc oncogene (25), and two 
were field case thymic lymphomas: T21-T and FT1, from which a cell line of the 
same name was established (142). Interestingly, the FT1 tumour and cell line 
also has a proviral insertion at c-myc ((100) and discussed in section 3.1.3). 
Furthermore, all the other tumours which were rearranged at Fit-1 contained an 
activated Myc gene except for tumour T21-T. Together, this suggests that the 
Fit-l common integration locus harbours a gene which is activated by FeLV 
insertion and collaborates with c-myc in T cell leukaemogenesis, although this 
relationship may not be exclusive. Moreover, occupation of Fit-l by FeLV was 
implicated as a late progression step in tumour development (25).
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Figure 3.1 Restriction map and sites of proviral integration in the Fit-1 locus. 
This figure is based on information described previously (25;42). The positions 
and orientations of proviral integrations for each tumour and cell line (FT1) are 
shown. The position of the conserved Fit-l probe is shown (open box). 
Restriction enzmye abbreviations: E, EcoRA\ SI, Sstl; K, Kpn\\ X, Xbal\ H, 
Hindlll; P, Pstl.
The Fit-1 locus has been mapped to feline chromosome B2 which carries several 
known oncogenes including Pim-1 and c-myb, both of which have been 
implicated in T cell leukaemogenesis (42). However, restriction mapping 
indicated no close linkage to these genes and northern blot analysis of RNA from 
primary tumours rearranged at Fit-l revealed no evidence of long-range 
activation. Moreover, initial analysis of two other loci identified as common 
FeLV integration sites in T cell lymphomas, Flvi- 1 (49) and Flvi-2 (23) 
(subsequently found to encode Bmi-1, also a c-myc collaborating gene (19;24)), 
excluded the possibility that these genes were linked to Fit-1.
A stretch of conserved sequence from the Fit-l locus allowed the mapping of the 
murine homologue using the European Interspecific Backcross between Mus 
musculus and Mus spretus (EUCIB) (157). Three recombinants were detected in 
119 backcross progeny screened for both the Fit-l and Ahi- 1 loci, a murine 
retroviral integration locus which is closely linked to c-myb on chromosome 10 
(17; 18). This total of 119 mice represented an initial random screening panel and 
a second panel o f known chromosome 10 recombinants. Based on EUCIB 
algorithms these data placed Fit-l approximately lcM proximal to Ahi-1 on
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mouse chromosome 10 (Figure 3.2). However, preliminary Southern analysis 
with a c-myb probe in the feline tumours with rearrangements at Fit-1 excluded 
the possibility that insertions at this common insertion locus actually represented 
insertions within the c-myb oncogene (42). Thus, Fit-\ was assumed to be a 
novel locus.
chr. 10
^-D10Mit153 
075
6.38 
1.02 _L Ahi-]
4.08
D10Mit16
Figure 3.2 Genetic linkage map of the Fit- 1 and Ahi-1 common insertion loci on 
mouse chromosome 10. The positions of these loci were determined relative to 
each other in 119 interspecific backcross progeny (157). Also shown are the 
positions of the anchor markers D10Mitl53, Dmdl and D10Mitl6. 
Recombination distances between loci are given in centiMorgans and are listed 
on the left.
To search for a gene affected by insertion at Fit-l, DNA flanking the cluster of 
proviral insertions was screened for sequences that are single copy, conserved in 
evolution and expressed as RNA in a tumour specific fashion. To this end, three 
Fit- 1 positive X phage clones were isolated spanning approximately 30kb of 
genomic sequence (?iRFl, A.HT301B2 and A.HT58A3). Southern blot 
hybridisation with a probe derived from the major insertion cluster revealed a 
region of unique sequence which showed evidence of cross-species hybridisation, 
the Fit-l probe (Figure 3.1). This region also contained a long open reading
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frame with some features of an internal coding exon. However, the Fit- 1 probe 
failed to show any evidence of a transcription unit which was altered as a result 
of viral insertion at Fit-1. In addition, the application of the exon trapping 
technique revealed several candidate exons none of which showed evidence of 
homology to published sequences or of expression in either normal or tumour 
material. These preliminary results, together with an illustration of the Fit- 1 X 
phage clones and subclones, are summarised in Figure 3.3.
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Figure 3.3 Summary of the Fit-1 locus illustrating the status of the Fit-1 
locus prior to the start of this study. The lines above the restriction map 
show the extent of the phage clones obtained from the locus, only the >*RF1 
clone is shown in detail. The arrowheads indicate the positions and 
orientations of the integrated FeLV proviruses in individual tumours. The 
open boxes represent the XRF\ subclones while the shaded boxes below 
show domains for which DNA sequence is available, which are conserved 
across species (zooblot), or which hybridise to cellular RNA. (a) the 
conserved f i t - \  probe, (b) putative exons identified by exon trapping. 
Restriction enzyme abbreviations: E, ZscoRI; H, Hind\\\\ K, Kpn\\ P, PstV, 
S, SaH\ SI, Sstl\ X, Xbal.
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A 1.4 Kb tumour specific RNA was identified in the FT1 cell line using a probe 
derived from the 3' end of the insertion cluster (H. Tsujimoto, Tokyo, Japan, 
unpublished results). However, reproducible signal could not be obtained on 
northern analysis. Furthermore, screening of a cDNA library did not identify any 
cDNA clones which hybridise to the probe. In addition, several weakly 
hybridising transcripts were identified by northern blot analysis using probes 
from around the insertion cluster, however none were expressed in a tumour 
specific manner. The search for transcripts up until this point has been severely 
hampered by the limited availability and relatively poor quality of primary 
tumour RNA.
3.1.3 The FT1 cell line
The FT1 T cell line was established from a cat with a spontaneous thymic 
lymphosarcoma (142). This cell line was shown to be rearranged at c-myc by 
Southern blot analysis. The c-myc rearrangement is due to the direct integration 
of an FeLV provirus immediately upstream and in the opposite transcriptional 
orientation to c-myc (100), illustrated in Figure 3.4. The LTR of this integrated 
provirus has three copies of an enhancer-like sequence (100). Therefore, the high 
level of c-myc transcript seen in FT1 RNA by northern blot analysis (142) is most 
likely due to enhancer insertional activation of c-myc.
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exon 1 exon 2
Figure 3.4 Partial restriction map illustrating the site of proviral insertion at c- 
myc in the FT1 cell line (100). The orientation of the provirus is upstream and in 
the opposite orientation to the direction of transcription of the c-myc gene 
(arrow). Only exons 1 and 2 of the c-myc gene are shown (closed boxes). 
Restriction enzyme abbreviations: K, Kpril\ S, Sail.
In addition to a proviral integration at c-myc, the FT1 cell line also has an 
insertion at Fit-l (H. Tsujimoto, unpublished) and it is this property which has 
made this cell line invaluable in the search for transcribed sequence at the Fit-1 
locus. Previous studies were limited by the availablility and the viability of 
primary tumour RNA. However, FT1 cells represent a renewable source of both 
RNA and DNA with a rearrangement at Fit- 1 for further analysis of the Fit- 1 
locus.
3.2 Results
3.2.1 Strategy for identifying transcription units at the Fit-l locus
The evidence strongly suggested the presence of a gene at Fit- 1 because 16% of 
tumours analysed for rearrangements at Fit-1 had an FeLV provirus inserted 
within this region. However, northern blot analysis with unique sequence probes 
from the insertion cluster failed to show any evidence of a transcription unit 
which was activated by viral insertion in primary tumour RNAs. Using the FT1 
cell line, an unlimited supply of rearranged DNA and RNA, I set about to 
systematically search for transcript(s) which are altered as a result o f viral 
insertion at Fit-1. For this analysis, probes derived from the ARF1 genomic
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phage clone which spans the region surrounding the insertion cluster were 
isolated. Figure 3.5 outlines the strategy used to search for transcribed sequence 
in the FT1 cell line which were altered compared to a control cell line (3201, a 
feline T cell line with no rearrangement at F it-1). The XRF1 subclone 2 is used 
as an example in this figure (see also section 3.2.1). However, this analysis was 
performed accross the entire A.RF1 clone.
1. Identification of single copy sequence
It is likely that DNA which encodes a protein product will be single copy, unless 
it is part o f a multi-gene family. Therefore, the DNA surrounding the proviral 
insertion cluster was screened to identify such sequences which could represent a 
gene targeted by these pro viruses. To this end, A.RF1 subclones (see Figure 3.3) 
were digested with various restriction enzymes (Figure 3.5A) and blotted on 
nylon membrane as outlined in section 2.2.8. The Southern blot was then 
hybridised with [a 32P] dCTP labelled total genomic DNA from the 3201 cell line.
Any DNA fragments which strongly hybridised to 3201 DNA after 
autoradiography were discarded since they represent repetitive sequences (Figure 
3.5A and B, asterisk). Fragments which did not appear to hybridise on a short 
exposure were identified as single or low copy number sequences and were used 
for further analysis. For example the lkb EcoRl/Pstl fragment indicated by the 
arrow in Figure 3.5A, did not hybridise strongly to total DNA on the Southern 
blot o f this gel (Figure 3.5B, arrow) suggesting that this fragment did not contain 
repetitive sequences. Other DNA fragments from subclone 2 hybridised strongly 
to total DNA suggesting that these sequences occur frequently in the genome, for 
example the 400bp EcoRl/Pstl fragment (Figure 3.5A and B, asterisk). A 
putative single-copy fragment was then gel purified (section 2.2.4) and used to 
probe a Southern blot of 3201 DNA digested with various restriction enzymes 
(Figure 3.5C). In this example, the lkb EcoRl/Pstl fragment from subclone 2 is 
confirmed as single copy as determined by the single band hybridising to this 
probe on Southern analysis (Figure 3.5C).
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(A)
Figure 3.5 Summary of the procedure used to identify 
transcription units at the Fit-\ locus
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Figure 3.5 Strategy to identify transcription units at the Fit-1 locus. (A) 
Ethidium bromide stained agarose gel of subclone 2 DNA digested with 
various combinations of restriction endonucleases described below. (B) 
The Southern blot hybridised with genomic DNA (3201). The asterisks 
in A and B represent the 400bp EcoRUPstI repetitive sequence and the 
arrows in A and B highlight the single copy lkb EcoRl/Pstl fragment 
from subclone 2. (C) 3201 cell DNA digested with restriction enzymes 
(below) and hybridised with the single copy probe identified above. (D) 
Northern blot of FT1 (11), 3201 (12) and T3 (13) total cellular RNA 
probed with the single copy probe identified above.
M, ^ H in d lll m arkers; 1, E coR l/Sa ll;  2, E coR l/X bal; 3, Xbal; 4, 
EcoRUPstI; 5, XbaUPstl; 6, PstUSalI; 7, XbaUSall; 8, EcoRl; 9, Sstl; 10, 
BamHl.
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2. Detection of transcripts
A DNA probe which hybridised to a single band (or very few bands) on Southern 
blot analysis of total cat DNA (Figure 3.5C) was then used as a probe on northern 
blot analysis of FT1 RNA (Figure 3.5D). A probe which hybridises to FT1 RNA 
on northern would then be used to screen a cDNA library to isolate and 
characterise the putative gene.
3.2.2 Further analysis of the A,RF1 clone failed to identify a transcription 
unit which was altered as a result of viral insertion at Fit-l
Initial mapping of repetitive sequences within the A,RF1 clone revealed a number 
of single and low copy number sequences which were then used as probes on 
FT1 northern blots to search for any sequences which were transcribed. The 
results are summarised in Figure 3.6.
The entire subclone 7 which contains the conserved open reading frame has been 
extensively analysed on northern blot previously, identifying a number of RNAs 
which hybridise to probes from this region (Figure 3.6, pale blue boxes). 
However, none of these RNA species were expressed in a tumour specific fashion 
and therefore were not pursued (R. Fulton, unpublished). Further analysis of FT1 
RNA with the conserved Fit-\ probe (derived by PCR using the or I f  and orlr 
primers detailed in Appendix 1) and a series of other unique sequence probes 
from this subclone also failed to show evidence of transcription units which were 
activated by viral insertion (not shown). Similarly, probes from subclones 3 and 
6 did not hybridise to any transcripts on FT1 or control RNAs (not shown).
Probes from subclones 5 (Pstl/Xhol fragment); A (Xhol/EcoRl fragment); and 2 
(.EcoRl/Pstl fragment, discussed above) hybridised to very faint bands at 3.0kb 
and 1.7kb on FT1 total RNA (Figure 3.6, dark blue boxes and Figure 3.5D). 
However, the signal washed off at high stringency, was not reproducible, nor was 
there any signal seen on Poly (A)+ selected mRNA. If this represented a true 
gene then one would expect the signal to be enhanced on mRNA.
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Subclone A contains two putative exons identified by exon trapping (R. Fulton, 
unpublished). Therefore, to further characterise sublone A for the presence of 
functional exons, DNA sequencing o f the subclone and northern blot analysis 
with the putative exons was carried out. The 648bp subclone A was fully 
sequenced confirming the presence of putative splice acceptor and donor sites 
defining the supposed exon 1 and exon 2 regions (Figure 3.7, underlined 
sequences). These putative exons were also found to flank a region with 
homology to the feline repetitive DNA satellite monomer, FA-SAT. The 483bp 
FA-SAT monomer is a family of relatively G/C rich sequence which comprise 1- 
2% of the feline genome and have been found to be localised at the telomeres of 
chromosomes (158).
In addition, a possible open reading frame was predicted in exon 2, but not from 
exon 1 through to exon 2 (Figure 3.7). Sequence analysis using the computer 
algorithm, Gene ID (BioMolecular Engineering Research Center, Boston 
University, geneid@darwin.bu.edu), predicted with medium probability the 
presence of a first exon within the putative exon 2 sequence. Furthermore, low 
copy number probes corresponding to exon 1 (a 69bp oligonucleotide probe, 
fitA3, Appendix 1) and exon 2 (generated by PCR with the primers fitAl and 
fitA2, Appendix 1) hybridised to the faint bands again at 3 and 1.7kb in FT1 total 
RNA (not shown). However, as before the signal disappeared with a high 
stringency wash, it was not reproducible, nor was it enhanced on Poly (A)+ 
selection of mRNA. Moreover, zooblot analyses with both exon 1 and 2 probes 
were negative (not shown). Together these results suggest that the putative exons 
1 and 2 do not represent true exons.
3.2.3 Analysis of subclone 4 reveals that the ^RFl clone is rearranged
Several probes from subclone 4 were found to be single copy by Southern 
analysis including the Sstll/Ncol fragment (Figure 3.6). However, this probe 
gave unexpected results on Southern blot analysis. Therefore, to clarify the 
restriction map around the A.RF1 subclone 4, the restriction maps of FT1 and 
XRF\ were compared. These results are summarised in Table 3.1.
85
e x o n l
51
TCTTGTGCAC CTGTACTCAG
S /A
TACGTGGTGT
£CCTTGGAAA TGACTTGGTG ATGTTCCAGT
TTCTATGCTG AATGATCCTA CATCGCTTCT GGACCCCAAG
S /D
101 TGCGAGACTT TGGTGGGTCC CAP
151
201
251
TGGGGAG AGAGCCCTAG CTAGGGTTAG
GGTTTGGTCC AGGGATGTCC CCAGATGCAA AGTGACTCAA GTCTCTTGAT
CTCCCTCGAG GGCTGAAGTG AGGGCCCATG TGACGGTGCG GGTCAAGTGT
AGCATTAGGT TTCGGTTGAG GGTTCTGGTT AGGGGTAGGG TTAGGTCCCA
3 01 GGAAG DTCCT GGCTCTGAGT CCACAGCAGT GCAGTTGTCT CCCCGAAGGg
3 51 CTGAGTTGAG GGCACATGGG AGGATGCCGA TCATTTTTAG TATTTCCGTT
__________________________  e x o n 2
401 CCATTlCCAq ACAACTGTAT GGGCCATTGG TTGTGTAGGC CTCAgCAATC
S /A M L  K F Q
451 ATTTCAGAAA GCTGTAGCCC GGCCTGAAAA ACgACATGCT GAAGTTCCAG
501
V L S G M I  L H C F W T P G
GTTCTATCTG GAATGATCCT TCACTGCTTC TGGACCCCAG GTGTGTGGTG
S /D
551 TTGTCAGACT TTGGTTTTGG GTGTCCATGG GTAAGAGCCT TAGCTAGAGT
601 ATGGTTCCAT CCAGGGTCGT CTCCAGGCTG AAACAACACC ACTGTTGT
Figure 3.7 Nucleotide sequence and predicted amino acid sequence of 
the Fit- 1 subclone A. The shaded areas indicate the 2 potential exons 
identified by exon trapping, exonl and exon2. The potential splice 
acceptor (S/A) sites and splice donor (S/D) sites are underlined. The 
boxed area indicates the region with homology to the FA-SAT repetitive 
satellite monomer. The predicted amino acid shown above the nucleotide 
sequence indicates the potential first exon predicted by the computer 
algorithm, Gene-ID.
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For example, the Sstll/Ncol probe from the A.RF1 subclone 4 hybridises to a 
10.5kb iscoRI fragment in FT1 genomic DNA. However, the same probe 
hybridised to a 5.5kb band in A.RF1 as predicted from the restriction map of 7.RF1 
shown in Figure 3.6. The same Southern blot, when probed with the conserved 
Fit-\ probe, hybridised to the expected sized fragments in both the A,RF1 clone 
and genomic DNA (not shown). This suggests that the A.RF1 clone is chimaeric, 
possibly due to a recombination event during the original cloning manipulations 
so that the 5' end of the clone is rearranged (Figure 3.6). Therefore all results 5' 
of the Sstl site at the junction between subclones 4 and 6 may be invalid since 
this region could potentially be derived from anywhere in the genome.
Table 3.1. Comparison of restriction fragment sizes with the subclone 4 
Sstll/N col probe in FT1 and 7,RF1 DNA.
EcoRl Sstl Kpnl EcoRl/Sstl
FT1 DNA 10.5kb 20kb 23kb 7kb
XRFl DNA 5.5kb 6.5kb 9kb 1.8kb
3.3 Discussion
Ten out of 63 thymic lymphomas screened were rearranged at Fit-1, strongly 
suggesting that a gene involved in tumorigenesis is affected by viral insertion at 
Fit-1. However, despite systematic searching across the entire ^RFl clone for a 
transcription unit which was altered as a result of viral insertion in the FT1 cell 
line, no definitive evidence of the presence of a gene at the Fit-\ locus was 
identified (summarised in Figure 3.6). There are a number of possible 
explanations why none have been detected and these are discussed below.
1. The cluster of proviral insertions at the Fit-\ locus may influence a gene 
which is outwith the region covered by the phage clones. The ability of retroviral 
insertions to affect gene expression over long distances has been demonstrated 
(28;41;64;65;159). For example, provirus integration at the Mlvi-A and Mlvi- 1 
loci which map 30kb and 270kb downstream of Myc respectively (64;65) have
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been shown to enhance Myc expression by c/s-acting mechanisms operating over 
large distances (64). Clearly, this would make the search for a gene affected by 
proviral integration at Fit- 1 a very difficult task.
2. The Fit-\ gene may consist of a number of very short exons which could 
easily be missed by the method utilised to search for transcription units at Fit-1. 
For example, the Ahi- 1 gene was originally identified as a common integration 
site in 16% of Abelson pre-B cell lymphomas (17), and has subsequently been 
found to encode a gene which consists of a number of short exons (P. Jolicoeur, 
unpublished). Exon trapping was used to identify these short exons, a technique 
which identified two candidate Fit-l exons (Figure 3.7). DNA sequence from the 
putative exons 1 and 2 showed no evidence of matches to published sequences, 
evolutionary conservation or of expression in either normal or tumour RNA, 
despite the presence of putative splice acceptor and donor sites. Therefore, I 
concluded that exons 1 and 2 were not true exons. This illustrates the caution 
which must be used when interpreting results from this system since spurious 
splicing events may occur at cryptic splice acceptor and donor sites present in the 
sequence which is being analysed.
3. Proviral integrations at Fit-l may result in inactivation of gene expression 
which may have been missed by northern blot analysis. Such inactivation by 
proviral insertion has been observed in myeloid leukaemias of BXH-2 mice 
where integration in both alleles of Evi-2 results in the inactivation of the NF1 
tumour suppressor protein (33). It is unlikely that integration at Fit-l inactivates 
a tumour suppressor because rearrangements have not been observed in both 
alleles o f Fit-l in any of the tumours or cell lines (42). However, it is possible 
that one allele has been inactivated by proviral integration while the other allele 
has undergone additional (epi)genetic mutations resulting in its inactivation. This 
could occur in a number of ways including point mutation or hypermethylation of 
the DNA which has been associated with gene inactivity (160).
4. Another possible explanation for the lack of an obvious transcription unit at 
the Fit- 1 locus is that it may be present only at very low levels which are 
undetectable by northern blot analysis. An alternative approach to examine this 
would be to perform PCR on reverse transcribed cDNA (RT-PCR).
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CHAPTER 4
Chapter 4
4. Cloning and characterisation of the human homologue of Fit-1
4.1 Introduction
16% of feline thymic lymphomas screened were found to be rearranged at Fit-1 
(25;42) suggesting that a gene involved in tumorigenesis is affected by viral 
insertion at Fit-\. However, no evidence of a transcription unit activated by 
proviral insertion has been found in the 30kb of DNA flanking the insertion 
cluster (chapter 3 and H. Tsujimoto, unpublished).
As discussed, a gene which is distant from the insertion cluster may be the target 
of viral integration at Fit-1. However, because of the constraints o f working with 
a species where relatively little is known about its genome, and in view of the 
conservation of the Fit-l domain across species, it was decided to isolate the 
human homologue of F it-1. There is a far greater wealth o f resources available 
for large-scale genomic analysis in humans compared to cats, primarily owing to 
the Human Genome Project. Therefore, by isolating large human genomic 
clones, the search for adjacent genes in human rather than feline DNA could be 
extended.
4.2 Results
4.2.1 Isolation of a human cosmid clone containing the Fit-1 region
Fit-l has been mapped to feline chromosome B2 (42), much of which has been 
shown to be homologous to human chromosome 6 (161). Therefore, to isolate 
the human homologue of Fit-1, a human chromosome 6 specific cosmid library 
(RessourcenZentrum/PrimarDatenbank (RZPD), Berlin, Germany (162)) was 
screened using the conserved feline Fit- 1 probe.
The library consists of a single gridded high density hybridisation filter, 
representing approximately 36,844 clones with an average insert size of 40-50kb. 
The filter was hybridised essentially as described in section 2.2.8 using the
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conserved Fit-1 probe (not shown). One confirmed positive clone was identified; 
clone ICRFcl090188Q5 (cosmid 1).
4.2.2 Restriction map of the F it-l positive human chromosome 6 cosmid 
clone
A crude restriction map of the human Fit-1 region was generated by digesting 
DNA from the 45kb cosmid 1 clone with various restriction enzymes. Restriction 
analysis was performed with a series of single and double digests using the 
restriction endonucleases Sail, Xhol, Clal, Xbal, Sstl, Pstl, Hincll, Hindlll and 
EcoRl. A Southern blot of the size separated DNA fragments was hybridised 
with the conserved Fit-1 probe (Figure 4.1). These restriction mapping data are 
summarised in Figure 4.2A.
To generate a detailed partial restriction map flanking the region hybridising to 
the Fit-1 probe in the human genome, an 11.5kb EcoRl fragment was subcloned 
in pUC18 and characterised by restriction mapping with the following restriction 
enzymes: Sstl, Hindlll, Pstl, Xbal, Pvull, Hincll and EcoKV and hybridised with 
the conserved Fit-1 probe (not shown). The flanking sequences of the Fit-1 
probe were mapped to a 1.2kb Pvull fragment (Figure 4.2B). In this physical 
map only the closest restriction sites to the Fit-1 probe could be identified with a 
number of enzymes (indicated in parenthesis).
4.2.3 The feline Fit-1 open reading frame is conserved in humans
In the cat, a putative long ORF was identified within ?lRFl subclone 7; the Fit-1 
probe (R. Fulton, unpublished and Figure 3.6). To isolate the region of the 
human genome which has homology to the feline Fit-1 probe and to establish if 
this putative ORF was maintained, the 1.2kb Pvull fragment which hybridised to 
the Fit-1 probe was subcloned and sequenced. This fragment was blunt end 
cloned in pBluescript SK+ as described in section 2.2.7. Positive colonies 
containing the Fit-1 homologous Pvull fragment were identified by Grunstein 
and Hogness hybridisation analysis (153). A Fit-1 positive clone was sequenced 
with the M 13 universal forward and reverse primers (Appendix 1) as described in 
section 2.2.9.
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Figure 4.1 Southern blot analysis and restriction mapping of cosmid 1. 
1 pg of cosmid 1 DNA was digested with the restriction enzymes shown, 
separated on 0.6% agarose gels and hyridised with the human Fit- 1 
probe. Southern blots were washed at high stringency (0.1 X SSC, 0.5% 
SDS, 60oC). Molecular size markers were X Hindlll restriction 
fragments and are indicated in kilobases. Restriction enzyme 
abbreviations: C, Clal; E, EcoRl; H2, Hincll; H, Hindlll; P, Pstl; Pv, 
PvwII; Rs, Rsal; S, Sail; SI, Sstl; Xb, Xbal; Xh, Xhol
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Figure 4.2 R estriction map of the human F it-1 region from the human 
chromosome 6 cosmid clone, cosmid 1 (A); and the EcoRl subclone (B). The 
position of the F it-1 probe is indicated (closed box), the arrow indicates the 
direction of the open reading frame. The location of the vector (Lawrist 4) is 
also indicated (open box) with the positions and orientations of the SP6 and T7 
prim er sequences. The hatched box represents the F it-1 positive P vull 
subclone which has been fully sequenced. Restriction enzyme abbreviations: 
C, Clal; E, EcoRl\ HII, Hincll; H3, Hindlll; P, Pstl; PII, Pvull; RV, EcoRV; S, 
Sail; SI; Sstl; Xb, Xbal; Xh, Xhol. Partial restriction sites are indicated in 
parenthesis.
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A comparison of the DNA sequence from the feline and human Fit-\ domains 
was carried out using the GCG (Genetics Computer Group, Wisconsin) computer 
algorithm. This alignment reveals that the human Fit-1 sequence is 
approximately 80% identical to the feline DNA sequence over 517bp (Figure 
4.3A and (157)). Moreover, the potential splice acceptor and donor signals are 
highly conserved between the cat and human DNA sequences. At the amino acid 
level, the open reading frame present in the feline peptide sequence is maintained 
in the human genome (Figure 4.3B). The feline and human peptide sequences are 
76% identical over 41 amino acids at the start of the sequence falling to 16% 
identity over 25 amino acids in the middle of the sequence. The homology rises 
again to 77% over 22 amino acids at the C terminus. Furthermore, a number of 
the changes are conservative amino acid substitutions.
To generate a human Fit-l probe, PCR was performed using the Pvull clone as 
template and primers designed from this sequence: primers huorf-f and huorf-r 
(Appendix 1 and Figure 4.3A). Both the human and the feline Fit-l probes 
hybridise to the same fragment on a feline genomic DNA Southern blot (not 
shown) confirming that this probe represents the true human equivalent of the cat 
locus.
4.2.4 The human Fit-1 probe is conserved but is not transcribed
The feline Fit- 1 probe was previously shown to be conserved in mammalian 
evolution (157). Therefore, owing to the homology of the human and feline Fit-l 
DNA sequences, one would expect the human Fit-l probe to show evidence of 
cross species conservation. Consequently, zooblot analysis was performed on 
DNA from various species with with the human Fit-1 probe (Figure 4.4). This 
identified discrete bands in human, monkey, mouse, dog, cow and rabbit DNA 
which hybridised to the probe, thus confirming the conservation of the human 
Fit-l locus. This analysis suggests that it might play an important role in the 
biological function of the cell. Flowever, despite this intriguing conserved open 
reading frame at Fit-1, no transcripts were identified on northern blot analysis
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Figure 4.3 A. DNA sequence comparison of the human and feline Fit- 1 regions. 
A comparison o f the DNA sequences between the feline (F) and human (H) Fit- 1 
DNA sequence derived from the Pvull Fit-l positive subclone is shown. 
Accession numbers: feline Fit-1, AF113885; human Fit-1, AF113886. Gaps 
have been introduced for maximum alignment. The putative splice donor and 
splice acceptor sites which are conserved between feline and human are 
underlined; the huorf-f and huorf-r oligonucleotide primers which amplify the 
human Fit- 1 probe and the or IF and orlR  primers which amplify the feline Fit- 1 
probe are indicated in bold.
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H NWFSGTVNTCSLEELQFCVRSCDRRPVAFSYTSTTQVAWCRVKKKSYFP 5 0 
F NWFSGTVSTCSLEECQLCLRSCDRRAMAFSYTRTTQVTWCLVPKKKKFD -50
H FEA-QKLPASGVWTLPSCLDVCSLVYGDSCSILSLCHMVYR 91  
F LRSCQPMSCCTLSVFVSGCFSVCSHVYCDSCSVLSLCHMVHK 92
H3 * S PETASLWSCCD- AAFMSGCLFPCVR* 78
Figure 4.3B. Predicted peptide sequence comparison of the human and feline 
Fit- 1 regions. A comparison of the predicted peptide sequences from the feline 
(F) Fit-1 open reading frame (bold type) and the human (H) Pvull clone. The 
upper sequence is the predicted human peptide sequence in reading frame 1. The 
boxed sequence is the predicted human peptide sequence in reading frame 3 (H3). 
Gaps have been introduced for maximum alignment. Key: (I), identity; (:), 
conservative amino acid change; (.), neutral change. This figure shows that the 
open reading frame in the feline Fit-l sequence is conserved in the human, 
however maximum alignment requires a short frame shift from reading frame 1 
to 3.
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Figure 4.4 Zooblot analysis with the human F/7-1 probe. Interspecies 
zooblot (Clontech Laboratories, Inc.) containing 4pg of genomic DNA 
per lane digested with EcoRI was probed with the human F/7-1 probe. 
The blot was washed at low stringency (three times in 2 X SSC, 0.5% 
SDS, 60oC). The sizes of the ZHindlll DNA size markers are indicated 
(kb).
using poly A+ selected mRNA extracted from various human T cell leukemia 
lines (not shown).
4.2.5 Relevance of Fit-1 to human tumours
As discussed in section 3.1, Fit-1 has been mapped to feline chromosome B2 (42) 
and mouse chromosome 10, lcM  from Ahi-1, a common insertion locus which 
has been mapped 35kb downstream of c-myb (18; 157). The localisation of Fit-1 
to human chromosome 6 has now been confirmed by the isolation of the 
homologous region from a human chromosome 6 cosmid library. Thus, we can 
infer that the likely position o f Fit-1 on chromosome 6 is somewhere in the 
vicinity of c-myb at 6q23.3-q24 (163). The long arm of chromosome 6 (6q) is 
often affected by genetic changes where deletions o f 6q (6q-) are among the most 
frequent chromosomal aberrations observed in malignant lymphomas and 
lymphoblastic leukaemias (164; 165). This suggests the existence of sequences 
involved in the control of cellular growth within the long arm of chromosome 6.
A human T cell leukaemia line which is not 6q-, the CEM cell line, has been 
reported to have chromosomal changes at 6q and rearrangements at the c-myb 
promoter region (166). Therefore, to establish whether the CEM cell line is also 
rearranged at Fit-1, a Southern blot o f CEM and control (Jurkat) DNA digested 
with Pstl, EcoRl and Sstl was hybridised with the human Fit-1 probe (Figure 
4.4A). Interestingly, this identified two closely linked restriction fragment length 
polymorphisms (RFLP) in CEM DNA at the Fit-l locus. The Pstl genomic 
fragment which hybridises to Fit-\ in Jurkat DNA is 6.5kb, whereas in CEM 
DNA there is an additional Fit-\ hybridising fragment of approximately 9kb 
(Figure 4.5A, arrowhead). Furthermore, the EcoRl/Sstl double digest has an 
additional Fit-\ hybridising band at lOkb which is not present in the control 
(Figure 4.5A, arrow). This suggests that both the Pstl and the Sstl restriction 
enzyme sites are lost in a subset of CEM cells. These data are summarised in 
Figure 4.5B.
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Figure 4.5 A. The CEM cell line has two RFLPs at Fit- \ . 20pg of CEM (C) 
and control (Jurkat, J) DNA was digested with the restriction enzymes as 
shown and hybridised with the human Fit- 1 probe. Southern blots were 
washed at high stringency (0.1 X SSC, 0.5% SDS, 60oC). Molecular size 
markers were X Hindlll restriction fragments and are indicated in kilobases. 
This figure demonstrates that CEM DNA has an RFLP at Fit- 1 with a Pst\ 
digest (arrowhead), and with Sstl (arrow).
Figure 4.5B. Partial restriction map of the human Fit- 1 region highlighting 
the positions of the Pstl and Sstl sites which are lost in a subset of CEM cells 
(arrows). The position of the F it-l probe is also illustrated (closed box). 
Restriction enzyme abbreviations: E, EcoRl; H2, H incll’, H3, Hindlll', P, 
Pstl; P2, Pvull] RV, EcoRV; SI; Sstl; Xb, Xbal.
To further characterise the apparent rearrangement seen in CEM DNA with the 
Fit-1 probe, CEM DNA was analysed by Southern blot with a number of 
restriction enzymes and hybridised with the human Fit-1 probe. This analysis 
failed to reveal any further RFLPs at Fit- 1 in CEM DNA (not shown). 
Furthermore, cloning of the region surrounding the Pstl and the Sstl restriction 
sites in CEM DNA, and subsequent sequence analysis confirmed that these 
RFLPs were simple base change polymorphisms, only differing from Jurkat DNA 
at the Pstl and/or Sstl restriction enzyme sites (Table 4.1).
Table 4.1 Summary of the CEM clones which have a Pstl and Sstl 
restriction enzyme site.
clone Pstl site Sstl site
5.1 - -
5.3 + T
5.4 - -
30.1 - +
30.3 + +
8f - -
a clone 5.3 did not extend as far as the Sstl genomic site.
4.3 Discussion
In order to extend the search for adjacent genes in a species where there are 
greater resources available for genomic analysis, the human Fit- 1 homologous 
region was cloned from a chromosome 6 cosmid library. From analysis of DNA 
sequence from a Pvull subclone homologous to Fit-1, the putative long open 
reading frame identified in the cat within the XRF1 subclone 7 (Figure 3.6) was 
found to be conserved in humans (Figure 4.3B). Apart from a short frame shift, 
the differences were mainly conservative amino acid changes, further 
emphasising the importance of the Fit- 1 region. Despite this high degree of 
conservation, the human Fit-l probe did not identify any transcripts on northern 
blot analysis. However, the human Fit- 1 probe will serve as a useful tool to 
identify novel proto-oncogene(s) which are closely linked on chromosome 6.
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The long arm of chromosome 6 is the site of frequent genetic alterations, most of 
which are concentrated around 6q23 (164; 165; 167-169), the likely position of 
human Fit-1 based on linkage analysis in the mouse (157). Together, these 
examples lend support to the presence of a tumour suppressor gene or a gene 
involved in the control of cellular growth at this region of chromosome 6.
Although it has been reported that c-myb gene activation is not involved in 6q- 
abnormalities of lymphoid tumours (170), an acute lymphoblastic leukaemia cell 
line (CEM) has been identified with a submicroscopic deletion within 
chromosome 6q involving c-myb (166). This deletion results in the loss o f a 
highly conserved region of the c-myb promoter in this cell line. However, no 
effect has been noted on c-myb promoter activity. Therefore, it is unclear what 
the effect of this deletion is. It is possible that it may induce subtle changes in the 
expression of c-myb or that it may have an effect on another loci in this region of 
chromosome 6.
Therefore, the involvement of Fit- 1 in the CEM cell line was investigated 
revealing an apparent rearrangement at Fit-\ with Pstl and Sstl digests (Figure 
4.5A). This was of great interest because of the relatively close proximity of c- 
myb to Fit-1 implied by linkage analysis in the mouse. However, a series of 
additional digests failed to reveal any further rearranging bands with the Fit-1 
probe in CEM DNA. Furthermore, sequence analysis showed that CEM 
sequence only diverged from control (Jurkat) sequence by a single base 
substitution at either or both of the closely linked Pstl or Sstl restriction sites. 
Although this RFLP was found to be due to a simple base change polymorphism 
in the restriction sites, a possible role for Fit-1 in the CEM cell line is still worth 
bearing in mind.
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CHAPTER 5
Chapter 5
5. Generation of a cosmid and PAC contig of the human Fit-1 region
5.1 Introduction
The conserved feline Fit- 1 probe and a series of other unique sequence probes 
from 30kb of DNA flanking the insertion cluster failed to show any evidence of a 
transcription unit which was activated as a result of viral insertion. Furthermore, 
the human Fit-l probe also failed to identify transcripts in either normal or 
tumour RNA. This was surprising considering that 16% of the feline lymphomas 
screened were rearranged at Fit-1, suggesting that this region o f the chromosome 
harbours a gene which is involved in lymphomagenesis.
However, as alluded to in chapter 3, pro viral integration at Fit-l may influence a 
gene which is outwith the region covered by the phage or cosmid clones. 
Therefore, I entered upon a wider gene hunting investigation in the human 
genome by generating a contiguous physical map around the Fit-l locus. Initially 
this was achieved by screening a chromosome 6 specific cosmid library for 
cosmid clones which overlap with cosmid 1, and subsequently by isolating 
overlapping PAC clones which can accommodate much larger inserts.
5.1.1 Contig assembly and genomic mapping studies
A number of cloning vectors have been designed for large scale genomic 
mapping studies of complex genomes. The relative merits of each of these are 
summarised in Table 5.1. A major consideration for the choice of cloning vector 
is the size of exogenous insert DNA that is maintained. YACs (yeast artificial 
chromosomes) were developed as high-capacity cloning vectors that can be 
transformed into yeast where they are maintained as artificial chromosomes 
(171). YACs can propagate exogenous DNA of up to l,000kb in length. 
Whereas, cosmids can only accommodate an average of 40kb of insert DNA. Of 
intermediate size are BAC (bacterial artificial chromosmes) and PI derived 
bacteriophage based cloning systems. BAC vectors are based on the E.coli 
fertility plasmid (F factor) and can propagate exogenous DNA inserts of up to
105
300kb (172). The traditional bacteriophage PI packaging system can accept 
inserts o f 70-100kb in length (173). More recently, a modification of the 
bacteriophage PI cloning vector was developed, the PAC (PI-derived artificial 
chromosome), which can carry inserts o f up to 300kb, but more typically around 
130-150kb (174). Each of these cloning vectors have their advantages and 
disadvantages which are summarised in Table 5.1.
Table 5.1 The relative merits of various vehicles of large scale genomic
mapping studies
Cloning 
vector 
....Y A C ...
Advantages Disadvantages Reference
..
Very large inserts (up to 
lOOOkb).
Low transformation
efficiency.
Chimaerism3.
Insert instability. 
Difficulties in DNA 
manipulation.
BAC Large inserts (> 300kb).
No chimaerism or instability. 
Electroporation b.
Easy DNA manipulation0.
DNA recovery low.
No positive selection of 
recombinants.
(172)
PAC Large inserts (100-300kb). 
No chimaerism or instability. 
Electroporation15.
Easy DNA manipulationc. 
Can select for recombinants.
Small insert size Relative to 
YACs.
(174)
T l73)PI
derived
Reasonably large inserts (70- 
lOOkb).
Can select for recombinants. 
No chimaerism or instability.
Smaller insert size than 
PACs.
Elaborate in vitro packaging 
system required.
Cosmid Relatively small inserts (35- 
50kb).
Easy DNA manipulation. 
Chromosme specific 
libraries available.
Relatively small inserts (35- 
50kb).
Frequent insert instability.
(176)
a Chimaeric clones are generated by either co-ligation of unlinked sequences, or by in vivo 
recombination following the transformation of multiple YACs into the same yeast cell (175). 
b The advantage o f electroporation based transfer o f DNA is that it avoids the use o f elaborate 
packaging systems and reduces site-specific recombination events. 
c Transformation in E.coli allows for simple alkaline lysis based DNA recovery (89).
106
5.1.2 Sequence-tagged sites (STS) and genomic mapping
Following the identification of a clone from a genomic library which contains the 
sequence of interest, a contiguous physical map surrounding this region can be 
generated. A number of fingerprinting procedures have been utilised to 
determine overlap and to generate an ordered representation of clones (a so-called 
contig).
The mapping of complex genomes has been revolutionised by the advent of 
sequence-tagged site (STS) content mapping as a strategy for identifying clones 
which overlap (177). STSs are single copy sequences of typically 200-500bp in 
length which are used to construct genetic and physical maps of the genome. 
Each site is defined by a unique set o f PCR primers which amplify a specific 
single copy product under specified PCR conditions (reviewed in (178)). STS 
content mapping is based on the assumption that any two clones which share the 
same STS must overlap. Thus, any unique sequence in the genome can be used 
as an STS to identify overlapping clones which represent a specific region of the 
genome. Furthermore, because a STS is simply described by a set o f specific 
PCR primers, STS based mapping allows for community access through a 
database (177).
A parallel to STS content mapping involves the use of primers for Alu sequences 
(,4/w-PCR) which was first described by Nelson (179). Inter-y4/w PCR is a 
method whereby DNA sequences which fall between Alu repeats in the human 
genome are amplified to generate random probes or STSs which can be used to 
identify clones that overlap. In this way, two clones which share a similar pattern 
of Alu-PCR fragments after gel electrophoresis must overlap. Similarly, in 
chromosomal walking, Alu specific primers and primers derived from the vector 
can be used to amplify sequence from the end of a particular clone, again to 
identify overlapping clones (178; 179).
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The ultimate goal o f the Human Genome Project is to sequence the entire human 
genome. Toward this end, genetic and physical maps of the chromosomes are 
being constructed using techniques such as those discussed above. A vast and 
ever increasing number of genomic regions have been mapped, perhaps most 
notably a YAC contig map which covers 75% of the human genome (180). 
Emphasis in the earlier stages has been to characterise regions containing genes. 
There are various ways in which regions coding for a gene may be identified such 
as those discussed in section 1.2.1. In addition, ESTs (expressed sequence tags), 
which are STSs derived from a cDNA clone, have also aided in the mapping of 
the human genome and have the added advantage of directly pointing to an 
expressed gene (181).
5.2 Methods
5.2.1 Screening of a PAC library by PCR
The human PAC library (number 704) from RZPD, consists o f 39 primary pools 
of clones which have been pooled in a three dimensional system from a series of 
96 well microtitre plates. The library is screened by performing PCR on lp l of 
primary pool using standard cycling conditions (section 2.2.6) and either the 
huorf-f / huorf-r primers (to amplify the human Fit-l probe sequence) or the 
coslSP66 / coslSP67 primers (to amplify the cos7 probe sequence). Positive 
pools were identified by visualisation of the PCR product following gel 
electrophoresis and ethidium bromide staining. A positive pool was confirmed 
by hybridisation of a Southern blot o f the PCR products with a probe derived 
from the PCR primers used (either the human Fit-l probe or the cos7 probe). 
Based on the positves identified from the primary pools, secondary pools are then 
obtained from RZPD and a second round of PCR screening performed. In this 
way the specific X, Y coordinates o f the corresponding clone(s) were identified 
and requested from RZPD. Positive clones were confirmed by Grunstein and 
Hogness colony hybridisation analysis (153).
5.2.2 Pulsed Field Gel Electrophoresis (PFGE)
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1 pig of PAC DNA was digested with various combinations of rare-cutting 
restriction enzymes according to the manufacturer’s instructions and loaded into 
each well of a 200ml 1% agarose gel in 0.5 X TBE. Pulsed-field gel 
electrophoresis (CHEF-DR II Pulsed Field Electrophoresis Systems, Bio-Rad) 
was run at 6V/cm for 16 h with a pulse time of 1-6 s in 0.5 X TBE kept at a 
constant temperature of 14°C. As molecular weight markers, 5Kb Ladder, X 
50Kb Ladder (Bio-Rad) and X Hindlll fragments (GibcoBRL) were used. 
Following electrophoresis, the gels were stained with ethidium bromide.
5.2.3 Southern blot transfer of large DNA fragments
Since large DNA fragments cannot be transferred efficiently, DNA fragments 
separated by PFGE were cleaved before transfer onto membranes by UV 
irradiation at 60mJoules (Spectrolinker XL-1500 UV Crosslinker, Spectronics 
Corporation). Following cleavage, the size separated fragments were equilibrated 
in transfer buffer (0.4N NaOH, 1.5M NaCl) for 15 min and the DNA transferred 
onto Hybond-N+ (Amersham) by capillary blotting in transfer buffer for at least 
48 hours. The membrane was neutralised in 0.5M Tris-HCl pH7.0 for 5 min, 
followed by equilibration in 2 X SSC. The complete transfer of DNA from the 
gel to the membrane was confirmed by staining the gel post transfer with 
ethidium bromide and viewed on a short wave UV transilluminator (UVP Inc.). 
Specific DNA fragments were detected by hybridisation as described previously 
(section 2.2.8.5) using the human Fit- 1 or c-myb exon 2 probes.
5.3 Results
5.3.1 Isolation of an overlapping cosmid clone
In order to extend the search for genes flanking the Fit-l locus in the human 
genome, the RZPD chromosome 6 cosmid library was screened for clones which 
overlap with the Fit- 1 positive cosmid clone (cosmid 1). To this end, probes 
from the termini of cosmid 1 were isolated and used to re-probe the cosmid 
library filter. The cosmid vector (Lawrist 4) contains the SP6 and T7 promoter 
primer sites which flank the cloning site. Therefore, by performing cycle 
sequencing reactions with IRD41 fluorescent labelled SP6 and T7 primers (see
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section 2.9) and using cosmid 1 DNA as template, DNA sequence from the 
termini of the cosmid 1 DNA insert was obtained (not shown). By comparing the 
DNA sequence with published sequences (NCBI Blast search), repetitive 
elements, such as Alu repeats, were identified and excluded. Any sequence 
which did not reveal any homology with known repetitive elements was used to 
design STS PCR primers. If the sequence obtained with the SP6 or T7 primers 
was repetitive, another round of cycle sequencing was performed by desigfting 
primers based on the available sequence. Figure 5.1 shows two sets of STS PCR 
primers from cosmid 1 termini: coslSP66 and coslSP67 from the SP6 end of the 
clone; and coslT75 and coslT76 from the T7 end of the clone (Appendix 1).
Following the identification of the STS primers described above, the DNA 
between these primers was amplified by PCR (Figure 5.1) using standard 
conditions (section 2.2.6). To confirm that these sequences were single copy, the 
PCR products were gel purified, labelled with [a 32P] dCTP and used to probe a 
Southern blot of total human DNA (Jurkat) digested with various restriction 
enzymes. Two probes, coslSP667 and coslT756 from the SP6 and T7 termini of 
cosmid 1 respectively (Figure 5.1) were identified and confirmed as single copy 
by Southern blot analysis. However, when used to probe the RZPD chromosome 
6 cosmid library filter, only the coslSP667 probe from the SP6 terminus of 
cosmid 1 identified an overlapping clone, ICRFcl09B0915Q5 (cosmid 7), and 
from then on this probe was renamed the cos7 probe. Thus, the generation of an 
overlapping contig extending in both directions from the Fit-\ region was not 
possible.
5.3.2 Isolation of overlapping PAC clones
To extend genomic mapping in both directions around the Fit-\ region, it was 
decided to isolate PAC clones positive for Fit-l and/or cos7. PACs offer several 
advantages over cosmids, most notably the significantly larger insert size which 
can be accommodated compared to cosmids (Table 5.1). The human PAC library 
(number 704) from RZPD was screened by two rounds of PCR as outlined in 
section 5.2.1. The PCR primers used were huorf-f and huorf-r (Appendix 1) to
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SP6
Cosmid 1
T7
cos 1SP66 cos 1SP67
PCR
coslT76 coslT75
PCR
coslSP667 probe coslT756 probe
Purify PCR fragment Purify PCR fragment
Probe Southern blot Probe Southern blot
Single copy probe, 
identified
single copy probe 
identified
Probe library Probe library
cos7 probe No overlapping clone
Cosmid 7
Figure 5.1 Strategy to identify clones which overlap with cosmid 1. Not to 
scale. The arrows indicate the positions of the SP6 or T7 cycle sequencing 
primers from the vector sequence. The half arrows indicate STS primers (see 
Appendix 1 for sequence and Table 5.3 for nomenclature). The solid boxes 
represent probe fragments derived from STS PCR.
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amplify the conserved human Fit-1 open reading frame; and coslSP66 and 
coslSP67 (Appendix 1) to amplify the cos7 probe sequence. These primer sets 
amplify single copy sequences of 478bp and 498bp respectively and represent a 
pair of STSs from the Fit-l region. Following primary and secondary PCRs, four 
PAC clones were confirmed as positive for one or both of the above STSs (Table
5.2).
Table 5.2 The Fit-1 and cos7 positive PAC clones
RZPD clone name Clone Fit-l cos 7 Size (kb)
LLNLP704L0612 PAC b + + 140
LLNLP704P0794 PACe + - 130
LLNLP704L01315 PA Cn + + 135
LLNLP704M01112 - P A C * ....... - 125
5.3.3 STS content mapping of PAC and cosmid clones
To generate a contiguous map of the region encompassing the Fit-l and cos7 
positive PAC and cosmid clones, end-specific STSs were designed to 
demonstrate overlap within the contig. DNA sequence information derived from 
both insert ends of each PAC and cosmid clone was generated by sequencing 
with the SP6 and T7 IRD-41 labelled cycle sequencing primers from the cloning 
sites of the cosmid (Lawrist 4) or PAC (pCYPAC-2N) vectors.
This allowed the development of PCR assays specific for STSs from both ends of 
each clone, except for PAC b where only one end-specific STS could be 
generated due to incomplete sequence data. STS primer pairs from the SP6 and 
T7 insert ends of each clone are shown on Table 5.3. Using standard PCR 
cycling conditions (2.2.6), each terminal STS primer pair was used to analyse 
DNA from the four PAC and two cosmid clones to determine which contained 
these STSs and hence establish overlap. These data are summarised in Table 5.3 
and Figure 5.2. For example, the PAC b end-specific STS from the T7 terminus 
of this clone (bT72 and bT73) is present in PAC clones b, e and n (Figure 5.2, 
red). Therefore, the T7 insert end of PAC b overlaps with PACs e and n, but not 
with PAC p or cosmids 1 and 7.
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Table 5.3 Summary of STS content mapping
Clone Fit-l cos7 | Terminal STS primer 
pairs a
Positive P A C /  cosmid 
clones
cosmid 1 +
coslT75 & coslT76
+
cos 1SP66 & cos 1SP67
b, e, n, 1 
b, n, p, 1,7
cosmid 7 -
cos7T71 & cos7T72
+
| cos7SP61 & cos7SP62
b, P, 7
b, e, n, p, 1 ,7____
b, e, n
PAC b +
bT72 &  bT73
+  |
PAC e +
eT71 &  eT72 
eSP61 &  eSP62
b, e, n, p, 1, 7 
e, n
PACn +
nT71 &  nT72
+  i
I  nSP61 &  nSP62
b, n, p, 7
e, n
P AC p -
pT71 &  pT72
+
pSP62 & pSP63
b, p 
b, e, n, p, 1
a Nomenclature: each primer is named after the clone from which it is derived, from either the 
T7 or SP6 terminus and a specific number depending on how many rounds o f sequencing/PCR 
were required to identify single copy sequence. For all primer sequences, see Appendix 1.
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cosmid 1 cosiSP66  
coslSP67
coslT76
coslT75
(cos7)
cos7T71 
cosT72 1
cos7SP62 cosmid 7 
cos7SP61
bT73 ■«— bT72
PACe eT71 eT72 eSP62 ~ e S P 6 1
PAC n
nT71 nT72 nSP62 nSP61
pT71 pT72 pSP63 pSP62 PAC p
Figure 5.2 STS content mapping o f the cosmid and PAC clones around F it-1. 
This figure shows the positions o f  the end-specific STS primer pairs from each 
clone (half arrows). The solid line below each STS primer pair represents the 
PCR product. The other clones which also contain this STS (as determined by 
PCR) are also shown directly above or below this. In this way clones which 
overlap were determined. As an example, the PAC b STS primer pair (bT72 
and bT73) and PCR product are highlighted in red This figure is not drawn to 
scale. For nomenclature, see Table 5.3 and for primer sequences, see Appendix 
1.
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5.3.4 Sequence analysis of PAC clones reveals homology to c-myb
Whilst sequencing from the T7 end of PAC p, a comparison of this sequence with 
the database of published sequences (NCBI Blast search) revealed 99% 
homology to the c-myb oncogene over 727bp (Figure 5.3). This places c-myb and 
Fit-\ within the same contiguous region of the human genome. The region of 
homology falls between the nucleotides 19081 to 19807 of the c-myb gene. This 
is synonymous with the region around exon 10 of this gene (Figure 5.3).
5.3.5 Long-range restriction mapping of overlapping PAC clones by PFGE 
places Fit-1 lOOkb upstream of c-myb
Following the identification of Fit-\ and c-myb on the same PAC clone, three 
overlapping PAC clones spanning the entire cloned region (PACs b, n and p) 
were characterised by pulsed-field gel electrophoresis (PFGE) to establish the 
proximity of Fit-l and c-myb on human chromosome 6. DNA was digested with 
the rare-cutting restriction enzymes Notl (which excises the insert from the 
vector), TfosHII, Clal, EclX  I, Sail and Sstl I in various combinations and separated 
by PFGE (section 5.2.2 and 5.2.3). Southern blots o f the size separated DNA 
fragments were hybridised with the human Fit-l probe (generated by PCR with 
the huorf-f and huorf-r primers, Appendix 1). Following stripping of the probe, 
the filter was hybridised with a human c-myb exon 2 specific probe (generated by 
PCR with the exon2f and exon2r primers, Appendix 1). One representative 
Southern blot of the PAC b clone hybridised with Fit-\ (Figure 5.4A) or c-myb 
(Figure 5.4B) is shown. This result confirms the sequencing data which places c- 
myb within the same contiguous region. Southern blot analysis of PACs n and p 
are not shown. A long-range restriction map of approximately 200kb of cloned 
DNA surrounding the Fit- 1 region is presented in Figure 5.5. These data placed 
Fit- 1 and c-myb on a single PAC clone, approximately 1 OOkb apart.
5.4 Discussion
To extend the search for a closely linked proto-oncogene which may be the target 
o f insertion at Fit-1, overlapping cosmid and PAC clones extending in both 
directions were isolated and characterised. An overlapping contig map spanning
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727 TTTACCTTGGAATTGTTTAAGGAACACCTAGTTTTTTCCCAGAACTTTAGTGTTCTGAGA P
I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I
19081 TTTACCTTGGAATTGTTTAAGGAACACCTAGTTTTTTCCCAGAACTTTAGTGTTCTGAGA M 
667 GACACAGTTTATTATTCAAGAATTTTCCATATAATGTAAACCTTCTGTAATACTAATTTT P
I II I I I I I I II I I i II I I I I I II I I I I I I I II II I I I I I M II II I I I I I I I II II II I I
19141  GACACAGTTTATTATTCAAGAATTTTCCATATAATGTAAACCTTCTGTAATACTAATTTT M 
607 GGTTCATAGATTATTAAAGAGAAAAAACAAAGTATGAAAGGAAACTATTAATTATTAACT P
I ; 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I I I I I I I 1 1 1 1 1 1 I I 1 1 1 1 1 1 1 1 1  MM 1 1 1 1 1 1 1 I I 1 1 1 1
192 01 GGTTCATAGATTATTAAAGAGAAAAAACAAAGTATGAAAGGAAACTATTAATTATTAACT M 
54 7 ATTATTTTCCCCAAAATCACTAAAGCCTTTTAAATGTTAATAAAGAACACATCTCATTCT P
I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I II II I I I I I I I I I I I I I I I I I I I I I
192 61 ATTATTTTCCCCAAAATCACTAAAGCCTTTTAAATGTTAATAAAGAACACATCTCATTCT M 
4 87 CTTTAATGACAAGTGTCATTTATTGAGAGTATTTTCTCACAGTTTTGCAAGTTTTTCAGC P
I I II I I II I I II I I I II I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
193 21 c t t t a a t g a c a a g t g t c a t t t a t t g a g a g t a t t t t c t c a c a g t t t t g c a a g t t t t t c a g c  m
42 7 AATGACCCTAAATTTTATTTCTTGGAAACCACACCCAAATCCTGGGTGCTCAATTGAAAT P
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
193 81 AATGACCCTAAATTTTATTTCTTGGAAACCACACCCAAATCCTGGGTGCTCAATTGAAAT M 
367 AAAACAATACCCTAGTCAATATAACATGCTTGTTAGCATCTTTATTATTTAATATAGTGG P
I I I I I I II I M I M I I I II I M I II M II M I II M M II I I I I  I I I I M I I I I  I 11 I M
19441  AAAACAATACCCTAGTCAATATAACATGCTTGTTAGCATCTTTATTATTTAATATAGTGG M 
3 07 GTCAGGAAAACATTCTTGTTATCTAGGTGTGATTTTTAAATTGGGGAGAATAAAGAATTA P
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
195 01 GTCAGGAAAACATTCTTGTTATCTAGGTGTGATTTTTAAATTGGGGAGAATAAAGAATTA M 
24 7 CCATCTAATCTAAGTATTTTTTCTTTCTCTCCATATTTAGTTCTTAAACACTTCCAGTAA P
I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I II I I I I I I I I II I I I I I
19561  CCATCTAATCTAAGTATTTTTTCTTTCTCTCCATATTTAGTTCTTAAACACTTCCAGTAA M 
187 CCATGAAAACTCAGACTTGGAAATNCCTTCTTTAACTTCCACCCCCCTCATTGGTCACAA P
I M I II I I M I I M I N I  II I N  11111 I I 111111 11 111 11111 I I 11111 11 I 11
19621  CCATGAAAACTCAGACTTGGAAATGCCTTCTTTAACTTCCACCCCCCTCATTGGTCACAA M 
12 7 ATTGACTGTTACAACACCATTTCATAGAGACCAGACTGTGAAAACTCAAAAGGAAAATAC P
I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I II I I I I I I I
19681  ATTGACTGTTACAACACCATTTCATAGAGACCAGACTGTGAAAACTCAAAAGGAAAATAC M 
67 TGTGTAAGTCTTTGGTTCAGGAATAAAATGATTTATCTTATTTACTTATATTTAATTAAT P
I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I M I
19741  TGTGTAAGTCTTTGGTTCAGGAATAAAATGATTTATCTTATTTACTTATATTTAATTAAT M 
7 GGAATAT P
l l l l l l l
19801  GGAATAT M
Figure 5.3 Blast search results with PAC p terminal sequence. This figure shows 
the homology between sequence derived from PAC p (P) with human c-myb (M) 
sequence between 19081 and 19807 bp. Exon 10 lies between 19601 bp and 
19743 bp of the human c-myb gene (accession number U22376, Westin EH and 
Gorse KM, unpublished).
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Figure 5.4A Southern blot analysis of PAC b DNA hybridised with the human 
Fit-1 probe. The approximate positions of the DNA size markers (5kb ladder 
and X ladder) are shown on the left in kb. Restriction enzyme abbreviations: N, 
Notl; XI, EclXI; B, /fasHII; SII, SstU; S, Sail; C, Clal. Washing conditions: 
three times at 0.1 X SSC, 0.5% SDS, 60oC, 20 min.
Figure 5.4B Southern blot analysis of PAC b DNA hybridised with the c-myb 
exon2 probe. The approximate positions of the DNA size markers (5kb ladder 
and X ladder) are shown on the left in kb. Restriction enzyme abbreviations: N, 
Notl; XI, EclXI; B, /fasHII; SII, Sstll; S, Sail; C, Cla\. Washing conditions: 
three times at 0.1 X SSC, 0.5% SDS, 6O0C, 20 min.
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approximately 200kb of genomic sequence was generated using a combination of 
STS content mapping and long-range restriction mapping by PFGE (Figure 5.5).
A high degree of homology with the c-myb proto-oncogene was identified in 
PAC p (Figure 5.3) suggesting that Fit-1 and c-myb are closely linked on 
chromosome 6. Southern blot analysis confirmed this linkage and placed Fit-1 
approximately lOOkb upstream of c-myb (Figure 5.4B). Recent genetic linkage 
data in the mouse placed Fit-l lcM  proximal to the Abelson MuLV common 
insertion site, Ahi-1, which has been previously mapped to mouse chromosome 
10, 35kb downstream of c-myb (Figure 3.2 and (18; 157)). lcM  is approximately 
equivalent to 2Mb in physical distance. Clearly, this figure is inconsistent with 
the human physical mapping data and this disparity is discussed further in chapter 
7.
Three lines of evidence suggest that Fit-l maps upstream o f c-myb. Firstly, 
sequence analysis of the T7 terminus of PAC p reveals that it carries sequence 
homologous to exon 10 of c-myb (Figure 5.3). Secondly, PAC b DNA hybridised 
specifically with an exon 2 c-myb probe (Figure 5.4B). Thirdly, a cluster of rare 
cutting restriction enzymes which cleave DNA at CpG containing sites (SstlI, 
ZfasHII and EclXl, Figure 5.5A), is consistent with previous results which suggest 
the presence of a CpG island at the 5' end of the c-myb gene (170).
A possible explanation for the close linkage of Fit-l to c-myb is that proviral 
integration within this locus activates c-myb expression by a long-range enhancer 
insertion mechanism. Such long-range cis activation of gene expression has been 
demonstrated previously for c-myc, Evi-l and Cyclin D1 (28;41;64). Although 
initial analysis did not detect any abnormalities in c-myb expression in primary 
tumours rearranged at Fit-1 (42), the FT1 cell line with a proviral insertion at Fit- 
1 made it possible for subtle changes in c-myb expression to be investigated.
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Chapter 6
6. Analysis of c-myb expression in the FT1 cell line
6.1 Introduction
The Fit- 1 locus has now been mapped close to c-myb in the human and mouse 
genomes (Figures 5.5 and 3.1 respectively and (157)). If the physical map of Fit- 
1 and c-myb is conserved in the feline genome, it is conceivable that proviral 
insertion within the Fit-l region affects expression of the c-myb gene. This 
possibly deregulated expression may be responsible for the genesis of the 
observed T cell lymphomas, a hypothesis which is further supported by the 
observation of activated c-myb in other lymphomas of T cell origin (182; 183).
Long-range c/s-activation by proviral insertion has been observed previously for 
the c-myc oncogene where proviral insertions at the 3' end of the gene up to 
300kb away have been shown to activate its expression (63;64). Therefore, due 
to the close proximity of Fit-1 and c-myb and the lack of transcription units 
activated by proviral insertion within 30kb of cloned feline genomic DNA, the 
expression of this oncogene was analysed in the FT1 cell line which is rearranged 
at Fit-1. The expression of c-myb in primary tumours earring proviral insertions 
at Fit-l has been analysed previously (42). However, its expression has never 
been determined in a cell line where more subtle alterations in expression can be 
explored.
6.1.1 The c-myb oncogene
c-myb is a member of a family of nuclear transcription factors which also 
contains A- and B-myb. c-Myb plays a central role in proliferation, 
differentiation and apoptosis, primarily in haematopoietic cells (184), but also in 
non-haematopoietic cells such as bovine smooth muscle cells (185). The loss of 
N- or C-terminal sequences or its deregulated expression can convert c-Myb into 
a potent transforming protein in haematopoietic cells (186).
6.1.2 c-Myb in differentiation, proliferation and apoptosis
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The expression of c-myb is predominantly confined to undifferentiated 
haematopoietic cells and as the cells mature expression disappears. The role of c- 
Myb in differentiation can be demonstrated in homozygous null mutant mice 
which do not survive past day 15 of foetal development and where 
haematopoiesis is severely impaired (187). Furthermore, immature myeloid or 
erythroid cells constitutively expressing wild type or truncated c-myb continue to 
proliferate in the presence of differentiation inducing agent, implying a crucial 
role for c-myb in haematopoietic cell development (188-190). c-Myb has also 
been shown to regulate a wide range of genes which are important for 
differentiation (reviewed in (184)).
A large body of evidence exists suggesting a significant role for c-myb in 
proliferation as illustrated by its frequent activation in neoplasia (186). c-Myb 
activity is directed to the G,/S phase of the cell cycle (Figure 6.1) (191; 192) and 
it has been demonstrated that c-myb, when co-microinjected with c-myc, can 
drive quiescent bovine smooth muscle cells to progress into the S phase of the 
cell cycle (193). As cells enter terminal differentiation, c-myb expression is 
suppressed (Figure 6.1). This is supported by the observation that myeloblastic 
leukaemia M l cells, which can be induced to terminally differentiate with 
interleukin 6 (IL6), continue to proliferate in response to IL6 when they 
constitutively express c-myb (190). Initial studies with anitisense c-myb 
oligonucleotides which inhibit c-Myb function resulted in the inhibition of 
growth of haematopoietic cell lines and blocked cells in the G /S  phase of the cell 
cycle, providing direct evidence of a role for c-Myb in proliferation (194; 195). 
These results have been consolidated with observations confirming that c-Myb is 
required for cell cycle progression: firstly, an inducible, dominant negative c- 
Myb construct resulted in the inhibition of proliferation in T cells and arrest in G, 
(196); and secondly, ribozymes specifically directed against c-myb result in arrest 
o f cell growth in smooth muscle cells (197).
That c-Myb plays an important role in regulating proliferation can be further 
demonstrated by the genes which it has been reproted to transactivate. These
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include c-myc which also has a central role in proliferation (see section 1.2.8). A 
number o f studies support a role for c-myb in the transactivation of the c-myc 
promoter in vitro by direct binding to the c-myc promoter region (198; 199), and 
that the constitutive expression of c-myb abolished the downregulation of c-myc 
during differentiation (190).
GO
Ic-Myt/
c-Myb
G2,
G1
t c-Myb,
Apoptosis
Terminal
differentiation
Figure 6.1. c-Myb and the cell cycle. The levels of cellular c-Myb increase 
during the G]/S phase of the cell cycle and decrease as cells enter G0 (indicated 
by single arrows). The effects of over-expression of c-Myb (as indicated by the 
double arrows) on apoptosis and terminal differentiation are also shown.
In addition to proliferation and differentiation, a role for c-Myb in apoptosis has 
recently been described in T cells and myeloid cells (183;200). The first study 
utilised an inducible, dominant negative c-Myb protein in the EL4 T cell 
lymphoma line and in transgenic mice. Activation of this mutant resulted in an 
increase in apoptosis which directly correlated with the downregulation of the 
anti-apoptotic protein, Bcl-2 (183). The second study used a temperature- 
sensitive mutant of the E26 avian leukosis virus encoding myb-ets. In this system 
culture of myeloid cells at the non-permissive temperature inactivates v-myb and 
the cells die by apoptosis and again this correlated with downregulation of Bcl-2
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(200). In both systems the forced expression of Bcl-2 rescued cells from 
apoptosis. A further report confirmed that the constitutive expression of c-myb in 
the CTLL-2 T cell line results in resistance to apoptosis and again this was 
associated with the direct regulation of the Bcl-2 promoter (201). However, a 
study in primary haematopoietic cells transformed with an inducible C-terminal 
truncated c-Myb protein which also resulted in the downregulation of Bcl-2 
expression, was not associated with an increase in apoptosis (202). This disparity 
could be due to the proposed cell-type specific anti-apoptotic effect of c-Myb 
(200;202) and/or that other additional mechanisms are involved in c-Myb 
induced apoptosis, such as different apoptotic pathways.
6.1.3 Structure and regulation of c-Myb
The c-Myb transcriptional transactivator protein has three major domains (Figure
6.2) encoded by 15 functional exons: an amino-terminal functional DNA binding 
domain; a central transactivation domain; and a carboxy-terminal negative 
regulatory domain (NRD) involved in the inhibition of transactivation by c-Myb 
(203).
EVES motif 
& ser528
DNA binding TA LZ T
1  i
NRD
Figure 6.2. c-Myb protein structure and functional domains. The locations of the 
DNA binding, transactivation (TA), leucine zipper (LZ) and negative regulatory 
(NRD) domains are shown for the normal (p75) c-Myb protein. Also shown are 
the approximate positions of the EVES motif and serine 528 (ser528).
The regulation of c-Myb transcriptional transactivation activity is complex with 
transcriptional and post-translational regulation occurring. The NRD plays an 
important role in the regulation of c-Myb activity and transformation as
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demonstrated by deletions of this region which result in an increase in 
transcriptional transactivation (203-207).
The NRD contains a putative leucine zipper (LZ) motif which may be 
responsible, at least in part, for the negative regulation of c-Myb (204;207). This 
property may be through protein-protein interactions mediated by the LZ motif 
(207;208). It has also been suggested that this region is involved in the 
autoregulation of c-Myb activity by homodimerisation resulting in a protein 
unable to bind DNA (209). These interactions are impaired in c-Myb mutants 
carrying a defective LZ motif. The negative regulatory role o f the LZ domain 
can be further demonstrated by the frequent proviral insertion in exon 9 which 
lies within this domain (68; 102), and by deletion of exon 9 which is associated 
with enhanced transcriptional activation (210). Furthermore, an alternatively 
spliced form of c-Myb (p85) which has an additional 121 amino acids in humans 
encoded by the alternative exon 9A, also disrupts the LZ motif (211). Again this 
has been shown to result in increased transactivation compared to wild-type p75 
c-Myb (210;212).
The FAETL motif lies within the LZ domain and by deletion analysis has been 
shown to be required for transactivation and transformation by c-Myb. The 
disruption of this motif results in the increase of both the transactivating and 
transforming capacities of c-Myb, possibly through loss of interaction with a 
negative regulating factor mediated by the LZ domain (213).
Another C-terminal NRD motif, the EVES motif, is involved in the regulation of 
c-Myb by mediating intramolecular interactions with the N-terminal DNA 
binding domain (214). Furthermore, this motif was shown to mediate 
mtermolecular interactions with the transcriptional coactivator p i 00 which also 
contains a highly related EVES domain. Interestingly, the EVES motif also 
contains a highly conserved serine 528 which, when phosphorylated has been 
shown to negatively regulate the activity of the c-Myb protein (215). Dash et al 
suggest a model in which c-Myb interacts with pi 00 via its EVES m otif resulting
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in an activated form of c-Myb. c-Myb could then be inactivated by an interaction 
with the C-terminal EVES motif of c-Myb with the N-terminus o f c-Myb, a 
reaction which is likely to be regulated by phosphorylation of serine 528 (214). 
A recent study suggests that the coactivator p i00 was phosphorylated and 
activated by the serine/threonine protein kinase Pirn-1 which in turn stimulated c- 
Myb transcriptional activity (216).
An important means of regulation of c-myb expression is by attenuation, thus 
providing a sensitive mechanism of regulation by blocking transcriptional 
elongation at the onset of terminal differentiation (217;218). The attenuation site 
has been mapped to a position within intron 1 of the gene (219). A further level 
of control is by increasing the stability of c-Myb either at the RNA level (220) or 
the protein level (221).
6.1.4 c-Myb and cancer
Deregulated expression as well as structural alterations of c-myb are associated 
with a range of haematopoietic neoplasms (188-190). The oncogenic activation 
of c-myb by insertional mutagenesis has been implicated in myeloid leukaemias 
(68;69), B cell lymphomas (71;72) as well as promonocytic leukaemias (102) and 
truncation of either end of c-Myb has been shown to be sufficient for 
transformation (222).
Proviral integration often occurs within the first three exons of c-myb resulting in 
the activation of a potent transforming protein (69;72;102;102;223). Thus 
transcription from the relatively strong LTR promoter together with the loss of 
the attenuation site within intron 1 is thought to be responsible for the 
deregulation of transcriptional control. The minimal region of c-Myb truncation 
in B cell lymphomagenesis has been identified and results in the deletion of only 
20 amino acids by ALV insertion producing a very potent transforming protein 
(72). C-terminal truncation by retroviral insertion has been shown to occur 
within exon 9 of c-myb, within or near the leucine zipper motif (68; 102) possibly 
reflecting the putative negative regulatory role of this motif discussed above.
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Retroviral insertions have also been observed which result in the truncation of c- 
Myb within exon 14 (101).
Aberrant c-myb expression has been observed in human neoplasia of 
haematopoietic and non-haematopoietic origin (224). Amplification of c-myb has 
been detected in a number of patients with acute myeloid leukaemia (AML) 
(225;226) while in another study defective c-myb and c-myc mRNA tumoverwas 
observed in cells from patients with AML (227). A reduction in the number of 
malignant haematopoietic colony-forming units in patients with chronic 
myelogenous leukaemia (CML) was demonstrated following exposure to c-myb 
antisense oligodeoxynucleotides (194;228) and more recently by transfection 
with an intracellular anti-c-myb single-chain antibody, an approach which is 
thought to be more specific for the functional knockout of the c-myb gene (229). 
In addition, the immature T cell acute lymphoblastic leukaemia (ALL) line, 
CEM, has lost a large portion of the c-myb promoter (166). Although 
amplification of Myb appears to be the most common abnormality of this gene in 
human leukaemias, truncated expression has been observed in the human CML 
cell line TK-6 (230). This form showed evidence of increased transactivation 
relative to wild-type c-myb probably due to the lack of the negative regulatory C 
terminal domain.
Despite the relatively common occurrence of c-myb abnormalities in human 
neoplasia, the large-scale molecular mapping of the c-myb locus at chromosome 
6q23.3-6q24 did not reveal any rearrangements or deletions within IMbp of the 
gene (170). However, a study of haematopoietic cells cultured from a patient 
with AML showed that the amplification of normal sized c-myb mRNA 
correlated with chromosomal abnormalities in the region 6q22-24 (226).
6.2 Methods
6.2.1 c-myb RNA stability studies
To determine the stability of c-myb RNA, FT1 and 3201 cells (5xl05/ml) were 
treated with 5p.g/ml of the RNA synthesis inhibitor, actinomycin D (Sigma) for 0,
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0.25, 0.5, 1, 2, 3, 4 and 8 hours. Actinomycin D was dissolved in 100% ethanol 
as a 1 mg/ml stock solution and 5|ig/ml was added to the culture medium. Total 
RNA was extracted from treated cells and northern blot analysis was performed 
on 20pg as described in sections 2.2.2.6 and 2.2.8.2. The filters were 
sequentially hybridised with the probes described in the text. The half-life of the 
c-myb message was estimated from densitometric scans of autoradiographs using 
Phoretix ID Plus (NonLinear Dynamics Ltd.) and gapdh RNA as standard.
6.3 Results
6.3.1 c-myb gene expression is upregulated in FT1 cells
To determine if  provirus integration within the Fit-1 locus in the FT1 cell line 
enhances c-myb expression by long-range activation, northern blot analysis was 
performed on 5qg of poly (A)+ enriched mRNA and 40pg of total RNA extracted 
from exponentially growing cells (FT1 and 3201). This analysis was performed 
by hybridisation with a feline c-myb exon 2 specific probe which was generated 
using the conserved human exon 2 primers (exon2f and exon2r, Appendix 1). 
The filter was then stripped of probe and hybridised with a gapdh probe to 
control for RNA loading.
Expression of c-myb in the FT1 cell line and control (3201) is shown in Figure 
6.3. This reveals that the feline c-myb transcript is similar in size to the human 
and murine homologues, approximately 4kb. A three day exposure of the 
northern blot (Figure 6.3A) shows that the absolute level of c-myb mRNA in the 
FT1 cell line (lane 1) is elevated approximately two fold over the control sample 
(lane 2). This analysis also revealed a 7.5kb transcript which hybridises to the c- 
myb specific probe in FT1 cells (lane 1) which is not present in 3201 cells (lane 
2). Furthermore, a shorter exposure time (Figure 6.3B) reveals a 4.4kb species in 
FT1 mRNA which is not present in 3201 mRNA. Thus, c-myb mRNA from the 
FT1 cell line with a Fit- 1 rearrangement is over-expressed compared to the 3201 
cell line and also exhibits two larger transcripts which are not present in the 
control sample.
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Figure 6.3 c-myb expression levels in FT1 cells. (A) Northern blot 
analysis of 5jag poly (A)+ FT1 mRNA (lane 1) or 3201 mRNA (lane 
2); and 40|ug of FT1 (lane 3) or 3201 (lane 4) total RNA. A feline 
c-myb exon 2 probe was used in this analysis and the filter was 
washed 3 times in 0.5 X SSC, 0.5% SDS at 60oC. (B) a shorter 
(overnight) exposure of the same blot highlighting the 4.4kb FT1 
specific band. (C) The same northern blot probed with gapdh and 
washed 3 times in 0.1 X SSC, 0.5% SDS at 60oC.
A number of other feline T cell lines not rearranged at Fit-1 were analysed for 
expression levels of c-myb message to determine whether the enhancement of the 
c-myb transcript was due to an abnormality specific for the FT1 cell line. Total 
RNA was extracted from the following cell lines: FT1, 3201, M yal, T3, F422, 
FL74, FL4 and T3C1. Northern blot analysis was performed on 40pg of each 
RNA using the feline c-myb exon 2 probe (Figure 6.4A) and a gapdh probe to 
control for RNA loading and integrity (Figure 6.4B). Densitometric analysis of a 
scanned image of the autoradiograph was performed using gapdh RNA as 
standard. The relative abundance of the c-myb message in each cell line is shown 
in Figure 6.4C. The results of this analysis confirmed that expression of the c- 
myb gene is upregulated in the FT1 cell line approximately two fold over 3201, 
T3, F422, FL74 and T3C1 cells, suggesting that proviral insertion within the Fit- 
1 locus in the FT1 cell line may indeed have a long-range effect on c-myb gene 
expression.
6.3.2 The c-myb gene is not rearranged in the FT1 cell line
To confirm that the over-expression of c-myb observed in the FT1 cell line is not 
due to proviral insertion within the c-myb gene itself, genomic DNAs from FT1 
and 3201 cells were examined by Southern blot analysis for polymorphisms in 
restriction fragments which hybridise to c-myb probes. The feline c-myb exon 2 
probe did not reveal any restriction fragment length polymorphisms (RFLP) in 
FT1 DNA (Figure 6.5A, lanes 1, 3 and 5), suggesting that the 5' end of c-myb is 
not rearranged. Furthermore, FT1 Southern blot analysis using mouse cDNA 
probes spanning the entire c-myb gene (the 2kb Ncol and the 2.5 kb EcoRl 
fragments from the plasmid pT7p/c-myb (231)) did not reveal any RFLPs (not 
shown).
In addition, fragments which hybridised to the c-myb exon 2 probe (Figure 6.5A) 
did not coincide with fragments which hybridise to the conserved feline Fit-\ 
probe on the same filter (Figure 6.5B). Although a very similar sized Kpnl 
genomic Fit-\ fragment also appeared to hybridise to the c-myb probe (Figures
6.5 A and B, lanes 5 and 6), the rearranged Fit-\ hybridising fragment in FT1
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Figure 6.4 c-myb expression levels in feline T cell lines. Total RNA 
(40pg) from the various feline T cells indicated was extracted and 
analysed by northern blotting with a feline c-myb exon 2 specific probe 
(A). The filter was washed 3 times in 0.5 X SSC, 0.5% SDS at 60oC. 
After removing the probe, the same filter was hybridised to a gapdh 
probe to determine the approximate amount of RNA per lane (B).
The relative abundance of c-myb RNA in feline T cell lines
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Figure 6.4C The relative abundance of c-myb RNA in feline T cell lines. 
Densitometry of a scanned image of the autoradiograph shown in Figure 
6.4A was performed using Phoretix ID Plus, NonLinear Dynamics Ltd. 
The relative signal intensity was calculated as a ratio of the gapdh signal 
shown in Figure 6.4B
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Figure 6.5 Southern blot analysis of c-myb and Fit- 1 in the FT1 
cell line. FT1 and 3201 DNA digested with Sstl, Pst\ and Kpn\ was 
immobilised on a Southern blot and probed with the feline c-myb 
exon 2 probe (A) or the feline Fit- 1 probe (B). Both Filters were 
washed at high stringency (0.1 X SSC, 0.5% SDS at 60oC).
DNA did not hybridise to the c-myb probe (compare lanes 5 in Figures 6.5A and 
B). This suggests that two similarly sized but distinct Kpnl fragments hybridise 
to both probes. Therefore, the FT1 cell line is not rearranged at c-myb, 
suggesting that it is proviral insertion within Fit- 1 rather than c-myb which is 
responsible, at least in part, for the over-expression of c-myb.
6.3.3 c-myb RNA is more stable in the FT1 cell line
c-myb transcription is controlled at the level of transcriptional arrest and mRNA 
turnover (217;220;232). To determine if the increased abundance of c-myb 
mRNA observed in the FT1 cell line is due to a decrease in the turnover rate of 
this message, the half-life of c-myb RNA was determined. FT1 and 3201 cells 
were treated with actinomycin D to inhibit de novo RNA synthesis for 0, 0.25, 
0.5, 1, 2, 3, 4 and 8 hours as described in section 6.2.1. Cytoplasmic RNAs were 
then isolated and analysed by northern blot using the feline c-myb exon 2 probe 
(Figure 6.6A). As controls, the filters were also hybridised with a gapdh probe 
(to control for RNA loading and integrity) and a histone H3.2 probe (to verify 
that RNA synthesis has been blocked). The latter probe was generated by PCR 
using the primers hisf and hisr described in Appendix 1 (233). Autoradiographs 
of these northern blots are shown in Figure 6.6B and C respectively.
Densitometric analysis of a scanned image of the autoradiographs shown in 
Figure 6.6A and C was performed using gapdh RNA as standard. The relative 
abundance of the c-myb and histone H3.2 RNAs at each time point are shown in 
Figures 6.6D and E respectively. Histone H3.2 RNA degraded with a half-life of 
approximately one hour (Figure 6.6C and E) confirming that RNA synthesis has 
been blocked in both cell lines. The results also show that c-myb RNA turned 
over with a half-life of approximately 3 hours in the 3201 cell line, consistent 
with the reported half-life o f this transcript (193;220). However, in the FT1 cell 
line the half-life of c-myb RNA was significantly increased to approximately 8 
hours (Figure 6.6D). This could account for higher steady state levels of c-myb 
transcript in FT1 cells.
135
FT1
3201
in locn m cn in
o o o t - c m c o ^ - oo o o o t - c m c o ^ oo (hrs)
4  0 - ,  m  -  ■* m m m m m m r n  Feline, c' myk^•u exon 2
B
1.4 gapdh
histone
H3.2
Figure 6.6 c-myb RNA half life. 3201 and FT1 cells were treated with 
actinomycin D for the indicated times (hours) and total RNA (20ju.g) was 
extracted. The northern blot was sequentially hybridised with feline 
c-myb exon 2 (A), gapdh (B) and histone H3.2 (C) This figure shows 
that the c-myb transcript in the FT1 cell line has a longer half life 
compared to the 3201 cell line. The half life of histone H3.2 RNA is not 
significantly different between the two cell lines.
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Figure 6.6 (continued) c-myb RNA half-life. Densitometry of a scanned 
image of the autoradiograph shown in Figure 6.6A (c-myb) was performed 
using Phoretix ID Plus and is expressed as a ratio of the gapdh signal (D). 
Densitometry of a scanned image of the autoradiograph shown in Figure 6.6C 
(histone H3.2) was performed as above (E). The half-lives of the c-myb and 
histone H3.2 RNAs were estimated from the time taken (in hours) for half the 
message to be degraded.
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6.4 Discussion
The location of F it-1 approximately lOOkb 5' to the human c-myb gene suggests 
that proviral integrations within this locus may activate c-myb gene expression in 
a manner analagous to the long-range cis activation observed with the c-myc gene 
(63;64). Northern blot analysis indicates that the relative level of c-myb mRNA 
is perturbed in the FT1 cell line with a rearrangement at F it-l, suggesting that 
proviral integration at Fit-1 may activate its expression in cis (Figure 6.3). This 
analysis also revealed two larger mRNA species which are present in FT1 but not 
control cells, discussed further in chapter 7.
The enhanced c-myb expression observed in the FT1 cell line is not due to FeLV 
integration within this gene since Southern blot analysis revealed no 
rearrangements at c-myb in FT1 DNA using probes spanning the entire gene 
(Figure 6.5A and not shown). This result is in agreement with previous Southern 
analysis on primary tumour DNA hybridised with a c-myb probe which was 
carried out by our collaborator, H. Tsujimoto (42). In this study, tumours 
rearranged at Fit-\ revealed no RFLPs except for one, tumour T3-1T, where the 
rearranged fragment did not coincide with the rearranged Fit-\ fragment. It is 
possible that tumour T3-1T has proviral insertions at both the Fit-\ and c-myb 
loci, however lack of intact primary tumour material has not allowed the 
clarification of this issue.
c-myb activity is regulated at several levels (discussed in section 6.1.3). At the 
transcription level, control is primarily through attenuation of transcriptional 
elongation, a property which has been mapped to a region within intron 1 of the 
gene (217-219). c-myb gene expression is also regulated by a change in the 
stability of the message: as cells are artificially induced to enter differentiation, 
there is a rapid decline in mRNA levels due to a reduced half-life of this 
transcript as well as increased attenuation (220). In FT1 cells which are 
rearranged at F it-\, the c-myb message appears to be more stable than control 
cells and this may contribute to the over-expression of this gene observed in the 
FT1 cell line (Figure 6.6). Indeed, the increase in the half-life is so significant
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that it may account for the entire increased steady-state level in FT1 RNA. 
However, the possibility that other factors, such as reduced transcriptional 
pausing are also involved cannot be ruled out.
Two leukaemia specific c-Myb proteins which are truncated within the C- 
terminus by 248 or 96 amino acids have been shown to have significantly 
increased half-lives compared to full length c-myb (221;234). W olff et al suggest 
that these observed increases o f c-Myb protein stability due to proviral 
integration within exons 9 or 13 may contribute to the inappropriate expression of 
c-Myb in monocytic leukaemia. Furthermore, c-myb mRNA has been shown to 
be upregulated in patients with acute myeloid leukaemia and this was shown to 
be associated with enhanced stability of this transcript (227).
Higher steady-state levels of c-myb may result in an increased survival of the FT1 
T cell lymphoma line, c-myb has been shown to regulate Bcl-2 expression 
resulting in protection from apoptosis (183;200). Therefore, it is conceivable that 
changes in c-myb RNA stability which result in the inappropriate expression of c- 
myb might confer increased survival on the FT1 cell line due to a decrease in 
apoptosis. Alternatively, the FT1 specific 4.4kb c-myb mRNA (Figure 6.3A) 
could represent an alternatively spliced product or one which has been initiated at 
a variant promoter and it may be this transcript which is more stable (discussed in 
greater detail in chapters 7 and 8).
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Chapter 7
7. Analysis of FT1 specific c-myb transcripts
7.1 Introduction
Northern blot analysis revealed that not only is the relative level of c-myb mRNA 
enhanced in the FT1 cell line, but that two larger mRNA species are present in 
FT1 which could not be detected in control cells (Figure 6.3). This observation 
raises the possibility that proviral insertion at Fit-\ may favour the expression of 
the larger transcripts. An attractive candidate for the 4.4kb FT1 specific c-myb 
message is the alternatively spliced form of c-myb previously identified in 
human, mouse and chicken which encodes a larger protein of approximately 85- 
89kDa (211;235;236). The 89kDa protein is generated from an alternatively 
spliced mRNA that contains an additional 121 amino acids in human and mouse 
which is derived from an alternative exon between exons 9 and 10, termed exon 
9A. Therefore, it is possible that the 4.4kb RNA which is specific to FT1 cells 
contains these additional 363bp of sequence, a figure which is consistent with the 
increase in size of this product from approximately 4.0kb to 4.4kb (Figure 6.3).
The c-myb exon 9 sequence spans the putative leucine zipper domain, a motif 
which is thought to be involved in the negative regulation o f c-Myb activity 
(204;207). The transcript encoding the larger protein which contains exon 9A in 
addition to exon 9 disrupts this motif, possibly resulting in a protein which is 
more resistant to negative regulation or one which has defective inter- or intra­
molecular interactions. Although the function of this form is currently unknown, 
transfection studies have shown that it results in increased transcriptional 
activation of a luciferase reporter gene in avian myelomonoblasts (212). This 
study also showed that, although this form of c-Myb was able to mediate 
leukaemic transformation, there was no direct correlation of transcriptional 
activation and transformation efficiency.
7.2 Methods
7.2.1 Semi-quantitative reverse transcriptase PCR (RT-PCR) assays
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Total RNA was extracted from cells as described in section 2.2.2.6. First-strand 
cDNA synthesis was generated using the First-strand cDNA Synthesis Kit 
(Amersham Pharmacia Biotech) which utilises M-MuLV reverse transcriptase. 
5 jig of total RNA and 5 pi of bulk first-strand reaction mix was used according to 
the manufacturers’ instructions. The first-strand reaction was primed with 0.2pg 
of the Afod-d(T)]8 bifunctional primer provided with the kit (see Appendix 1 for 
primer sequence). Following synthesis o f the first-strand cDNA, the double­
stranded RNA:cDNA heteroduplex was heat-denatured at 90°C for 5 min and 3pi 
aliquots were amplified by PCR using sets of primers specific for c-myb (exon9f 
and exon l l r ,  Appendix 1) or hypoxanthine phosphoribosyl-transferase (HPRT5' 
and HPRT3', Appendix 1). PCR was performed essentially as described in 
section 2.2.6 except that 3mM MgCl2 was used and cycling was performed for 25 
cycles (c-myb) or 18 cycles (HPRT). The PCR products were run in a 1.5% 
agarose gel (section 2.2.3) and transferred to Hybond N membranes (Amersham) 
by standard Southern blotting procedures (section 2.2.8.1). The Southern blots 
were probed with c-myb (exon 9 or FE9A; see text for details) or HPRT (a 312bp 
PCR fragment amplified from residues 269 - 580 of Mus spretus cDNA using the 
HPRT5' and HPRT3' primers, see Appendix 1).
7.3 Results
7.3.1 Analysis of an alternatively spliced form of c-myb in the FT1 cell line
To determine if the 4.4kb FT1 specific c-myb message was derived from an 
alternative splicing event involving exon 9A, a probe specific for exon 9A was 
generated. A pair of PCR primers (huex9af and huex9ar, Appendix 1) were 
designed from two regions of exon 9A which were relatively well conserved in 
human, mouse and chicken. A feline exon 9A fragment of the expected size 
(357bp) was generated following PCR using 3201 DNA as template and standard 
cycling conditions (section 2.2.6, not shown). This fragment was gel purified 
(section 2.2.4) and used as a probe, the FE9A probe.
The FE9A probe was hybridised to the same poly (A)+ mRNA northern blot 
which was previously probed with the c-myb exon 2 probe (chapter 6). The
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FE9A probe hybridised to the 4.4kb mRNA which was previously seen with the 
exon 2 probe, but not to the 4.0kb species (Figure 7.1, lanes 1 and 2). This 
confirmed that the larger 4.4kb message, which was specific to FT1 RNA, was 
indeed derived from an alternative splicing event involving exon 9A. Moreover, 
the exon 9A containing c-myb species was more abundant in FT1 RNA (lane 1) 
compared to 3201 RNA (lane 2). Densitometry was performed on the northern 
blot shown in Figure 7.1 and this showed that exon 9A is approximately five “fold 
more highly expressed in FT1 than 3201 cells.
The structure o f feline exon 9A was further analysed by PCR amplification of 
cDNAs derived from FT1 and 3201 cells (section 7.2.1). Using oligonucleotide 
primers corresponding to DNA sequences from the 5' end of human c-myb exon 
9 (exon9f) and the 3' end of exon 11 (exonllr), PCR amplification yielded 
products of 499bp and 862bp (Figure 7.2A). The major band at 499bp is the size 
expected for a product which does not contain exon 9A, while the 862bp product 
corresponds to the size expected for a fragment containing the entire 363bp exon 
9A.
Southern blot analysis of the PCR products was performed using a c-myb exon 9 
specific probe generated by PCR using the oligonucleotide primers exon9f and 
exon9r (Appendix 1) and standard cycling conditions (section 2.2.6). The exon 9 
probe hybridised to both the 499bp and the 862bp products confirming that they 
are both specific to the c-myb gene (Figure 7.2B). A duplicate Southern blot of 
the PCR products was hybridised with the FE9A probe identifying the 862bp 
product as containing exon 9A sequences, but not the 499bp product (Figure 
7.2C). A 650bp product also hybridised to the exon 9A probe. The likely origin 
of this product is from another splicing event which utilises the 3' portion of exon 
9A, termed exon 9A \ This species has previously been identified in chicken 
mRNA and is 210 bp shorter than exon 9A (237). An identical aliquot of first- 
strand cDNA was amplified using the HPRT primers (HPRT5' and HPRT3') to 
control for RNA loading. The Southern blot of the PCR products probed with an 
HPRT probe is shown in Figure 7.2D.
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Figure 7.1 c-myb exon 9A expression levels in FT1 cells. (A) Northern 
blot analysis of 5 jag poly (A)+ FT1 mRNA (lane 1) or 3201 mRNA (lane 
2). A feline c-myb exon 9A specific probe (FE9A) was used in this 
analysis and the filter was washed three times in 0.1 X SSC, 0.5% SDS at 
60oC. (B) The same northern blot probed with gapdh, washing 
conditions were as for FE9A.
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Figure 7.2 RT-PCR analysis of FT1 cells. (A) Ethidium bromide stained 
agarose gel of PCR products following amplification of cDNAs derived from 
the following RNAs (each panel is identical): (M) (|)X 174/HaeI 11 DNA 
markers; (1) no RNA negative control; (2) 3201 RNA; (3) FT1 RNA. Primer 
sets for the PCR reactions are as follows: exon9f and exon llr  (A, B and C); 
HPRT5' and HPRT3' (D). (B) Southern blot hybridisation of the gel shown in 
(A) using the human c-myb exon 9 probe. The filter was washed three times in 
0.5 X SSC, 0.5% SDS at 60oC. (C) A duplicate Southern blot of the gel 
shown in (A) hybridised with the FE9A probe. The filter was washed three 
times in 0.1 X SSC, 0.5% SDS at 60oC. (D) Southern blot hybridisation 
using the HPRT probe. The filter was washed three times in 0.1 X SSC, 0.5% 
SDS at 60oC.
To calculate the level of exon 9A-containing c-myb message, densitometry was 
performed on the Southern blot shown in Figure 7.2B which has been probed 
with a c-myb exon 9 probe. Since this probe detects RNA species which contain 
as well as those which lack exon 9A sequence, the amount of probe hybridised is 
proportional to the amount of each isoform of c-myb. By calculating the area 
under the curve, exon 9A-containing cDNA was found to be present at 
approximately 9% of the total c-myb signal from 3201 cells. In contrast, exon 
9A-containing cDNA was present at levels o f approximately 25% in FT1 cells.
7.3.2 Feline c-myb exon 9A sequence
To determine the DNA sequence of feline c-myb exon 9A, the FT1 RT-PCR 
products shown in Figure 7.2A were cloned in pCRII TOPO (Invitrogen) as 
outlined in section 2.2.7. Colonies containing c-myb sequence with and without 
exon 9A were isolated by performing Grunstein and Hogness colony 
hybridisation (153) using the FE9A and the exon 9 probes, respectively. Several 
clones containing exon 9 hybridising sequences from FT1 and 3201 cDNAs were 
obtained and sequenced using the universal M l3 forward and reverse primers 
(section 2.2.9, not shown). However, clones containing exon 9A sequence were 
only obtained from FT1 cDNA, possibly due to the under-representation of this 
form in 3201 cells. The sequence of feline exon 9A is presented in Figure 7.3. 
As for the human and mouse c-myb exon 9A, the feline exon was found to 
contain 363 bases which encode 121 amino acids (211;238).
The nucleotide sequences (Figure 7.4A) as well as the deduced amino acid 
sequences (Figure 7.4B) for feline, human, murine and chicken exon 9A were 
aligned to demonstrate homology. These comparisons show that feline and 
human c-myb exon 9A share the highest degree of homology at the nucleotide 
level (89% identity) and at the amino acid level (80% identity). The regions of 
maximal homology appear to be clustered into three boxes. Most notably, the C- 
terminal 12 amino acids of exon 9A are identical in all organisms (Figure 7.4B). 
These residues were previously shown to be highly conserved between human, 
mouse and Drosophila (211), chicken (237) and now the cat (Figure 7.4B). This
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e x o n 9  f
1 ACACAGAACC ACACATGCAG CTACCCCGGG TGGCACAGCA CCACCATCGC
51 TGACCACACC AGACCTCATG GAGACAGTGC ACCTGTTTCC TGTTTGGAAG
101 AACACCACTC CACTCCCTCT CTGCCTGTGG ATCCTGGCTC CCTACCTGAA
151 GAAAGTGCCT CTCCAGCAAG GTGCATGATC GTCCACCAAG GCACCATTCT
201 GGATAATGTT
>|rSA
AAGAACCTTT TAGAATTTGC AGAAACACTT CAATTTATAG
251 ATTCTGATTC TTCATCATGG cGTGATCTCA GCAGTTTTGA ATTCTTTGAA
301 GAAGCAGAGT TTTCACCTAG CCAACATCAT GCAGGCAGAG CCCTAAAGCT
351 TCAGCAAAGA GAGGGCAGTC TGAATAGACC TGCAGGAGAG CCTAGCACAA
401 GGGTGAACGC TCTCAAGTTG AGTGAGGGTT CACTTGACCC GCTCAAGCCC
451 TTACCTCCcT CGAGGCACGG CACAGTTCCA CTGGTCATCC TTCGAAAAAA
501 GCGCGGCCAG GCAAGCCCCT TAGCCACTGG AGGCTCTAGC TCCTTCCTAT
551 TTGCTGGCGT CAGCAGCTCA
>JrSD
ACTCCCAAGC GTTCCCCTGT CAAAAGCCtA
601 CCCTTCTCCC CTTCACAGTT CTTAAACACT TCTGGTAACC ATGAAAACTT
651 AGACTTGGAA ATGCcTTCTT TAACTTCTAC CCCTCTCAAT GGTCACAAAT
701 TGACTGTTAC aACACCATTT CATAGAGACC AGACTGTGAA AACTCAAAAG
751 GAAAATACTA TTTTTAGAAC TCCAGCTATC AAAAGGTCAA TCCTAGAAAG
801
851
CTCTCCAAGA
TTAAATACGG
ACTCCTACAC
TCC
CGTTCAAACA TGCACTTGCA GCTCAAGAAA
e x o n l l r
Figure 7.3 Sequence of the feline exon 9A. The PCR products from FT1 
cDNAs using the oligonucleotide primers exon9f and exonl lr were cloned and 
sequenced as outlined in section 2.2.7. The positions of these primers are 
underlined. The boundaries of exon 9A are shown by the location of the splice 
acceptor (SA) and splice donor (SD) sites; the entire exon 9A sequence is 
shown in bold. The DNA sequence was obtained from both strands of two 
clones; ambiguities are shown in small letters.
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e x 9 a f e  1 TTTATAGATTCTGATTCTTCATCATGGCGTGATCTCAGCAGTTTTGAATTCTTTGAAGAA
e x  9 a h u  1 TTTATAGATTCTGATTCTTCATCATGGTGTGATCTCAGCAGTTTTGAATTCTTTGAAGAA
ex9am u 1 TTTATAGATTCTGATTCT. . . TCGTGGTGTGATCTCAGCAGTTTTGAATTCTCTGAAGAA
e x 9 a c h  1................TTTCAGGATCCTTCATCATGGGGTGATCTCAGCAGTTTTGAATTCTTTGAAGA.
c o n s e n s u s  1 t t ta ta g a T tc tG A T tC T tc a T C a T G G  GTGATCTCAGCAGTTTTGAATTCTtTGAAGAa
e x 9 a f e  61 . . . GCAGAGTTTTCACCTAGCCAACATCATGCAGGCAGAGCC................CTAAAGCTTCAG
e x 9 a h u  61 . . . GCAGATTTTTCACCTAGCCAACATCACACAGGCAAAGCC................CTACAGTTTCAG
ex9am u 58 GCGGCAGCTTTTTCACCTAGCCAGCAGCCCACAGGCAAAGCCTTCCAGCTTCAGCTTCAG
e x 9 a c h  54 . . CACAGACATTCTGGCTGGCAAAGCTACCTCAGGCACAGCC................GTGCAGCTGCAG
c o n s e n s u s  61 gCAGa tT T tc a c C T a G C c A a c a tc  cgCAGGCAgAGCC cTacAGcTtCAG
e x 9 a f e  112 CAAAGAGAGGGCAGTCTGAATAGACCTGCAGGAGAGCCTAGCACAAGGGTGAACGCTCTC
e x 9 a h u  112 CAAAGAGAGGGCAATGGGACTAAACCTGCAGGAGAACCTAGCCCAAGGGTGAACAAACGT
ex9arnu  118 CAAAGAGAGGGCCATGGGACTAGATCTGCAGGAGAGCCTAGCCTGAGGGTGACCAGGCGA
e x 9 a c h  106  CATGGAGGGGCCAGTGCTTGTAGACCTCCAGGACTCCCCATCTCAAACCTGAGCAAAACC
c o n s e n s u s  121 CAaaGAGaGGgCagTg g a  TAgAcCTgCAGGAgagCCtAgC caA gggT G A aC aaac
e x 9 a f e  172 AAGTTGAGTGAGGGTTCACTTGACCCGCTCAAGCCCTTACCTCCCTCGAGGCACGGCACA
e x 9 a h u  172 ATGTTGAGTGAGAGTTCACTTGACCCACCCAAGGTCTTACCTCCTGCAAGGCACAGCACA
ex9am u 17 8 GTGCTGAGCGAGGCATCGCTCGGCCCAC................ACTCACCCCAAGCGAGGCACAGCAAG
e x 9 a c h  166 ATGTCAAGTCAGAGCCCTCCTGGCTCACCAAAGTCCTTGTCTGCCTCGCAGGGCAGTGTG
c o n s e n s u s  181 a tG ttg A G tg A G g g  tC a C ttG aC cC aC  a a g  C T ta c C tc c  C gagG caC aG ca a
e x 9 a f e  232  GTTCCACTGGTCATCCTTCGAAAAAAGCGCGGCCAGGCAAGCCCCTTAGCCACTGGAGGC
e x 9 a h u  232  ATTCCACTGGTCATCCTTCGAAAAAAACGGGGCCAGGCCAGCCCCTTAGCCACTGGAGAC
ex9am u 232  GTTCGGCTGGTCGTCCTACGAAAAAGGCGGGGCCAGGCCAGCCCCCTAGCCGCTGGAGAG
e x 9 a c h  226  GCTCCATGGG. . . TCCTTCGCAAAAGGAGAGGGCATGCCAGCCCCTTAGCCAGTGGCCCC
c o n s e n s u s  241 gtTCcactGGtcaTCCTtCGaAAAAagcGgGGcCAgGCcAGCCCCtTAGCCacTGGaggc
e x 9 a f e  292 TCTAGCTCCTTCCTATTTGCTGGCGTCAGCAGCTCAACTCCCAAGCGTTCCCCTGTCAAA
e x 9 a h u  292 TGTAGCTCCTTCATATTTGCTGACGTCAGCAGTTCAACTCCCAAGCGTTCCCCTGTCAAA
ex9am u 2 92 CCTAGCCCCTCCCTCTTTGCTGACGTCATCAGCTCAACTCTCAAGCATTCCCCTGTCAAA
e x 9 a c h  283 AGTAGCACCTTGGGATTGGCTGACGGCAGCAGCTCAACTTCTAAGCACTCCCCTGTCAAA
c o n s e n s u s  301 TAGC C C T tc taTTtGCTGaCGtCAgCAGcTCAACTcccAAGCgtTCCCCTGTCAAA
e x 9 a f e  352 AGCCTACCCTTCTCCCCTTCACAGTTCTTAAACACTTCTGGTAACCATGAAAACTT
e x 9 a h u  352 AGCCTACCCTTCTCTCCCTCGCAGTTCTTAAACACTTCCAGTAACCATGAAAACTC
ex9am u 352 AGCCTACCCTTCTCTCCCTCGCAGTTCTTGAACACTTCCAGCAACCATGAAAACTC
e x 9 a c h  343 AGCCTGCCCTTCTCTCCCTCGCAGGTAGATCAAGACTTCTGCACAGATGTTACTAA
c o n s e n s u s  361 A G C C TaC C C TTC TC tC C cTC gC A G tTcttaaA cactTccgG  A accA T G aaA act
Figure 7.4A Comparison of feline exon 9A DNA sequence with homologous 
sequences from various organisms. The alignments were performed with the 
computer programme GCG and the most highly conserved residues were highlighted 
using Boxshade (http://www.ch.embnet.org). Red indicates identity; periods indicate 
gaps in the alignment. ex9a, exon 9A; fe, feline; hu, human; mu, murine; ch, chicken.
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e x 9 a f e  1 DSSSWRDLSSFEFFEE.AEFSPSQHHAGRA.. LKLQQREGSLNRPAGEPSTRVNALKLSE
e x 9 a h u  1 DSSSWCDLSSFEFFEE. ADFSPSQHHTGKA.. LQFQQREGNGTKPAGEPSPRVNKRMLSE
ex9am u 1 D. SSWCDLSSFEFSEEAAAFSPSQQPTGKAFQLQLQQREGHGTRSAGEPSLRVTRRVLSE
e x 9 a c h  1 DPSSWGDLSSFEFFED.TDILAGKATSGTA.. VQLQHGGASACRPPGLPISNLSKTMSSQ
c o n s e n s u s  1 SSW DLSSFEF Ee G A l Q g r G P v  S
e x 9 a f e  58 GSLDPLKPLPPSRHGTVPLVILRKKRGQASPLATGGSSSFLFAGVSSSTPKRSPVKSLPF
e x 9 a h u  58 SSLDPPKVLPPARHSTIPLVILRKKRGQASPLATGDCSSFIFADVSSSTPKRSPVKSLPF
ex9am u  60 A SLG PH S.. PQARHSKVRLWLRKRRGQASPLAAGEPSPSLFADVISSTLKHSPVKSLPF
e x 9 a c h  58 SPPGSPKSLSASQGSVAPWV.LRKRRGHASPLASGPSSTLGLADGSSSTSKHSPVKSLPF
c o n s e n s u s  61 V LRKkRG ASPLA G S A SST KrSPVKSLPF
e x 9 a f e 118 SPSQ
e x 9 a h u 118 SPSQ
ex9am u 118 SPSQ
e x 9 a c h 117 SPSQ
c o n s e n s u s 121 SPSQ
Figure 7.4B Comparison of feline exon 9A predicted amino acid sequence with 
homologous sequences from various organisms. The alignments were performed with 
the computer programme GCG and the most highly conserved residues were 
highlighted using Boxshade (http://www.ch.embnet.org). Red indicates identity; blue 
indicates similarity; periods indicate gaps in the alignment. ex9a, exon 9A; fe, feline; 
hu, human; mu, murine; ch, chicken.
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high degree of conservation between such diverse species might suggest an 
essential biological function for an exon 9A containing c-myb gene.
7.4 Discussion
An alternatively spliced transcript of the c-myb gene involving the alternative 
exon 9A was first identified in a mouse myeloid tumour cell line (238). Since 
this initial report, c-myb exon 9A has also been identified in the human and 
chicken genomes (211;237). Sequences homologous to c-myb exon 9A have also 
been identified in the murine B-myb gene (239) and the Drosophila c-myb gene 
(211;240). The results presented here indicate that c-myb exon 9A sequence also 
exists in the cat (Figure 7.2). Comparisons of feline, human, murine and chicken 
exon 9A sequences show a high degree of conservation at both the nucleotide and 
protein levels (Figure 7.4). Previous analyses have shown that the last 12 amino 
acids in exon 9A are highly conserved in a very diverse group of organisms 
including human, mouse, chicken, sea urchin and Drosophila (211;212;237). 
The preservation of exon 9A sequences through evolution suggests an essential 
biological function of this form of the c-myb gene.
It has previously been observed that, although exon 9A was expressed in all 
chicken haematopoietic tissues tested, cells from yolk sac contained the highest 
levels o f this alternatively spliced c-myb mRNA (236). Exon 9A-containing c- 
myb RNA in yolk sac was present at 15% of the normal 4.0kb c-myb message, 
while the other tissues contained only 1-3%. Results presented in this chapter 
have shown that the level of exon 9A-containing RNA in 3201 cells was 
estimated to be about 9% of the amount of total c-myb RNA (Figure 7.2B). This 
is in agreement with values seen previously (235;236). However, a substantially 
larger proportion of c-myb from FT1 cells contained exon 9A, approximately 
25% of the total c-myb signal (Figure 7.2B). These data are in reasonable 
agreement with the levels of the 4.4kb transcript observed on the northern blot 
hybridised with a feline c-myb exon 2 probe shown in chapter 6 (Figure 6.3B). 
Densitometry of this blot showed that the 4.4kb c-myb message is present at
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approximately 30% of the total c-myb signal in FT1 mRNA, while in 3201 
mRNA this form was virtually undetectable. The slight variation seen between 
these figures may be due to disproportionate amplification of cDNA products 
during PCR or the indistinct nature of the exon 9A and normal forms of c-myb 
bands seen on the northern blot shown in Figure 6.3B on which densitometry was 
performed.
151
CHAPTER 8
152
Chapter 8
8. General Discussion
Proviral tagging has proved to be a powerful tool for the identification of novel 
genes in retrovirus-induced tumours of the mouse, chicken and cat where more 
than 60 genes have been found as targets for insertional mutagenesis (Table 1.1). 
The set of genes identified in this way overlaps significantly with those identified 
by non-retroviral means such as oncogenes present at chromosomal 
translocations and those which have been amplified in tumorigenesis. This 
illustrates the value of this approach in identifying genes which are involved in 
naturally occurring neoplasia.
The Fit- 1 locus was initially identified by proviral tagging in cats using a 
naturally-occurring FeLV strain carrying a w-myc oncogene. This locus was 
found to be occupied by helper provirus in 16% of feline T cell lymphomas 
screened (25;42). Thus, precedent suggests that the Fit- 1 locus harbours a gene 
which collaborates with Myc in T cell neoplasia. Preliminary analysis failed to 
identify a transcription unit which was altered as a result of proviral insertion at 
Fit-1, despite the isolation of 30kb of genomic sequence and the identification of 
a stretch of unique sequence which is conserved in mammalian evolution (157). 
Therefore, the purpose of this study was to extend the search for transcripts 
which were affected by proviral integration at Fit-l using the FT1 T cell 
lymphoma line which is rearranged at both Fit-l and c-myc, a resource which 
was not previously available for this analysis.
To search for a gene affected by insertions at F it-l, a 15kb feline genomic X 
phage clone (^R Fl) which spans the major insertion cluster (Figure 3.3) was 
screened for sequences that are single copy, conserved in evolution and expressed 
as RNA specifically in the FT1 cell line. This strategy (outlined in Figure 3.5) 
was utilised across the entire clone. No clear evidence of a transcription unit 
affected by viral insertion was identified. However, this analysis did reveal a
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region of the XRF1 which was not contiguous in genomic DNA, possibly due to a 
spurious recombination event which may have occurred during cloning.
Possible reasons for the failure to identify transcripts in the vicinity of the 
clustered integration sites were discussed previously (section 3.3). The most 
likely explanation is that the cluster of proviral insertions at Fit- 1 may be 
influencing the expression of a gene which is outwith the 30kb o f cloned 
sequence. A precedent for such an event is seen with the c-myc oncogene which 
was found to be the target of proviral insertions at the M lvi-\lpvt-\IM is-\ and 
Mlvi-4 loci which map 270kb and 30kb downstream respectively (61;63;64). 
Therefore, in view of the conservation of the Fit-l domain, we chose to extend 
the search for adjacent genes in human DNA where there are greater resources 
available for genomic analysis.
The Fit-l locus was previously mapped to feline chromosome B2 (42). Using the 
EUCIB panel o f mice and the conserved Fit-l domain, the locus was 
subsequently mapped to mouse chromosome 10 close to Ahi-1, a murine 
retroviral integration locus which is 35kb downstream of c-myb (18; 157). Much 
of feline chromosome B2 has been shown to be homologous to human 
chromosome 6 (161), and the human c-myb gene has been mapped to human 
chromosome 6 at 6q23.3-24 (163). Therefore, to isolate the human homologue of 
Fit-1, a human chromosome 6 specific cosmid library was screened with the 
conserved Fit-l probe identifying a single clone containing this sequence. 
Nucleotide sequence analysis of the human Fit-l homologous domain revealed 
that the long open reading frame present in the feline sequence is 80% identical at 
the DNA level to the corresponding region in the human genome (Figure 4.3A). 
The presence of conserved sequences would suggest that this region has been 
maintained through evolution because it plays an important biological function. 
However, probes encompassing these open reading frames (the feline and human 
Fit-l probes) failed to reveal any expressed RNAs on northern blot analysis. 
This was surprising considering their conservation and the presence of features of
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an internal coding exon such as the putative splice acceptor and splice donor sites 
highlighted on Figure 4.3 A.
The physical linkage of Fit-1 and c-myb was demonstrated when a Fit-1 positive 
PAC clone was found to contain sequences homologous to c-myb (Figure 5.4B). 
Long-range restriction mapping and pulsed field gel electrophoresis mapped the 
Fit-1 region approximately lOOkb upstream of c-myb on human chromosome 6 
(Figure 5.5). Murine c-myb has been mapped to chromosome 10 which also 
harbours a number of common murine leukaemia virus (MuLV) integration loci 
including A hi-1, Mis-2 and more recently Mmti (Figure 8.1). Ahi-1 was 
identified as a common site of proviral insertion in Abelson induced pre-B 
lymphomas (17) and was mapped approximately 35kb downstream of c-myb 
(18). The Mis-2 locus was identified as a common integration site in Moloney 
MuLV induced thymic lymphomas in rats and was subsequently found to map 
160kb downstream of c-myb (59). Finally, M mll was identified as a novel 
integration site in MuLV induced promonocytic myeloid leukaemias. This locus 
was mapped 20-25kb upstream of c-myb (66).
- □ —
Mis-2
Figure 8.1. Comparative map of the mouse Fit-1, Mm/1, c-myb, Ahi-1 and Mis-2 
regions combining both the physical and recombination data between each of 
these loci on chromosome 10 (18;59;66). See text for more detail. Note that the 
physical position of Fit-1 on this figure is an estimate based on the human data 
and also that it is drawn with the c-myb gene in a 5'-3 ' orientation.
-3 /119
- 0 / 101- - 0 / 88 -
- 0/ 88 -
- o -
F/f-1 Mml 1 c-myb Ahi-I
20kb
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Genetic linkage analysis using the EUCIB panel of mice also placed the Fit-\ 
locus within this cluster of loci on mouse chromosome 10 (157). Of 119 
backcross progeney screened for both loci only three recombinants were detected. 
This total of 119 mice represented an initial random screening panel and a second 
panel o f known chromosome 10 recombinants. Based on EUCIB algorithms 
these data placed Fit-l approximately lcM from Ahi-\ (Figure 3.2).
Although I have been unable to map the physical location of Fit-l in the mouse 
due to difficulties in cloning the mouse homologue of the Fit-l probe, we can 
tentatively construct an integrated recombination/physical map of this cluster 
illustrating the putative position of Fit-1 based on the human data which places it 
lOOkb upstream of c-myb (Figure 8.1). Clearly, the genetic linkage analysis in 
the mouse which suggested a linkage of lcM, approximately equivalent to 
2000kb, is inconsistent with the physical analysis in the human genome. 
Although a true genomic difference between the species may exist, this 
discrepancy may reflect the limited resolution of the EUCIB map in this domain 
and/or the possible existence of a meiotic recombinational hot spot between the 
Fit-l and Ahi-1 regions. To clarify this apparent discrepancy, cloning of the 
mouse homologue of the Fit-1 domain using a mouse PAC library will allow the 
physical mapping relative to c-myb. The recent availability of feline PAC and 
BAC libraries will also serve as useful tools for the physical mapping of Fit-l 
and c-myb in the cat and this work is currently underway in collaboration with N. 
Yuhki (NCI Frederick, Maryland, USA).
The Fit-l locus was shown to be distinct from the Mmll common insertion locus 
by the failure of the conserved Fit-l probe to hybridise to the murine M mll PI 
clone number 5362, Genome Systems Inc., St. Louis, MI (66), even under low 
stringency conditions (not shown). However, as the M mll probe did not 
hybridise to human DNA, we have been unable to map the physical linkage 
between Fit-1 and Mmll in the human genome (L. Wolff, NIH, Bethesda, 
Maryland, USA, personal communication). The generation of cross-species 
probes from the Mmll locus should help resolve this issue.
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The most significant explanation for the clustering of integration sites in this 
region is that they have a common consequence, possibly the activation of c-myb 
gene expression by a long-range enhancer insertional activation mechanism. 
Indeed, the results of this thesis have shown that c-myb gene expression is 
upregulated in the FT1 cell line with a proviral insertion approximately lOOkb 
upstream of the c-myb gene (Figure 6.3). A precedent for such a clustering of 
insertions affecting a common target has been seen at the Gfi-\/Pal-l/Evi-5/Eis-l 
locus. Insertions at any one of these loci which lie within a 50kb domain, appear 
to activate Gfi-1 transcription in B and T cell lymphomas (37-39). Thus, 
independent proviral integrations in the Gfi-l/Pal-l/Evi-5/Eis-\ locus can 
activate Gfi-l expression over distances of up to 25kb, probably by an enhancer 
insertion mechanism.
Perhaps the best characterised example of long-range activation is the activation 
of the c-myc oncogene by retroviral insertion at the M lvi-1 or Mlvi-A loci within a 
300kb domain (63;64). Proviral insertions within either loci were shown to 
activate, in addition to M lvi-1 and Mlvi-A, the c-myc gene. Activation was shown 
to occur in cis using cell hybrids between rat thymic lymphoma cell lines 
rearranged at M lvi-1 or Mlvi-A and a murine T cell line (64). From this analysis, 
the over-expression of rat c-myc cosegregated with the rearranged loci while 
there was no effect on murine c-myc, providing strong evidence that provirus 
insertion exerts its long-range effect on c-myc in cis.
Other examples of long-range activation include the Evi-\ gene which has also 
been shown to be activated in cis by retroviral insertions 90kb 5' of the gene at 
the Cb-\/flm-2> locus, possibly by affecting the methylation state of the Evi-1 gene 
(28). Proviral integration at the Fis-1 locus is closely linked to the cyclin D1 
gene (Cyl-1) on mouse chromosome 7 where it has been mapped within 300kb on
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the 5' side of this gene. Further analysis revealed that proviral integration at Fis- 
1 can activate the expression of Cyl-1 in mouse lymphomas and that this may be 
functionally equivalent to the BCL\ translocation in human B cell lymphoma 
(41). More recently, a woodchuck hepatitis virus common integration locus (win) 
was mapped 150-180kb from N-rayc2 on the X chromosome in woodchuck liver 
tumours and was shown to be associated with enhanced expression of this gene 
(159).
It is possible that an analogous situation is operative in the Fit-l/M mll/c- 
myb/Ahi-\/Mis-2 cluster where activation of a common target (most likely c- 
myb) may be occurring in cis over distances of up to 160kb. This distance is 
within those seen previously, where enhancer elements have been shown to 
activate transcription from a gene up to 300kb away (discussed above). In favour 
of this hypothesis are the results of this study which reveal that the FT1 cell line 
which carries a proviral insertion within the Fit-1 locus shows evidence of 
enhanced c-myb expression (Figure 6.3). As there are no proviral insertions 
within the c-myb gene itself (Figure 6.4A), this suggests that proviral insertion at 
Fit-l is affecting the expression of c-myb. These results appear contrary to 
previous northern blot analysis of RNA from tumours carrying proviral insertions 
at Fit-1 (42). However, as these analyses were conducted on primary tumour 
RNA of variable quality, subtle changes in the expression of c-myb may have 
been missed.
Although proviral occupation of the Fit-l locus may be affecting c-myb 
expression in trans, a number o f lines of evidence suggest that this is not the 
case; most notably the failure to identify any evidence of a transcription unit 
which is affected by proviral integration at Fit-l. Furthermore, long-range 
restriction mapping of the human Fit-l/c-myb region did not identify a CpG 
island in the intervening DNA. As discussed previously, CpG islands are 
frequently associated with the 5' ends of genes and serve as useful indicators of 
the presence of actively transcribed sequence (107). However, they have only
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been associated with approximately 60% of genes. Therefore, the lack of 
evidence of a CpG island in the sequence flanking the Fit-1 locus does not 
necessarily exclude the possibility of another nearby gene which has yet to be 
identified.
O f particular interest when considering possible mechanisms for the long-range 
activation of c-myb by integration at Fit-1, is the observation that alf the 
proviruses except one are integrated in the same orientation (Figure 3.3). This 
pattern is not typical of promoter insertion, but signifies that an enhancer 
insertional activation mechanism may be occurring, a mechanism which is known 
to occur over long distances (discussed above). Moreover, the integrations 
mainly occur in regions of unique sequence and at least one of these regions is 
conserved in evolution (Figure 3.1, tumour J51-3T). This observation may 
reflect the presence of regulatory elements in this region that influence c-myb at a 
long distance and which may be disrupted by proviral insertion. Conversely, 
disruption of chromatin structure in the vicinity of the proviral insertion may 
have a downstream effect possibly by disturbing regulatory interactions between 
the Fit-1 region and c-myb. Such a postulate has been raised previously in a 
hypothetical model for the mode of activation of N-myc2 by integrations at the 
win common insertion locus (159).
Analysis of mRNA from the FT1 cell line which is rearranged at Fit-1 has now 
provided evidence of enhanced expression of the c-myb gene in this T cell 
lymphoma line compared to a number of other feline T cell lymphoma lines 
without rearrangements at Fit-1 (Figure 6.4). However, do proviral insertions at 
M m ll , Ahi-1 and Mis-2 also activate the expression of c-myb? This hypothesis is 
consistent with the lack of evidence of transcription units at Mmll and Mis-2, 
although there is some evidence of a novel gene at Ahi-1 (18). Northern blot 
analyses of RNA from tumours carrying proviral insertions at Ahi-l or Mis-2 
showed no evidence of strongly enhanced c-myb expression (18;59). However, 
as in the initial F it-1 studies, these analyses were conducted on primary tumour 
RNA and subtle changes in the expression of c-myb may have been missed. It is
159
interesting to note that two murine T cell lymphoma cell lines (p/m 16i and 
G1500 44i) were recently shown to carry insertions at Ahi- 1 (M. Stewart, 
unpublished). Therefore, these will serve as useful tools to analyse subtle effects 
on c-myb expression as a result of proviral integration at Ahi-1. Analysis of c- 
myb RNA and protein from murine myeloid leukaemias and cell lines with Mmll 
rearrangements also showed no obvious evidence of over-expression (66). To 
conclude, therefore, it is conceivable that these clustered insertions have a subtle 
effect on the expression of c-myb. However the possibility that these insertions 
affect another closely linked gene which has yet to be identified cannot be ruled 
out.
Northern blot analysis revealed not only that c-myb expression was enhanced in 
the FT1 cell line, but that there were also two additional mRNA species which 
hybridised to the c-myb probe with sizes of approximately 4.4kb and 7.5kb 
(Figure 6.3). These observations raise the possibility that proviral insertion at 
Fit-l favours expression of these larger transcripts. Further northern blot analysis 
of FT1 mRNA revealed that the 4.4kb message hybridised specifically to an exon 
9A (FE9A) probe (Figure 7.1). This analysis also showed that the exon 9A form 
of c-myb was approximately five fold over-expressed in FT1 compared to 3201 
mRNA.
Although over-expression of c-myb containing exon 9A has previously been 
shown to increase transcriptional transactivation of a reporter gene in avian 
myelomonoblasts (212), the function of this isoform is currently poorly 
characterised. Previous analysis showed that, although exon 9A was expressed in 
all chicken haematopoietic tissues tested, cells from yolk sac contained the 
highest levels o f this alternatively spliced c-myb mRNA (236). Exon 9A- 
containing c-myb RNA in yolk sac was present at 15% of the normal, 4.0kb c- 
myb message, while the other tissues tested contained only 1-3% of the exon 9A 
form. Schuur et al, therefore suggested that this isoform may play a role in 
differentiation of immature haematopoietic cells (236). However, neither the 
FT1 nor the 3201 cell lines can be classed as immature cell lines as their T cell
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receptor Cp chains are rearranged as assessed by Southern blot analysis (not 
shown). Further analysis of cell surface markers on these cell lines will be 
necessary to support this conclusion. Therefore, the exon 9A isoform of c-myb 
may play another role, possibly in the development of T cell lymphoma.
The importance of c-myb exon 9A is inferred from the conservation of this exon 
through evolution. In particular the 12 C-terminal amino acid residues are 
conserved in a very diverse group of organisms and genes including mouse B- 
myb\ c-myb from human, mouse, chicken, sea urchin, Drosophila and now the cat 
(Figure 7.4B and (211;212;237;239)). Thus exon 9A has been retained through 
evolution, suggesting a significant biological function of this isoform of c-myb.
Further evidence that this region of the c-myb gene plays an important function 
comes from the demonstration that exon 9 has been the site of insertional 
mutagenesis in at least two cases in myelomonocytic and promonocytic 
leukaemias (Figure 8.2(v) and (68; 102)). Furthermore, a number of lines of 
evidence suggest that disruption of the c-myb gene in the region around exon 9 
which encompasses the putative leucine zipper domain results in increased 
transcriptional activity. Firstly, a bovine T cell line in which exon 9 is deleted 
was shown to have a three fold increase in transcriptional activity compared to 
wild-type c-myb when cotransfected with reporter plasmids containing myb 
binding sites (210). Secondly, a study which involved the deletion of part of the 
negative regulatory domain encompassing the putative leucine zipper motif 
resulted in a significant increase in transcriptional transactivation which was also 
associated with an increased transforming activity (204). More recently, a human 
leukaemia cell line, TK-6, was found to have a c-myb gene which was truncated 
at the 3' end of exon 9, possibly due to a chromosomal translocation (241). 
Again, this form was associated with an increase in transactivation activity. 
Therefore, it appears that the disruption of c-myb within or near the putative 
leucine zipper which spans exons 9 and 10, is improtant for transactivation by c- 
myb and therefore may be important during transformation.
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Figure 8.2 Structure of the c-myb gene and protein. (A) Diagrammatic 
representation of the c-myb gene structure. Exons 1 to 15 are shown as solid 
bars; the alternative exon 9A is shown as an open bar. The arrows represent the 
sites and orientations of the most common retroviral insertions in murine 
promonocytic leukaemias and avian B cell lymphomas. The approximate 
position of the transcriptional pause (attenuation) site in intron 1 is indicated. 
The positions o f the exons are based on the published human c-myb gene 
(GenBank accession number U22376). (B) A comparison of the various c-Myb 
protein structures is shown. The positions of the DNA binding domain, the 
transcriptional transactivation domain (TA), the putative leucine zipper domain 
(LZ) are shown as well as the approximate positions of the negative regulatory 
domain and the FAETL and EVES motifs. This figure is based on the human c- 
Myb protein.
(i) Wild-type 640 amino acid (p75) c-Myb protein structure. (ii) Avian 
myeloblastosis virus (AMV) v-Myb protein; (iii) the avian leukaemia virus E26 
v-Myb protein which is expressed as a gag-myb-ets fusion protein; (iv) N- 
terminal truncated protein. The structure shown illustrates the minimal N- 
terminal truncation seen following retroviral integration within intron 1 resulting 
in a protein which is truncated by 20 amino acids, (72), more commonly 
integration occurs within introns 2 and 3 resulting in truncation of 47 or 71 amino 
acids respectively, promoter insertion (68;69); (v) C-terminal truncation 
following retroviral integration within exon 9 resulting in truncation of 240 or 
248 amino acids following use o f the proviral polyadenylation signal (68; 102); 
(vi) c-Myb protein arising form the use of the alternative exon 9A (solid box) 
(243;237;235); (vii) proviral integration within intron 14 results in truncation of 
c-Myb by 38 amino acids (101); (viii) structure of c-Myb from clone pMbm-2 
which contains unique 5' sequences which replaces exon 1 following use of the 
second c-myb promoter. This clone also contains an alternatively spliced exon 
between exons 8 and 9 (exon 8A, solid box) which results in the premature 
termination of these transcripts (166;243).
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As discussed above, the Fit-1 locus lies within a cluster of other common 
retroviral insertion loci on mouse chromosome 10 (Figure 8.1). Therefore, it will 
be interesting to see if  the exon 9A isoform of c-myb is also upregulated in cell 
lines which are rearranged at Ahi-1 and Mmll. The p/m 16i and G1500 44i 
mouse cell lines which are rearranged at A hi-1 will serve as useful tools in this 
analysis. Furthermore, the discovery of an additional cell line derived from a 
feline thymic lymphoma which is rearranged at Fit-1, the FT-G cell line~(H. 
Tsujimoto, unpublished), will clearly reinforce the conclusions on the effects of 
proviral insertion at Fit-1 seen in the FT1 cell line if it proves to also upregulate 
exon 9A-containing c-myb expression.
Evidence presented in this thesis suggest that the enhanced expression observed 
in the FT1 cell line is, at least in part due to an increase in the half-life of the c- 
myb transcripts (Figure 6.5). As discussed in chapter 6, c-myb has been shown to 
be controlled by attenuation of transcriptional elongation as well as by changes in 
RNA stabilty (217;218;220). Thus by decreasing the turnover o f c-myb mRNA 
in the FT1 cell line, over-expression of the transcript would be expected, an event 
which has been shown to be associated with tumorigenesis (189). It would be 
interesting to determine whether, in addition to an increased stability, c-myb is 
less prone to attenuation in the FT1 cell line, or whether an increase in the mRNA 
half-life is solely responsible for the observed increase in steady-state levels of c- 
myb transcript.
It is difficult to imagine how proviral insertion at Fit-1 could result in an increase 
in stability of the c-myb message, particularly when the majority o f insertional 
activation of the c-myb gene seen previously involves truncation of the gene 
product (186). However, the enforced expression of full-length c-myb has been 
associated with increased transformation in vitro (189). A possible conjecture is 
that proviral insertion affects promoter usage resulting in a transcript which is 
more stable; or perhaps retroviral insertion promotes alternative splicing using 
exon 9A, again resulting in a more stable transcript. Interestingly, a c-Myb 
protein associated with leukaemia which is truncated within exon 9 due to
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retroviral integration exhibited a four-fold increased half-life compared with wild 
type c-Myb protein (221). Such C-terminally truncated c-Myb proteins have 
been shown to produce a higher level o f transformation than cells expressing wild 
type c-Myb (189). More recently, it has been shown that an instability 
determinant is located within the putative leucine zipper domain (234). 
Therefore, it is possible that protein stabilisation may represent a common 
mechanism of oncogenic activation. It will be informative to screen the RNAs 
from actinomycin D treated FT1 cells shown in Figure 6.6 for expression levels 
of exon 9A to examine whether this isoform of c-myb is more stable in the FT1 
cell line. Furthermore, the development of a c-myb exon 9A specific antibody 
within our laboratory (M. Campbell) will also serve as a useful to study the 
stability of the exon 9A-containing protein in the FT1 cell line.
As alluded to above, FeLV integration at Fit- 1 may affect promoter usage in the 
c-myb gene. Indeed, a second promoter has been identified in the human c-myb 
gene (242). This promoter was identified from the cDNA clone pMbm-2 from 
the T-ALL cell line CEM which was previously found to contain a unique 26bp 
sequence replacing exon 1 (243). The second promoter (P2) was mapped to a 
highly conserved region at the 3' terminus of intron 1 (242). Interestingly, this 
clone from CEM cells was also shown to have undergone alternative splicing 
between exons 8 and 9 resulting in a C-terminal truncated Myb protein (Figure 
8.2(viii) and (243)). It will be interesting to examine the level of exon 9A 
containing c-myb expression in this cell line since the use of an alternative 
promoter may also be influencing alternative splicing using exon 9A of the c-myb 
gene. In addition, cDNA cloning of the exon 9A-containing form of c-myb from 
FT1 cells to analyse any differences in the 5' end of c-myb genes including exon 
9A would also tell whether this is a general phenomenon associated with 
alternative splicing of c-myb. Alternatively, an analogy with the c-myc oncogene 
may be drawn where retroviral insertion appears to favour transcripts initiated 
from the PI promoter in thymic lymphomas (244;245). Although the functional 
significance of this is unknown, it was suggested that alterations in P1/P2 ratios 
may serve as good indicators o f c-myc deregulation in thymic lymphomas.
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Proviral insertion at Fit- 1 may conceivably affect the methylation state of the c- 
myb gene in the FT1 cell line. CpG dinucleotides are frequently modified at the 
5' position of the cytosine ring by methylation (108), and hypomethylation has 
been shown to be associated with an increase in gene activity (160). 
Furthermore, the ability of a provirus to affect the methylation state of flanking 
sequence has been demonstrated previously and this was found to be associated 
with decreased gene activity (112). Thus, using the PAC contig, it will be 
informative to identify regions where analysis could be performed using 
methylation sensitive restriction enzymes to detect evidence of heterogeneity 
which corresponds with activity of c-myb.
Whatever the mode of activation of the c-myb oncogene in the FT1 cell line, its 
enhanced expression raises the novel prospect of cooperation between c-myc and 
c-myb in T cell lymphomagenesis since this cell line is also rearranged at c-myc. 
Support for this observation comes from several observations: (i) a role for c- 
Myb in apoptosis has recently been described in T cells and myeloid cells which 
directly correlates with the downregulation of the Bcl-2 anti-apoptotic protein, a 
known Myc collaborator (134;140;183;200); (ii) recent data show that in bovine 
vascular smooth muscle cells c-myc and c-myb can collaborate to promote cell 
cycle progression to S-phase (193); (iii) both c-myb and c-myc have been shown 
to be upregulated in patients with acute myeloid leukaemia and this was shown to 
be associated with enhanced stability of both RNA species (227); (iv) the protein 
product of the Pim- 1 oncogene, a known c-myc collaborator in lymphoid 
transformation, has been shown to bind to the transcriptional co-activator, p i00, 
stimulating c-Myb transcriptional activity (216); (v) finally, mice carrying a v- 
myb transgene directed to the T cell compartment develop T cell lymphomas, 
many of which show evidence of insertional activation at c-myc when accelerated 
by retroviral infection (K. Weston, ICR, London, personal communication). This 
last observation provides more direct evidence for synergy between c-myb and c- 
myc in T cell lymphoma development.
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This evidence raises the important questions of the mechanisms by which Myb 
and Myc synergise to promote the transformation of haematopoietic cells and 
why the activation of both genes never been observed before in c-myc transgenic 
mice. Leverson et al have attempted to address the latter question by suggesting 
that c-myb activation is a complex process involving multiple activating 
mutations which are unlikely to be observed by retroviral insertional mutagenesis 
of this gene. They also suggested that Pim-1 may stimulate a number of 
transcription factors so that its activation of c-myb alone is not sufficient to 
promote myc-initiated transformation (216).
To examine the synergy between c-myb and c-myc further, a transgenic cross has 
been set up in our laboratory (M. Campbell) in collaboration with K. Weston 
(ICR, London) which should lead to a better understanding of the role o f c-myb in 
Myc-induced tumorigenesis. It would also be interesting to cross Pim -1 and c- 
myb transgenic mice to examine whether there is an acceleration of tumour onset. 
If the Pim -1 and c-myb oncogenes do indeed belong to the same functional 
pathway then no acceleration should be expected.
The details of c-myb and c-myc cooperation in lymphomagenesis remain 
mysterious, particularly in view of their similar roles in the regulation of growth 
and differentiation and the fact that both proteins can inhibit apoptosis when 
over-expressed (133;201). However, the recent report which shows evidence of a 
collaboration between Pim-1 and p i 00 to enhance c-myb activity suggests that a 
novel signal transduction pathway linking c-myb, p i00 and Pim-1 may be 
involved (216).
Transgenic studies have allowed the assignment of oncogenes to different 
complementation groups as discussed in chapter 1 (Figure 1.7 and (20)). Is it 
possible to assign Fit-\ and c-myb to any of these groups? Previous analyses 
have suggested a strong association between insertion at Fit-l and c-myc 
activation (25). This analysis also identified proviral integration at both the Fit-1 
and Flvi-2 loci (the feline homologue of Bmi-1) in one tumour induced by FeLV-
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myc. Furthermore, although one tumour has previously been shown to carry an 
insertion at both Fit-1 and Pim-1 (25), the Fit-1 insertion was submolar while the 
Pim-1 insertion was more highly represented. This suggested that they probably 
belong to different tumour clones. Therefore, it is unlikely that F it-1 (and c-myb) 
belong to any of the complementation groups outlined in Figure 1.7 suggesting 
that they may form a novel complemenation group which can collaborate with c- 
myc in T cell lymphomagenesis.
In conclusion, I have reported the chromosomal location of the Fit-1 common 
integration locus on human chromosome 6 in close proximity to c-myb and a 
number o f other common insertion sites identified in the mouse, MmlMAhi- 
1/Mis-2. Furthermore, I have identified that the FT1 cell line which is rearranged 
at both Fit-1 and c-myc but not c-myb, shows evidence of over-expression of the 
c-myb oncogene. This cell line was also shown to over-express the exon 9A 
isoform of c-myb. Future studies which will be aimed at increasing our 
understanding of the synergistic relationship between Fit-1, c-myb and c-myc in T 
cell lymphomagenesis.
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